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Abstract
E09 is one of a series of fully synthetic indoloquinones developed for their ability to act as 
potential bioreductive anticancer agents. Pre-clinical studies suggested that E09 was an 
active drug which demonstrated preferential activity against solid tumour cell lines. 
However, disappointing results were seen in subsequent Phase II trials which failed to detect 
any significant antitumour activity. This was thought to be due, in part, to dose Limiting 
renal toxicity combined with E09's short half-life and instability. For these reasons E09 was 
felt to be a suitable drug to consider for encapsulation into albumin microspheres for use in 
locoregional therapy. This would have the benefit of delivering a high concentration of the 
drug to the tumour site whilst at the same time minimising systemic exposure and therefore 
toxicity. In addition, tire possible induction of hypoxia by the microspheres might enhance 
the drugs bioreductive activity.
A new technique was developed allowing the successful encapsulation of E09 into human 
albumin microspheres. This was an émulsification process which took place at room 
temperature using 6.25% gluteraldehyde as the chemical cross-linking agent. The E09- 
loaded microspheres produced by this metlrod had a median size of 19,9pm with 70% of the 
microspheres being greater than 12pm in diameter. This would enable them to lodge in the 
first capillary bed they encounter and makes them suitable for use in locoregional therapy. 
The drug payload of the microspheres, determined by HPLC analysis, was 1.24 ± 
0.2mg/100mg of microspheres, which represented the actual amount of chemically intact 
drug released from the microspheres. This appeared to be rapidly released following 
resuspension m comparison to other microsphere systems, but would be acceptable for a 
drug such as E09, whose mode of action is related to peak drug concentration rather than 
prolonged drug exposure.
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The antitumour activity of the E09-loaded microspheres was compared to free drug when 
given by direct intiatumoural injection in four tumour models. These were the 
subcutaneously grown human colonic xenografts; HT29 and BE and the murine 
adenocarcinomas of colon; MAC 16 and MAC 26. In the HT29 tumour no significant 
difference in antitumour activity was detected between the free drug (250pg) and the 
equivalent dose of drug-loaded microspheres. In the MAC 16 tumour twice the dose of 
E09-loaded microspheres (SOOpg) was required to produce equivalent antitumour activity to 
the free drug. In the MAC 26 and BE tumours, antitumour activity was detected witlr the 
free drug, but no antitumour activity was seen with the E09-loaded microspheres.
In an attempt to explain the differences which were seen in the antitumour studies between 
the free drug and the microspheres, pharmacokinetic analyses were performed in each of the 
tumour types. No significant differences were seen in the tumour pharmacokinetic profiles. 
Similarly, HPLC analysis failed to detect any obvious metabolites which might be indicators 
of drug activity. However, analysis was limited due to the lack of available data on E09 
metabolites in terms of standard curves and extraction efficiencies.
Direct intiatumoural injection of the E09-loaded microspheres is not the best way of 
assessing the potential of a drug delivery system. Therefore, a more clinically relevant 
model to assess the microspheres was developed. Preliminary in vitro and in vivo studies 
have established tire sensitivity of the HSN rat sarcoma cell line to E09. The liver of tire 
Lister Hooded rat has subsequently been implanted with HSN cells and treated by the 
adirrirristi'ation of free drug or microspheres via the hepatic artery. Further work is required 
to improve oir both the coirsisteircy of tumour growth within the liver, as well as tire 
technique of hepatic arterial injectioir, before definite conclusions can be made about 
whether eircapsulatiirg E09 irrto irricrospheres improves drug delivery to the tumour 
followiirg mtia-arterial administratioir.
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Introduction
1 Chapter 1
1.1 CANCER: AN INTRODUCTION
The term "cancer" is the collective name for a group of over 200 different diseases, each with 
its own characteristics and natural history. The group has in common growtli regulatory 
defects which allow uncontiolled proliferation of a single clone of cells. This growth, 
resulting in the formation of a tumour mass, can produce local invasion as well as 
dissemination around the body.
Cancer is a major cause of morbidity and mortality in the western world, and is tlie second 
commonest cause of death after cardiovascular disease. In the UK it accounts for around 25% 
of all deatlis. Current incidence rates mean that 1 in 3 people will develop cancer at some 
stage in their lives, the incidence increasing with age and of those, 50 - 60 % will probably 
die from their disease. Figure 1,1 details the ten most frequently diagnosed cancers for both 
males and females in Scotland (Scottish Cancer Incidence and Mortality Statistics 1998).
1.2 CANCER MANAGEMENT
The management of cancer requires a multi-disciplinary approach, and is dependent on both 
the stage and type of tlie disease. It can be divided into three main categories:
Curative
In tlie case of solid tumours such as colon or breast cancer this is usually when the cancer is 
still localised. Treatment is normally by surgery and/or radiotherapy. There are also some 
types of cancer; e.g. leukaemias, lymphomas, teratomas and some childhood tumours which 
can be cured with chemotlierapy alone.
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Figure 1.1 The ten most frequently diagnosed cancers (male and female) 
registered in Scotland in 1996. Non-melanoma skin cancer is 
excluded (Scottish Cancer Incidence and Mortality Statistics, 
Scottish Health Statistics, 1998).
Adjuvant
Systemic adjuvant therapy follows localised tieatment and is given when dissemination is 
undetectable, but assumed to be present based on the histology of the tumour. When used 
in tlie correct setting, adjuvant treatment has been shown to improve survival. Examples 
include breast cancer (Bonadorma et al 1995, Early Breast Trialist's collaborative group 1992), 
colon cancer (Moertel et al 1990), and osteosarcoma (Link et al 1986).
Palliative
Palliative treatment is administered to relieve symptoms caused by the tumour. Local 
symptoms can be tieated with localised therapy such as surgery or radiotherapy, but 
mcreasingly, systemic therapy is being used in this setting, to both improve patient well­
being and prolong survival.
1.2.1 Systemic Therapy
Systemic therapy, which can be used at all stages in the management of cancer can be 
divided into 3 main categories:
1.2.1.1 Hormonal Therapy
Tumours which develop in organs which are under hormonal control, such as breast and 
prostate cancer, sometimes retain their hormone sensitivity. The aim of treatment is to 
prevent tumour growth either by decreasing endogenous hormone production or by 
blocking the hormone effect at its receptor. In the case of breast cancer, the former can be by 
ovarian ablation, the use of luteinising hormone releasing hormone (LHRH) analogues and 
arornatase inhibitors such as anash'azole, which switch off oestrogen production. The latter 
is achieved by the use of anti-oestrogens such as tamoxifen which block the receptor site. 
Similarly, in prostate cancer, androgen ablation can be achieved by orchidéetomy or by the
use of an LHRH agonist which causes a reduction in androgen production. The use of an 
anti-androgen such as flutamide can prevent androgen binding to its receptor. (For detailed 
review the reader is referred to; Swain 1996, Erlichman et al 1997).
1.2.1.2 Biological/Cytokine Therapy
Cytokines are naturally occurring glycoproteins which, unlike endocrine hormones, can be 
secreted by various cell types throughout the body. Each cytokine may have several 
functions, but, because of tire complex interactions which can occur between the various 
cytokines, these have often been difficult to define. Cytokines have two main roles in the 
treatment of cancer:
i) Supporting treatment
Growth factors such as G-CSF and GM-CSF can be used to reduce the severity of 
chemotherapy-induced neutropenia and to accelerate bone marrow recovery following 
transplantation. (For review, the reader is referred to: Petros et al 1996, Griffin 1997).
ii) Antitumour activity
Many cytokines are used as antitumour agents. Interferons are used in the treatment of 
various types of leukaemias, multiple myeloma, renal cell carcinoma and Kaposi's sarcoma. 
Interleukin-2 is used in the treatment of renal cell carcinoma and Tumour Necrosis Factor 
(TNF) is used in the isolated limb perfusion of patients with advanced melanoma in 
combination with cytotoxic drugs. (For review, the reader is referred to: Witt et al 1996, 
Bukowski et al 1996, Rosenberg 1997).
1.2.1.3 Chemotherapy
The history of cancer chemotlierapy is relatively short. The first clinical studies took place in 
1943 with the alkylating agent nitrogen mustard (DeVita 1978). Since then, intensive 
research has led to the discovery of a wide variety of chemotherapeutic agents. They can be 
classified in a number of ways depending on their mode of action or their effect on the cell 
cycle. They include the Alkylating agents. Heavy metals. Antimetabolites, Antitumour 
antibiotics, Topoisomerase inhibitors and Tubulin binding drugs (Figure 1.2, Table 1.1). A 
more detailed review of chemotherapy is not appropriate for tlris thesis, but further 
information can be found in Chabner et al 1996 and De Vita et al 1997.
1.3 DRUG RESISTANCE IN SOLID TUMOURS
In Scotland, as in the rest of the western world, solid tumours are the commonest type of 
malignant disease, with lung (21.7%), prostate (14.8%) and colorectal (14.5%) cancer being 
the most common in men and breast (24.6%), lung (14.5%) and colorectal (13.1%) cancer 
being the most common in women (Figure 1.1: Scottish Cancer Incidence and Mortality 
Statistics 1998). Despite the range of cytotoxic drugs now available which have made a 
considerable impact on leukaemias, childhood tumours and the rarer forms of adult cancer 
such as teratoma and lymphoma, solid tumours remain relatively chemoresistant, A variety 
of mechanisms have been identified in solid tumour resistance, though many remain to be 
elucidated.
One well characterised example of drug resistance is the P170 glycoprotein (or multidrug 
resistance phenotype (MDR)), a 170 kD transmembrane glycoprotein (Juhano et al 1976, 
Endicott et al 1989), which acts as a pump capable of ejecting cytotoxic agents from the cell.
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Figure 1.2 Summary of the main classes of anticancer agents and their 
mechanisms of action.
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Table 1.1 A summary of the main classes of anticancer agents.
The drugs affected by this pump are the natural product anticancer agents such as 
anthracyclines, vinca alkaloids, taxanes and podophyllotoxins, with exposure to one of the 
drugs resulting in cross-resistance to a number of the otirer agents (Moscow et al 1988). 
Various methods have been used to try and circumvent MDR, but tlrey have met with 
limited clinical success e.g. verapamil and cyclosporin (For reviews see: Ford et al 1990, 
Raderer et al 1993). O tirer cellular proteins thought to be involved in resistance to natural 
product anticancer agents are the Multidrug Resistance associated Protein (MRP), associated 
with resistarrce to doxorubicin, etoposide and vincristine (Grant et al 1994) and the Lung 
cancer Resistance associated Protein (LRP) (Scheper et al 1993).
Tumour resistance to antimetabolites may occur as a result of an alteration in the drugs' 
inti'acellular target e.g. methodexate, where resistant cells can show increased quantities of 
the target enzyme dihydrofolate reductase (DHFR) due to amplified gene expression 
(Schmike 1984) or contain variant forms of the DHFR enzyme, both of which affect enzyme 
hihibition by the methotrexate (Goldie et al 1980). Other mechanisms of resistance include 
impaired polyglutarnation of metlrotiexate within the cell (Pizzorno et al 1989) leading to 
unpaired intracellular retention of metliotrexate and decreased uptake of methotrexate into 
the cell by reduced folate carriers (Goldman et al 1968). 5-Fluorouracil resistance can also be 
induced by the upregulation of its target enzyme, thymidylate synthase (Zang et al 1992).
Tumour resistance to alkylating agents can be associated witli changes in the cellular 
systems which allow drug detoxification to occur. Glutathione, an important detoxifying 
non-protein thiol, can be found in increased concentr ation, associated with increased activity 
of the enzyme Glutathione-S-transferase (GST) in cells which are resistant to alkylating 
agents (Bellamy et al 1991, Tew 1994).
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1.3.1 The Role of DNA Damage Recognition and Repair Mechanisms in 
Drug Resistance
Normal regenerating cell populations such as the bone marrow or the lining of the GI tract 
have the ability to monitor and repair damaged DNA or destroy cells with irreparable DNA 
ratlier than allow damaged cells to enter the cell cycle and potentially replicate this damage. 
P53 is one of the proteins found in the cell which, in response to DNA damage, causes either 
cell cycle arrest until the damage has been repaired or induces destruction of the damaged 
cell by apoptosis (Levine et al 1991, Keurbitz et al 1992). Mutations in the P53 gene are often 
found in tumour cells which may prevent normal cell regulation (Kemp et al 1994, Holstein 
et al 1991), resulting in cells with abnormal DNA, often as a result of treatment with 
radiation or drugs, being allowed to continue through the cell cycle and undergo cell 
division. Thus, as well as producmg cells which do not readily undergo apoptosis, cells with 
altered phenotypes are produced. This may result in new drug resistance patterns 
developing, potentially leading to higher levels of tumour resistance and to more advanced 
patterns of tumour growth and spread.
1.3.2 Physical Barriers as a Mechanism of Drug Resistance
This important mechanism of drug resistance relates to the physical nature of the solid 
tumour and its associated blood supply (Curti 1993).
1.3.2.1 Tumour interstitium
The mterstitial space within tumours is quite different to drat found in normal tissues and 
varies considerably between tumour types and tumour sites (Gullino et al 1962, Gullino et al 
1963). The interstitial space usually accounts for 14 - 34 % of normal tissue volume, but it is 
increased to 36 - 53 % m tumours (Gullino et al 1965, O'Connor et al 1984). This, together 
with the absence of lymphatic drainage, produces an increase in interstitial pressure which.
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if it exceeds iiiti’avascular pressure, causes closure of blood vessels resulting in impeded 
transport of drugs and other molecules within the tumour (Roh et al 1991, Jam 1987). 
Marked variations in the pro tern, type IV collagen and glycosaminoglycan levels in the 
tumour mterstitium are seen compared with the normal tissue (Gullino et al 1962, Gullino 
1964, Choi et al 1971, Jain et al 1987). Variations in oxygen concentration and pH have also 
been documented (Thistlewaite et al 1985, Vaupel et al 1991).
1.3.2.2 Tumour vessels
If a tumour is to increase in size beyond Im i# , it needs to develop its own blood supply 
(Chaphn 1992A). This is initiated by a variety of angiogenic factors released by the tumour 
or the hosts' inflammatory cells (Folkman 1993). The structure of tumour blood vessels 
differs from that of normal vasculature. The endothelial layer is often patchy with a variable 
basement membrane (Kaiser 1989) and the vessels lack both a nerve supply and smootlr 
muscle layer (Dvorak et al 1988) which may make them less responsive to vasoactive drugs. 
The vessels are highly tortuous with abnormal branchmg patterns and arterio-venous 
anastomoses are often found which contribute to the slowing of blood flow within the 
tumour. Blood vessels are unevenly distributed throughout the tumour mass and because 
no adequate collateral circulation is present (Chaplin et al 1992A), some areas witlrin the 
tumour receive a less than adequate blood supply (Jain et al 1994). Thus, the rapid growth 
of tire tumour, together with the problems created by the inadequate vascular network and 
the mterstitial tissue, can result in large areas of the tumour receiving an inadequate supply 
of esseirtial rrutiients, particularly oxygen, which has important implications for both 
tumour growtlr and tieatment.
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1.3.3 Tumour Oxygenation
The cell population of the tumour can be divided into tlrree main groups with respect to
tlieir oxygen status (Thomlinson et al 1955, Workman 1992A):
1. Well-oxygenated cells. These cells are usually close to the vascular network so they 
receive an adequate amount of both oxygen and nutrients.
2. Necrotic or anoxic cells. In areas where the oxygen and nuti'ient levels are not sufficient 
to maintam viability, the cells die, resulting in the areas of necrosis commonly found 
within solid tumours.
3. Hypoxic cells. These are a population of cells who exist at an oxygen level which is just 
sufficient to maintain viability, but which is suboptimal for proper cell growth and 
metabolism. The presence of this reduced oxygen tension has been confirmed in a 
variety of human tumours using mini-electrodes. These studies also found that the 
outcome of treatment correlated with the degree of hypoxia which was detected within 
the tumour (Gatenby et al 1988, Vaupel et al 1991).
Hypoxic populations can arise as a result of two different mechanisms:
1. Chronic or diffusion limited hypoxia. This type of hypoxia can last for several days 
and arises because the diffusion distance for oxygen is limited by metabolic 
consumption to approximately 150 - 200 gm from the blood vessel. This results in zones 
of chronically hypoxic cells being found at the interface between the oxic and the anoxic 
cell populations (Thomlinson et al 1955, Hall 1994).
2. Acute or perfusion limited hypoxia. This is a ti'ansient, reversible form of hypoxia and 
may be the result of mtermittent vascular occlusion caused by, e.g. a rise in the 
interstitial pressure of the tumour (Brown 1979, Chaplin et al 1986, Horsman et al 1992).
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1.3.4 The Consequences of Hypoxia
Areas of hypoxic cells commonly occur within solid tumours. The reduced oxygen tension 
and the lack of nutrients means the cells will proliferate at a slower rate in relation to the rest 
of tire tumour and lactic acid, produced as a result of anaerobic respiration, will result in a 
more acidic environment (Tamrock et al 1989). Hypoxic cells have been found to be 
significantly more resistant to radiation tlran their normoxic counterparts because tire lack of 
oxygen prevents the formation of the toxic free radicals which result in radiation induced 
DNA damage (Hewitt et al 1959, Hall 1994). Hypoxic cells may leave or move more slowly 
tlrrough the cell cycle which will affect Üreir response to most conventional cytotoxic agents 
(Born et al 1976, Koch et al 1973, Taimock et al 1981). The distance the cells are from the 
tumour vasculature may also prevent them from receiving adequate concentrations of drug 
(Vaupel 1977). In addition, hypoxia has been shown to enhance the frequency of DHFR gene 
amplification which will increase the resistance of the cell to methotrexate (Rice et al 1986).
1.3.5 Overcoming the Effect of Hypoxia in the Treatment of Solid 
Tumours
Fractionation of radiation, which is the administration of small regular doses of radiation 
(usually on a daily basis), may result in improved tumour oxygenation due to a reduction in 
tumour mass as the treatment progresses. This should result in increased tumour sensitivity 
to tire remaining radiation treatment (Souhami et al 1998, Coleman 1996).
Apart from fractionation, two other methods have been identified which attempt to 
overcome the effect of hypoxia in both the radiotherapeutic and chemotherapeutic treatment 
of solid tumours.
14
1.3.5.1 Increasing oxygen delivery to the tumour
The use of hyperbaric oxygen (Henlc 1981), blood transfusions (Dische 1991) and oxygen 
carrymg chemicals such as the fluorocarbons (Lustig et al 1989) have all been utilised to try 
to improve oxygen delivery to the tumour. While trials have shown some improvement in 
tumour response, it is unlikely that these methods alone will eliminate the hypoxic cell 
population. This is because the tumour adapts to the new oxygen level present within the 
tumour with tire result that a chronically hypoxic region persists, but is located further away 
from the tumour blood supply (Hirst 1993).
1.3.5.2 Using oxygen alternatives
1.3.5.2.1 Radiosensitisers
Radiosensitisers are unique agents which act as oxygen substitutes for hypoxic cells. The 
largest group of these are tire electron affinic radiosensitisers whose efficiency is related to 
their election affhrity. They diffuse out of the tumour blood supply and are absorbed by 
hypoxic cells where they mcrease the production of free radicals hr a mamrer similar to that 
of oxygen. They have no effect on well oxygenated cells.
The 5-niti'oinridazole, meti’onidazole (Figure 1.3), was the first of tlrese compounds to be 
tested. The median survival of the patients with glioblastoma treated with metronidazole in 
addition to radiotherapy was greater tlran those treated with radiotherapy alone (7 months v 
3 months). However, because tire study did not use a standard radiotherapy protocol, the 
maximum effect of the metr onidazole could not be properly assessed (Urtasun et al 1976).
The 2-niti'oimidazoles (Figure 1.4) are more electron affinic than metronidazole and 
therefore more efficient hypoxic cell sensitisers. Initial studies with oral misonidazole were 
limited by significant toxicities (nausea, vomiting and neuropathy) and while results
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Figure 1.3 Structures of the 5-nitroimldazole radiosensitisers: 
Metronidazole and Nimorazole.
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Figure 1.4 Structures of the 2-nitroimidazole radiosensitisers and 
bioreductive cytotoxins.
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suggested that there was some benefit in the treatment of head and neck cancer, they were 
not reproducible (For review, see Dische 1985). Analogues of misonidazole have been 
developed, of which the lead compound is Etanidazoie (SR 2508). Successful 
pharmacokinetic monitoring was carried out to minimise the dose dependent neurotoxicity 
(Coleman et al 1992) but, randomised phase III ti'ials in head and neck cancer have so far 
failed to show any benefit in the group treated with Etanidazoie in addition to standard 
radiotherapy (Lee et al 1995). Similarly, the addition of Pimonidazole (Ro 03-8799), a 
lipophilic 2-nitroimidazole, to radiotlierapy has failed to show any benefit in a randomised 
phase III study in cervical carcinoma (Dische 1992). This lack of activity is thought to be the 
result of a drug-induced reduction in blood flow to tlie tumour, an effect which had been 
identified in preclinical studies (Chaplin et al 1992B).
A newer 5-niti'oimidazole, Nimorazole (Figure 1.3), while a less potent sensitiser than the 2- 
nitroimidazoles, has produced a statistically significant improvement in survival in a phase 
III study in head and neck cancer carried out by The Danish Head and Neck Cancer Group 
(Overgaard et al 1991). This is thought to be related to the fact that it causes significantly less 
cumulative neurotoxicity tlran Etanidazoie and Pimonidazole which has allowed the drug to 
be given tliroughout the whole of the radiotherapy treatment. Further studies are in progress 
with this agent.
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1.3.5.2.2 Hypoxic cytotoxic agents (Bioreductive Drugs)
An alternative approach is to attempt to exploit the hypoxic environment found within 
tumours by using drugs which become chemically active under hypoxic conditions. The 
hypoxic environment promotes reductive reactions and drugs activated in this way have 
been termed bioreductives. They undergo metabolic activation by reduction via a number of 
enzyme pathways to produce cytotoxic species which are capable of covalently binding to 
DNA.
The enzymology of bioreductive activation, exemplified in Figure 1.5 by tire bioreductive 
mdoloquinone E09 which will be discussed in detail later (section 1.7), is complex and 
occurs via 1 or 2 electron reduction steps. The 1 electron reductases include enzymes such as 
cytochrome P450 reductase, xanthine oxidase and cytochrome h5 reductase. This step is 
reversible iir the preseirce of oxygeir which means that under aerobic coirditions the 
reductive metabolite formed will be back oxidised to the original product iir a process 
kirowir as redox cycling (Powis 1987). Although redox cycling results iir the formation of 
toxic superoxide aird hydroxyl radicals, these are less damaging to cells tlran the highly toxic 
drug metabolites that predominate in the hypoxic cells because the superoxide and hydroxyl 
radicals are rapidly mactivated by the cells normal protective enzymes (catalase and 
superoxide disnrutase). The 2 electi’oir reductases which include DT-Diaphorase and 
xairthine dehydrogenase are not usually oxygeir sensitive. This means that the reactive 
hrtermediates formed by this process are formed mdependeirtly of the oxygen status of tire 
cell and therefore occur in both oxic and hypoxic tumour cells.
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Figure 1.5 Possible routes for bioreductive activation of the indoloquinone. 
E09 by 1 and 2 electron reduction.
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1.4 CLASSIFICATION OF BIOREDUCTIVE DRUGS
1.4.1 Nitroimidazoles
During the development of the niti'oimidazoles as radiosensitisers, it became evident that 
some of the compounds being evaluated had a dual metliod of activation. As well as being 
radiosensitisers, the presence of an aziridine moiety resulted in bioreductive characteristics 
which also allowed them to act as cytotoxic alkylating agents.
The first compound RSU 1069 (Figure 1.4), a 2-niti'oimidazole witli an aziridine ring 
(Stratford et al 1986), entered clinical trials but there were problems with gastrointestinal 
toxicity which significantly limited the dose of drug which could be tolerated (Horwich et al 
1986). A pro-drug of RSU 1069, RB 6145 (Figure 1.4) was developed which demonstrated 
antitumour activity in preclinical studies (Jenkins et al 1990) and appeared less toxic (Sebolt- 
Leopold et al 1992). The active metabolites of RU1069 are the nitioradical (1 electron 
reduced), the nitioso (2 electron reduced) and the hydroxy lamine (4 electron reduced) 
anions which usually result in the formation of DNA monoadducts and occasionally DNA 
cross-linkage, although the precise nature of the covalent reaction products remain to be 
identified. In aerobic conditions the predominant reaction is, as expected, redox cycling 
using tlie 1 election reductase enzymes (Workman, 1992B).
1.4.2 Benzotriazine-N-oxides
The lead compound of tliis potent group of specific hypoxic cell cytotoxins is SR4233 (3- 
amino-l,2,4-benzoti'iazme 1,4-dioxide, WIN 59075, tirapazamine) (Zeman et al 1986) (Figure 
1.6). SR4233 undergoes a complex pathway of metabolic activation with 1 electi on reduction 
producing an oxidising niti'oxidal radical which then abstracts hydrogen from bases in the
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SR  4233
Figure 1.6 The structure of the lead Benzotriazlne-N-oxide: SR4233 (3-
amino,-1,2,4-benzotrlazine1,4-dioxide; WiN 59075;tirapazamine).
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DNA, resulting in both single and double stiand breaks without the formation of DNA 
adducts (Laderoute et al 1988). Agam tlris effect is lost in the presence of oxygen, as the 
niti'oxidal radical is back-oxidised to the parent molecule via redox cycling. A Phase II study 
using SR4233 in combination with cisplatin has suggested an improved response rate and 
survival benefit in non small lung cancer when compared to historical data with single agent 
cisplatin (Treat et al 1998). This has been confirmed in the Phase III CATAPULT -1 trial 
where both the response rate (27.5% v 13.7%, p<0.001) and tire median survival (34.6 weeks 
V 27.7 weeks, p<0.0078) were significantly better in the combined treatment arm (von Pawel 
et al 1998).
1.4.3 The Quinones
The quiirone bioreductives (Figure 1.7) include Mitomycin C (MMC) often regarded as the 
prototype bioreductive alkylating agent, together with more recently developed drugs such 
as the mdoloqumone, E09, which will be discussed in more detail later (Section 1.7). 
Bioreduction of the qumones can occur by means of both 1 and 2 electron processes. 1 
election reduction results in the formation of the semiquiirone free radical, which as 
previously indicated, in the presence of oxygen can undergo futile cycling back to the parent 
compound. 2 electron reduction results in the formation of a hydroquinone. In the case of 
MMC, reduction results in tlie activation at tlie C-1 position of the mitosene ring system 
which then alkylates at the N-2 position of guanine in tlie DNA. Subsequent loss of tlie 
carbamate group of the MMC results in the formation of a second centre at C-10 which then 
alkylates a second neighbouring guanine N-2. This can cause both inter- and inba-stiand 
crosslinks, resulting in a bis-adduct which fits into tlie minor groove of the DNA molecule 
(Tomasz et al 1987). Similar reduction is thought to occur with E09, but with the generation 
of 3 potential reactive centres due to the reduction of the aziridine ring and the hydroxyl 
groups.
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Figure 1.7 The structures of the quinone bioreductives mitomycin C (MMC) 
and the indoioquinone, E09.
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1.5 DETERMINATION OF BIOREDUCTIVE ACTIVITY
The relative ability of cytotoxic drugs to kill hypoxic cells has been traditionally expressed as 
the hypoxic cytotoxicity ratio or HCR (Stratford et al 1989):
Drug Concentration : 50% Growth Inhibition (oxic conditions)
HCR= -------------------------------------------------------------------------------------------
Drug Concentration : 50% Growth Inliibition (hypoxic conditions)
In the V79 cell line, MMC has an HCR of 2, which is weak compared to RSU 1069 and SR 
4233 which in tiiis cell line have HCRs of 66 and 50 respectively (Stratford et al 1989). 
However, when different cell hues are used, different results are seen, e.g. MMC has an HCR 
of 5 in the EMT6 mammary cell line (Keimedy 1987). The variation of the HCR across cell 
lines in vitro demonstrates the importance of testing drugs against more than one cell line 
when looking for activity. The difference in effect between cell tines is likely to be related to 
the heterogeneity of enzyme expression within the different cell types (Workman 1992B). 
This variation means that when assessing a tumour for a potential response to bioreductive 
therapy, the presence or absence of hypoxia which although obviously important, should 
not be the only deciding factor. The amount and type of bioreductive enzymes present 
witlrin the tumour, together with the presence of enzymes which allow for DNA repair and 
which protect the cell from oxidative stress effects also need to be assessed (Workman 
1992B).
Studies looking at bioreductive enzyme activity levels in tumours have shown that these are 
often elevated in comparison to normal surrounding tissues (Schlager et al 1990, 
Fitzsimmons et al 1996). This finding has lead to the concept of enzyme directed drug 
development which was first proposed by Workman and Walton. It suggests that if the 
enzyme profile of a tumour were known, it may be possible to modify the structure of a 
bioreductive drug to suit the catalytic preference of the reductase expressed in high levels in
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the tumour and/or to avoid activation by any enzymes expressed in normal tissue 
(Workman et al 1990A). Enzyme profiling could also be used to individualise treatment by 
selecting patients for a particular drug based on their individual tumour enzyme profile 
(Workman 1994).
1.6 POTENTIAL USES OF BIOREDUCTIVE DRUGS
As single antitumour agents, bioreductive drugs are unlikely to have a significant impact on 
tlie tumour because they will only kill the small, slowly growing, hypoxic cell fraction 
present within the tumour. Therefore, to maximise their potential benefit to patients the 
following str ategies might be employed:
1. Bioreductive drugs could be given in combination with more conventional therapy 
capable of killing the larger oxic part of the tumour, i.e. radiation or standard cytotoxic 
agents.
2. A bioreductive drug could be used which is capable of kilhng both oxic and hypoxic 
cells. One example of this is the cobalt (Ill)-nitrogen mustard complex, SN24771 (Wilson 
et al 1994).
3. The hypoxic region within the tumour could be enhanced. This can be achieved with a 
wide variety of agents which are capable of modulating tumour blood flow e.g. 
vasoactive drugs such as hydralazine, which by causing vasodilation of normal but not 
tumour related blood vessels results in tumour vascular shutdown (Chaphn 1989, 
Bremner et al 1990); biological response modifiers such as tumour necrosis factor (TNF) 
(Edwards et al 1991) and Flavone Acetic Acid (FAA) (Stratford et al 1990). The use of 
photo dynamic therapy, which causes hypoxia as a result of damage to the vascular 
endothelium, has also been mvestigated (Adams et al 1994). A further option might be 
the use of drug delivery systems which may interfere with blood flow to the tumour (see 
later).
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1.7 E09
E09 (3-hydroxy-5-aziridinyl-l-metliyl-2-(lH-indole“4,7-dione)-prop-P-en-a-01; NSC 382459; 
E85/053) is the lead compound in a series of fully synthetic rndoloquinones developed for 
their ability to act as potential bioreductive agents (Oostveen et al 1987). E09 has a
molecular weight of 288.3 and while similar to mitomycin C (MMC) in structure (Figure 1.7), 
it has shown a different antitumour profile in preclinical models. In in vitro studies E09 
demonsti’ated preferential cytotoxicity against solid tumours, particularly colon, central 
nervous system, melanoma, non-small cell lung and renal cell lines, with less than lO'^mol/1 
of E09 being required for 50% growth inhibition (GIso) in the majority of sensitive ceU lines. 
In contrast to the panel of solid tumour cell lines in which 49/56 demonstrated sensitivity to 
E09, less activity was seen against leukaemia cell lines with the murine P388 leukaemia line 
being amongst the least sensitive cell line tested (Glso = 4.8 x lOhnol/1) (Hendriks et al 1993). 
In tlie solid tumour cell panel, E09 appeared to be a more potent drug than MMC with a 
mean GIso of 1.7 x lQ-^mol/1 compared to MMC which demonstrated a mean GIso of 7.1 x IQ- 
^mol/1. E09 also demonstrated activity in MMC resistant cell lines such as die MCF-7 ADR 
cell line (Flendriks et al 1993).
The effect of E09 may be pH-dependent witii a reduction in pH from 7.4 to 5.8 increasing 
cell kill from 40% to 95% in DLD-1 cells (Phillips et al 1992). In some cell lines hypoxic 
conditions also appear to increase E09 activity. The concentiations of E09 required to 
reduce cell survival to 10% of die conti'ol population in the EMT6 mouse mammary cell line 
were 3 and lOng/ml for hypoxic and oxic cells respectively (Hendriks et al 1993).
Antitumour activity has been demonstrated in vivo following a single intraperitoneal 
injection of E09 in 2 out of 4 drug refractory murine adenocarcmomas. The MAC 16 tumour 
(T/C = 50% at 2mg/kg) and the MAC 26 tumour (T/C = 66% at 3m g/kg) were both 
sensitive to E09, whereas the MAC 13 and MAC 15A tumours were resistant to E09. The
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P388 murine leukaemia cell line was resistant to E09 in vivo as it had been in vitro (Hendriks 
et al 1993).
In human tumour xenograft models, E09 induced tumour regression in the gastric cancer 
GXF97 and the ovarian cancer MRI-H-207 xenografts following intravenous administration 
of the maximum tolerated dose of E09 on 2 separate occasions 1 week apart. Growth delay 
was observed in tire breast cancer xenograft MAXF449 and marginal antitumour activity was 
seen in the non-small cell lung cancer xenograft LXFL529. No activity was seen in the renal 
tumour xenograft RXL423 (Hendriks et al 1993).
In pre-clinical toxicology studies in Swiss GDI mice, the LDso (tire dose tlrat is lethal in 
approximately 50% of the mice) was 12.99mg/kg (95% confidence intervals; 11.6-15.4mg/kg) 
and 13.95mg/kg (12.3-17.0 m g/kg) in male and female animals. The corresponding LDio (the 
dose that is letlral in approximately 10% of the mice) values were 9.23mg/kg (7.4- 
10.5mg/kg) and 9.91mg/kg (7.9-10.5mg/kg). No specific drug related macroscopic changes 
were observed at autopsy. The only toxicities seen following a single dose of 9m g/kg were 
transient anaemia aird inflammatory changes both visibly and microscopically at the 
injection site. Following multiple mtia-peritoireal treatmeirts with l,5m g/kg E09 (daily for 5 
days every week for 4 weeks), there was a ti'ansient reduction hr body weight from day 9 
until day 28. Mmor changes in weight were also observed in the liver, testes, spleen and 
kidneys. Trairsient anaemia was again detected which was associated with an increase in 
ireutrophil and a decrease hr lymphocyte couirts. The only abnormalities seen on 
microscopic examination were reversible changes in the gastiointestinal ti'act which showed 
congestion of the blood vessels and haemorrhagic spots in the jejunum and lymphoid 
hyperplasia iir Peyer's patches. No bone marrow abnormalities were detected which 
coirtiasted witlr MMC where myelosuppressioir was the dose limiting toxicity (Hendriks et 
al 1993).
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In Wistar rats, following both a single dose of 0.45mg/kg (one tenth of the mouse equivalent 
LDio) inhavenously and 4 weekly doses of 0.45mg/kg, no abnormaHties were detected 
(Hendriks et al 1993).
E09 was found to undergo rapid clearance in rodents following intravenous administration. 
At the maximum tolerated dose of 12m g/kg in male C3H/He mice, the initial plasma 
concenti'ation (Co) was 1.8 ± 0.4jig/ml and the half life was 1.9 minutes witlr a large volume 
of distribution (Vd) of 7.5ml/ g. In comparison, MMC at the same dose has a half life of 16 
minutes with a peak plasma concentration 4 tirires greater tharr E09. Usmg HLPC analysis 
ireither E09 iror its metabolites could be identified in the tumour or tissues, but around 20% 
of the iirtravenous dose was detected as nretabolites in the uriire, suggesting that rapid and 
extensive rrretabolism of the drug had occurred (Workman et al 1992C). Similarly, in 
Sprague-Dawley rats receiviirg 3m g/kg of E09, the initial plasnra concerrtration was 1.5 ±
O.lpg/ml with a half life of 3.0 ± 0.2 minutes and a volume of distribution of 2.2 ± 0.2m l/g 
(Workman et al 1992C).
1.7.1 Enzymology of E09 Bioreductive Activation
As indicated previously (1.4.3), E09 urrdergoes bioreductive activation in order to generate 
tire active cytotoxic species. 1 or 2 electron reduction of the pareirt molecule results m the 
formation of either the semiquinorre or the hydroquinone (Sirritskamp-Wilms et al 1996) 
(Figure 1.5). However, m contrast to MMC, the role of the 2 electron reductase DT- 
Diaphorase in the bioactivation process appears to be much clearer. It is this relationship, to 
be discussed below, which prompted the errzyme directed drug development approach 
proposed by Workman and Walton (Workmarr et al 1990A).
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1.7.1.1 DT-Diaphorase
DT-Diaphorase (NAD(P)H:(qumone acceptor) oxidoreductase (ECl.699.2)) is a flavoproteiii 
which is ubiquitous among eukaryocytes and expressed in varying amounts in most tissues 
(Belinsky et al 1993). High levels of the enzyme normally occur in the stomach, bladder, 
colon and kidney, with low levels being documented in haematological tissues. DT- 
Diaphorase is thought to have two main physiological functions: causing reduction of tlie 
Vitamin K3 precursor and acting as a phase II drug metabolising enzyme (Ernster 1987). The 
latter function characterises it as a protective enzyme, playing an important role in the 
detoxification of chemically reactive metabolites such as the polycyclic hydrocarbons found 
in food, exhaust fumes and cigarettes. It also reduces the cells' exposure to oxidative stiess 
by by-passing the 1 election reductase pathways which produce the toxic free radicals and 
oxygen metabolites capable of causing further damage to the cell. There are several forms of 
DT-Diaphorase which are encoded by 4 gene loci, DIA 1-4 (Edwards et al 1980, Jaiswal et al
1990). Of these, Diaphorase 4 or NQOl accounts for the majority of the expressed enzyme 
and is thought to be the most important in bioreductive activation (Riley et al 1992). It is 
found on chromosome 16 (Jaiswal et al 1988) but is absent in 4% of the European population 
(Edwards et al 1980). The protein occurs as a dimer in vivo (Ernster 1967), witli more than 
90% of the protein being found in the cytosol fraction of the cell and the remainder being 
located in the Golgi apparatus and the mitochondrial and microsomal membranes (Riley et 
al 1992). DT-Diaphorase accepts NADH or NADPH as a cofactor (Ernster 1967).
Elevated levels of DT-Diaphorase are found in rat hepatic preneoplastic lesions induced by 
chemical carcinogens (Schor 1978). It is also induced by heavy metals, quinones, and 
isocyanates as well as by smoking and alcohol (Schlager et al 1990). This suggests it may 
represent an early stress response (Riley et al 1992) or it may have a role in the early defence 
mechanisms of the cell against carcinogenesis (Beyer et al 1988). Increased concentrations of 
DT-Diaphorase are often found in tumour tissues (Smitskamp-Wilms et al 1995, Riley et al
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1992) e.g. in lung cancers, DT-Diaphorase concenhations are up to 123 times higher tlian in 
normal tissue. Colon and breast tumours have also been noted to have up to 3 times the 
normal concentration of DT-Diaphorase (Schlager et al 1990).
7.7,1.2 DT-Diaphorase and E 09  sensitivity
A  good correlation has been noted between the level of DT-Diaphorase expression and E09 
sensitivity in cell lines, with cells which have the highest levels of DT-Diaphorase being the 
most sensitive under oxic conditions (Collard et al 1995, Fitzsimmonds et al 1996, Phillips et 
al 1992, Plumb 1994A, 1994B, Robertson et al 1994, Smitskamp-Wilms 1994). This is in 
contrast to MMC and the quinone, porifromycin, where no correlation has been shown 
between levels of DT-Diaphorase and cell sensitivity (Robertson et al 1992). E09 sensitivity 
can be abolished by the use of dicoumarol, but only in cells expressing high levels of DT- 
Diaphorase (Robertson et al 1994, Bando et al 1995, Smitskamp-Wilms 1994, Plumb et al 
1994B).
The potential importance of DT-Diaphorase in E09 activity has been demonstrated when 
human DT-Diaphorase genes were transfected into CHO (Chinese Hamster Ovary) cells. The 
subsequent sensitivity of the tr ansfected cells to E09 was found to correlate with their level 
of DT-Diaphorase expression (Gustafson et al 1996).
The human adenocarcinoma cell lines HT29 and BE have been extensively studied because 
of the difference in their DT-Diaphorase levels. The BE cell line has a single C to T mutation 
resulting in a proline instead of a serine in the DT-Diaphorase molecule. This results in cells 
which produce normal levels of DT-Diaphorase RNA and protein but the protein itself is 
inactive (Traver 1992). The HT29 cell line is rich in DT-Diaphorase and in vitro is 16.4-fold 
more sensitive to E09 than the BE cell line under aerobic conditions (Walton et al 1992A).
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The results appear to be similar in vivo. In the murine transplantable adenocarcinomas of 
colon, MAC 16 and MAC 26, it has been shown that MAC 16, which has 15-fold higher levels 
of DT-Diaphorase tlian MAC 26, is more sensitive in aerobic conditions to E09 than MAC 26 
(Workman et al 1990B, Walton et al 1992A).
The amount of DT-Diaphorase m xenografts has been shown to be lower than the DT- 
Diaphorase levels in the corresponding cell lines. This difference may be due to the presence 
of interstitial tissue in the tumour or microenvironmental factors in vitro, but suggests that it 
may be difficult to predict the activity of E09 in vivo based only on in vitro data (Collard et al
1995).
In our laboratory the chemosensitivity of a panel of 4 solid tumours (the human colon 
xenografts HT29 and BE and the murine colon adenocarcinomas MAC 16 and 26) to E09 did 
not correlate with the levels of DT-Diaphorase or the 1 electron reductases (cytochrome-P450 
reductase and cytochrome-b5 reductase) when measured in the tumours using cytochrome C 
reduction and menindione as the intermediate electi’on acceptors. This is unlikely to be 
related to the known difference in reductive capacity between human and murine DT- 
Diaphorase (Lewis et al 1994) because this difference is small and would not manifest itself 
at tlie concentration of E09 (lOOpg/ml) used in the study. When E09 was incubated in vitro 
with tumour homogenates, no correlation was seen between anti tumour activity and 
metabolite formation. A good correlation was seen between antitumour activity and the rate 
of disappearance of the parent drug (1*2=0 .8 6 ), which suggested tliat the capacity of a tumour 
to metabolise E09 ratlrer than bioreductive enzyme expression was the most important 
determinant of antitumour activity (Cummings et al 1998).
The role of DT-Diaphorase in hypoxic conditions is less clear. Using the HT29 and BE cell 
lines. Plumb et al have shown a 1000 fold enhancement in E09 cytotoxicity under hypoxic
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conditions for the BE cell line, whereas HT29 demonstrated only a 2 to 5 fold increase in 
sensitivity under the same conditions (Plumb et al 1994C). This has been confirmed in other 
cell lines where a clear inverse relationship was demonstrated between cellular DT- 
Diaphorase activity and hypoxic sensitivity to E09 (1*2=0.93) (Plumb et al 1994B). Others 
have also shown enhancement of activity under hypoxic conditions in cells which are low in 
DT-Diaphorase (Bando et al 1995, Robertson et al 1994). In DT-Diaphorase rich cells, the 
addition of dicoumarol, which inhibits DT-Diaphorase activity, inhibited the normal cell 
sensitivity to E09 in oxic conditions, but increased sensitivity in the same cells under 
hypoxic conditions. In contrast the presence of dicoumarol had no effect on E09 sensitivity 
in cells which were low in DT-Diaphorase in either oxic or hypoxic conditions (Plumb et al 
1994B). This suggests a role for the 1 election reductase enzymes, which are not inhibited by 
dicoumarol, in E09 activation (Bando et al 1995, Plumb et al 1994B, 1994C).
The relative roles of the 1 and 2 election reductases in the bioactivation of E09 may be 
dependent on the cellular environment. This includes factors such as pH, oxygen tension, 
the cells prohferative state and the mechanisms present for cellular repair. In aerobic 
conditions, the effect of one election reduction which is capable of generating the active 
species of E09 is minimised due to rapid redox cycling. Two electron reduction, on tlie other 
hand, is oxygen-independent and therefore increases in relation to the level of enzyme 
present within the cell. Under hypoxic conditions redox recycling is prevented, thus one 
election reduction allows the formation of active metabolites which are not subsequently 
reoxidised. This could account for the marked increase in activity seen in cells low in DT- 
Diaphorase when they are subject to hypoxic conditions.
Plumb et al postulate tliat it may be the semiquinone rather than the hydroquinone which is 
the active species of E09. The increased activity in cells which are rich in DT-Diaphorase 
which is seen in oxic conditions may be the result of a transient increase in the concentration
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of the semiquinone within the cell due to back oxygenation of the hydroquinone particle. 
This cannot occur under hypoxic conditions, hence the lack of enhancement seen in these 
cells in the presence of hypoxia. However, cells which are low in DT-Diaphorase 
demonsti’ate massive enhancement of activity under hypoxic conditions because the lack of 
redox cycling allows an increase in the semiquinone radical to occur within the cell (Figure 
1.5) (Plumb et al 1994B). This tlreory is however, based on in vitro results and does not 
explain tlie, albeit slight, mcrease in activity noted in the DT-Diaphorase rich cells which still 
occurs in hypoxia. However, it would agree with studies which investigated tlie chemical 
properties and reactivities of tlie semiquinone and the hydroquinone radicals with oxygen 
using pulse radio lysis techniques. These results suggested that the semiquinone and the 
hydroquinone radicals are hi equilibrium and that in the presence of oxygen the 
hydroquinone auto-oxidises, possibly via semiquinone mediated reactions (Butler et al
1996).
1.7.1.3 E 09  activity induced by DT-Diaphorase
E09 activation by DT-Diaphorase appears to produce a reactive species capable of 
interaction witli DNA. It can cause single strand breaks hi DNA plasmids with maximum 
activity at 10-50frM of E09. This is unaffected by superoxide dismutase, which indicates that 
the effect is mediated by an alkylathig agent ratlier than a free oxygen radical (Walton et al
1991). Inter-strand cross-linking has also been demonstrated which appears to be pH- 
dependarit, with cross-linking hicreashig as the pH rises from 5.5 to 7.0 (Bailey et al 1994, 
Maliepaard et al 1995). However, previous studies with E09 in vitro have shown that in 
DLD-1 and MCF-7 cell lines an increase in pH actually causes a reduction in cytotoxicity, 
suggesthig that inter-strand crosslinkage is not die main mechanism of action (Phillips et al
1992).
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1.7.2 Clinical Evaluation of E09
1.7.2.1 Phase I studies
Phase I studies have been carried out using two different schedules of E09 under the 
auspices of tlie EORTC (Schellens et al 1994, Verweij et al 1994). In the first study, E09 was 
given as a 5-minute infusion every 3 weeks to 32 patients with solid tumours (Schellens et al
1994). The maximum tolerated dose was 27mg/nP. The dose limiting toxicity was 
proteinuria associated with salt and water retention which was reversible by day 15 in all 
but 2 of the patients who went on to develop acute renal failure. In 2 of the 4 patients with 
grade IV proteinuria, a renal biopsy was performed which showed changes suggestive of a 
nimmial change glomerulopathy as well as degenerative changes in the tubules. This was 
not predicted in tlie preclinical data, but was thought to be related to the high levels of DT- 
Diaphorase found in tlie renal tissue of humans compared to other species (Riley et al 1992, 
Schlager et al 1990). No bone marrow toxicity was seen in any of the patients which 
confirmed the preclinical data. There was no cumulative toxicity and three patients had a 
partial response to E09.
Pharmacokinetic analysis showed that tliere was wide inter-patient variability with the 
clearance varying from 3.2-24 1/nim and the terminal half life varying from 0.8-29 minutes. 
The pharmacokinetics were related to the pharmacodynamic data with the area under the 
curve (AUC) of E09 being the parameter which correlated best with toxicity (proteinuria).
The dose recommended for Phase II studies was 22mg/ni^, but, because of the unexpected 
renal toxicity, and the wide variability in patient pharmacokinetics, it was suggested that 
individual dose adjustments should be made based on die plasma concentration in order to 
combine maximum exposure with mmimum toxicity (Schellens et al 1994). However, the 
multi-centi'e nature of the Phase II trial meant that it was not possible to allow 
individualisation of patient dosing.
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In a second phase I study a weekly schedule was employed (Verweij et al 1994). The dose 
limiting toxicity was again proteinuria at tire maximum weekly drug dose of ISmg/m^ and 
12mg/m2 was recommended for the subsequent phase II ti'ials. The weekly schedule 
reflected the highest dose intensity per course achievable, and it was therefore selected for 
the main Phase II study.
1.7.2.2 Phase II studies
Phase II studies were carried out employing the weekly schedule of 12mg/m^ E09 in 
patients with breast, colorectal, gastric and pancreatic cancer (Dirix 1996). Ninety-two 
patients entered the trials with the drug being generally well tolerated. Nausea and vomiting 
occurred in 26% and 13% of courses respectively. These were predominantly at grade I/II 
except for two documented grade III episodes of nausea and three documented episodes of 
grade 111 vomiting. Reversible proteinuria, the major toxicity, was documented in 45% of 
courses although there was only one documented case of grade III toxicity. However, no 
antitumour responses were seen in any of the patients, which suggested that this was not an 
active schedule in these tumour types.
A fur tirer study compared weekly (12mg/m2) E09 with a 3-weekly (22mg/m2) schedule in 
38 previously untreated patients with non small cell lung cancer (Pavlidis et al 1996). The 
major toxicity, proteinuria, was more severe in the 3 weekly arm (62.5 v 34.5% of courses). 
This arm also had increased asthenia (35 v 21%), nausea (27.5 v 15%) and vomiting (17.5 v 
5%). Interestingly, although no responses were observed in either group, the 3 weekly 
chemotherapy arm had a higher proportion of patients with stable disease (53 v 26%).
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1.7.3 Potential Reasons for Lack of E09 Activity
E09 has been shown to be an active drug both in vitro and in vivo. The lack of response in the
clinical trials is disappointing. Several potential reasons for this lack of activity can be
postulated:
1. The dose limiting toxicity of proteinuria found in both the weekly and the 3 weekly 
schedules is probably due to the high levels of DT-Diaphorase found in renal tissue and 
significantly limits the amount of drug which can be successfully administered to tlie 
patient.
2. E09 is generally known to be unstable with a short half life in vivo (Workman et al 
1992C). It is hydrolysed to the breakdown product E05A which is known to be a poor 
substi'ate for DT-Diaphorase and is much less cytotoxic than E09 (Bailey et al 1992).
3. There are problems in drug delivery to solid tumours as discussed previously (1.3.2). In 
particular, the often inadequate tumour vasculature, which, although providing a 
potentially enhancing hypoxic environment, may actually reduce the amount of drug 
reaching the tumour cells. The increase in interstitial tissue which can also be found in 
solid tumours may delay the arrival of the drug at tlie tumour cells. These factors will 
assume greater importance if, as is the case with E09, the drug has a very short haif-Hfe. 
It is interesting tliat the only responses seen in clinical trials were in the Phase I, 3 
weekly schedule which used higher doses of E09. There were also more patients with 
stable disease in the 3 weekly arm of tlie phase II study in non-small cell lung cancer 
compared to the weekly arm (Pavlidis et al 1996).
4. If E09 is eliminating only the hypoxic fraction of the tumour, then the remaining oxic 
fraction will continue to grow. This means that the usual methods of determining 
tumour response, which depend on change in tumour size, may not be the most 
appropriate as they are unlikely to detect any significant activity.
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1.7.4 Potential Developments Using E09
E09 could be considered for use in locoregional therapy. This would have the benefit of 
providing a high concentration of E09 where it was needed, at the tumour site, whilst at the 
same time reducing systemic exposure and therefore toxicity. In addition, depending on tlie 
metliod of drug delivery, enhancement of hypoxia may occur which could increase E09's 
activity still further as has been shown using hydralazine in in vivo models (Bibby et al 1992). 
This hypothesis is the major theme of the work presented in this thesis.
E09 may also have a role in combination with radiotherapy. Adams et al have shown that 
when E09 was used as a post irradiation sensitiser, it resulted in enhancement of cytotoxic 
activity when administered following a 10 Gy dose of radiation (Adams et al 1992). 
However, this combmation of metliods, whilst potentially affecting both the oxic and 
hypoxic fractions of the tumour, would not eliminate all of the problems mentioned above.
1.8 LOCOREGIONAL THERAPY
Conventional systemic chemotherapy has a relatively low therapeutic index, which means 
that increasing the dose of drug administered to fay to improve the antitumour effect will 
often result in a marked increase in systemic toxicity. Locoregional chemotherapy is an 
alternative method of drug administr ation which maximises the amount of drug which can 
be delivered to the target organ, thereby improving it's effectiveness, whilst at the same 
time, minimising systemic exposure and therefore toxicity. However, not all tumours are 
suitable for locoregional therapy as its utility depends on the site of the tumour to be 
targeted. One area where locoregional therapy has been extensively studied is in the 
treatment of liver tumours, either primary hepatomas or métastasés from e.g. colorectal 
tumours.
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1.8.1 Colorectal Cancer
Colorectal cancer is the third most common cancer in tlie western world. In Scotland alone, 
over 1700 people died from this disease in 1996 (Scottish Cancer Incidence and Mortality 
Statistics 1998). Liver métastasés are found in up to 25% of people at presentation 
(Bengmark et al 1969). In 50% of patients with metastatic disease tlie liver may be the only 
site of involvement (Kemeny et al 1980). Survival in patients with hepatic involvement is 
poor with a mean survival of 3 - 9 montlis (Wood 1984). Surgical resection is one option for 
the treatment of liver métastasés, but is unfortunately only suitable for a small percentage of 
patients (Bradpiece et al 1987, Ridge et al 1985). The mainstay of treatment for metastatic 
colorectal cancer is systemic therapy. The fluoropyrimidine, 5-Fluorouracil (5FU) is the most 
commonly used drug, but newer drugs such as irinotecan and oxaliplatin have become 
available which have demonstrated activity in metastatic colorectal cancer. For a detailed 
review of systemic therapy, the reader is referred to reviews by Coperchini (Coperchini et al
1995), Grem (Grem 1995), Meropol (Meropol et al 1995) and Steele (Steele 1995).
1.8.2 Locoregional Therapy and Colorectal Liver Métastasés
There are several reasons why colorectal liver métastasés may be suitable for treatment 
using locoregional therapy:
1. The liver is the only site of metastatic spread in 50% of patients (Kemeny et al 1980).
2. One theory for the spread of colorectal cancer is tliat it may occur in a "stepwise" 
maimer (Weiss et al 1986, 1989). This theory suggests that tumour cells spread from the 
bowel via the portal vein and become trapped within the liver where metastatic deposits 
form. These metastatic deposits are then responsible for spread to the rest of the body;
i.e. métastasés are derived from métastasés. Treating the liver with high dose therapy 
may therefore prevent or slow down the development of extra hepatic deposits.
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3. The liver has a dual blood supply: tlie hepatic portal vein and the hepatic artery. The 
normal parenchymal tissue is supplied mainly by the hepatic portal vein, whereas 
métastasés over 2 mm in diameter derive their own blood supply from tlie hepatic artery 
(Breedis et al 1954). This means that utilising the hepatic artery will incorporate a degree 
of selectivity into the treatment by increasing chemotlierapy exposure to neoplastic cells 
relative to normal hepatocytes (Sigurdson et al 1987). Furthermore, tumour blood 
vessels tend to lack the smooth muscle layer normally found in precapillary arterioles 
(Dvorak et al 1988) and have a more fenestrated capillary lining which is deficient in 
basement membrane (Kaiser 1989). This difference in the tumour vasculature may affect 
drug diffusion and alter the responsiveness to vasoactive substances which provides a 
furtlrer area for exploitation when planning treatment (Goldberg et al 1991A and B).
4. Locoregional therapy to the hver can produce high hepatic drug concentrations which 
may be important for drugs such as 5-FU and fluorodeoxyuridine (FUDR) which have 
steep dose-response curves (Chen et al 1980). Locoregional administration also allows 
drugs with high hepatic extraction rates to be given in high doses to the liver whilst 
mmimismg systemic exposure (Collins 1984).
1.8.3 Approaches to Locoregional Therapy
1.8.3.1 Hepatic artery infusion
This involves the placement of an indwelling catheter into the hepatic artery. The first 
treatments used percutaneous catheters and external pumps which were poorly tolerated 
due to problems with arterial thrombosis, infection, bleeding and catheter dislodgement 
(Tandon et al 1973). The development of implantable pumps and subcutaneous ports have 
resolved many of these problems and have made this type of therapy a more feasible option 
(Fordy et al 1995). The mam drugs used in hepatic arterial infusions have been FUDR,
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which has a 95% first pass extraction rate in the liver and 5FU, which has a lower first pass 
extraction rate of 19 -55% (Ensminger et al 1978).
Several non-randornised Phase II trials have been carried out using hepatic arterial infusions 
of FUDR and 5FU in patients with metastatic colorectal carcinoma. In a collected series of 
nine of these studies involving 375 patients receiving FUDR, the mean response rate was 
45% and the median survival was 17 months (Benson et al 1995).
There have been seven randomised Phase 111 trials comparing hepatic artery infusion witlr 
systemic therapy, and these are summarised in Table 1.2. The response rates were higher in 
tlie hepatic arterial arm, although all of tlie studies failed to detect a survival advantage. One 
study, which showed a higher response rate in the intrahepatic treatment arm compared 
with the intiavenous arm (50% v 20%), documented an increase in extrahepatic progression 
in tliose treated with locoregional therapy compared to those treated with systemic therapy 
(56% V  37%), though tliis did not appear to affect survival (Kemeny et al 1987).
There were several reasons why it was not possible to determine a survival advantage:
1. Most of the studies contained only small number of patients which meant that they did 
not have tlie statistical power to detect a survival advantage.
2. In some of the studies (3/7) a crossover design was used. While this had the advantage 
of demonstrating that a response could be obtained using hepatic artery infusion in 
those who had progressed in the systemic arm of the trial, it prevented a meaningful 
comparison of survival between the 2 treatment arms.
3. Those patients in the systemic arms were often undertreated e.g. a lower dose of drug 
was used than we now know to be effective or they were treated with single agent 5FU 
rather than a combination of 5FU and Folinic Acid.
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HAI IV Cross­
over  ,Croup T?iitiait
Numbers
Drug %
response
D ntg %
response
NCI
(Chang et al, 1987)
64 FUDR 62 FUDR 17 No
MSKCC
(Kemeny et al, 1987)
162 FUDR 50 FUDR 20 Yes
NCOG
(Hohn et al, 1989)
143 FUDR 42 FUDR 10 Yes
Mayo Clinic 
(Martin et al, 1990)
74 FUDR 48 5-FU 21 No
French
(Rougier et al, 1992)
163 FUDR 43 5-FU 9 No
City of Hope 
(Wagman et al, 1990)
91 FUDR 55 5-FU 20 Yes
English
(Allen-Mersh et al, 1994)
100 FUDR 40 No
Table 1.2 Summary of Phase III randomised trials of hepatic artery 
infusion (HAI) versus systemic (IV) fluoropyrimidines for 
colorectal liver métastasés.
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A meta-analysis of the literature has been performed to attempt to determine whetlier 
regional infusional chemotlierapy using 5FU or FUDR conferred any survival advantage 
over systemic therapy. Only prospective randomised trials which used tliese drugs were 
considered and the trials had to have reported on survival from time of randomisation until 
deatli. Only 6 out of 149 studies which were reviewed met these criteria and were included 
in the analysis. The information on 1 and 2 year survival was either taken directly from the 
study or calculated using Kaplan - Meier survival curves. Survival was expressed as a 
percentage at 1 and 2 years post randomisation. The survival difference was 10% at 1 year (p 
= 0.041) and 6.4% at 2 years (p = 0.124) m favour of the regional chemotherapy group. In the 
studies which did not allow crossover the survival advantage increased to 18% at 1 year 
(p=0.034) and 7% at 2 years (p=0.276). These data suggest a statistically significant survival 
advantage for locoregional therapy when compared to systemic therapy (Harmantas et al 
1996).
1.8.3.1.1 Hepatic artery infusion toxicity
The side effects of hepatic artery therapy are different to those seen with systemic therapy. 
Myelosupression and mucositis, tlie common side effects of systemic therapy, do not occur. 
The mam toxicities are hepatobiliary toxicity and gastroduodenal ulceration (Kemeny et al 
1984, Flohn et al 1986).
Biliary toxicity occurs because the bile ducts derive their blood supply from the hepatic 
artery (Northover et al 1979) and therefore receive a high dose of chemotherapy. Liver 
function tests need to be closely monitored and chemotherapy discontinued if they become 
abnormal. Endoscopic retrograde cholangiopancreatography (ERCP) has demonstrated the 
presence of lesions similar to those found in sclerosing cholangitis in 5-29% of patients who
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became jaundiced during hepatic arterial chemotherapy (Kemeny et al 1984, Hohn et al 
1985A, Shea et al 1986).
Gastr oduodenal ulceration occurs because aberrant branches to these organs can arise from 
tire hepatic artery. These should be carefully dissected out and ligated when the catheter is 
initially inserted into the artery (Hohn et al 1985B).
1.8.3.1.2 Reduction of hepatic artery infusion toxicity
Various methods have been employed to minimise the toxicity associated with hepatic 
arterial infusions. The hepatic arterial administration of dexamethasone may help reduce 
the portal triad inflammation which carr result in bile duct ischaemia. In a study exploring 
tire effect of dexamethasone during FUDR administration there was a trend towards a 
reduction hr bilirubin elevatiorr hr the dexametirasoire-treated group. The dexamethasoire- 
treated group also demonstrated a significairt increase in response rate (71% v 40% (p=G.03)) 
as well as a survival advantage (23 months v 15 morrths) wherr compared with the group 
treated with FUDR aloire (Kemeny et al 1992). Circadian modification may also influence 
toxicity. In a iron-randomised study, patients receivhrg tire chcadian modification tolerated 
almost twice the daily dose of FUDR with a decrease hr hepatic toxicity when compared 
with those receiving standard infusions of FUDR (Hrushesby et al 1990). Alternation of the 
hepatotoxic FUDR with the less toxic 5FU may also result in a reduction hr toxicity (Stagg et 
al 1991).
1.8.3.1.3 New approaches to infusional therapy
Extiahepatic disease develops in 40 -70% of patients undergoing hepatic arterial infusion, 
often when the patient is still respoirding in the liver. The use of combination systemic and 
hepatic tirerapy is undergoing further investigation as this may represent a more logical
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approach to disease management (Kemeny et al 1993). Preliminary studies adding Folinic 
Acid to FUDR have shown an increase in response rates and survival when compared with 
FUDR alone. Further studies are underway to evaluate this further and to attempt to reduce 
the increase in associated biliary toxicity (Kemeny et al 1994).
1.8.3.2 Chemoembolisation
Chemoembolisation combines a chemotherapeutic agent with an embolic agent. The 
chemotherapeutic agent can either be co-administered with the embolic material or it can be 
incorporated into the embolic material prior to the embolisation procedure in what is termed 
a drug delivery system.
1.8.3.2.1 Chemotherapy and embolisation
Embolisation alone has been used as a therapeutic procedure for many years. It has very 
little effect on patient survival but it can be useful in providing symptomatic relief (Allison 
1989). The benefit which is obtained is usually only temporary because of the rapid 
development of a collateral circulation which is not usually amenable to further embolic 
therapy. The addition of a chemotherapeutic agent, given by the same route during the 
embolisation procedure should, in theory, enhance the therapeutic effect of the embolic 
particles. This is because the reduction in blood flow caused by the embolic particles, in 
addition to producing ischaemia, should result in the prolonged exposure of the tumour to a 
higher concentration of the administered drug. This increase in exposure should increase 
drug extr action by the tumour and hence increase the antitumour effect.
Various types of embolic material have been used. These include both viscous material such 
as lipiodol (Bretagne et al 1988, Inoue et al 1993, Kobayashi et al 1987) and particulate 
material such as Ivalon (Chuang et al 1982), polyvinyl alcohol particles (Martinelli et al 1994)
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and collagen (Daniels et al 1992). Biodegradable microspheres have also been utilised (Carr 
et al 1997, Civarelli et al 1994, Ensminger et al 1985, Lorenz et al 1989).
Most of the experience in chemoembolisation via the hepatic artery has been in the treatment 
of unresectable hepatocellular carcinoma where Phase II ti'ials have demonstrated higher 
response rates than conventional systemic or intr a-arterial therapy (response rates of 25 -50% 
and median survival of 5 -36 months) (Benson et al 1995). Experience is more limited in the 
treatment of colorectal métastasés. The results of 4 of the studies are outlined in Table 1:3. 
The significance of the response rates and median survival is difficult to assess with such 
small numbers and further randomised studies witli larger patient numbers are required.
1.8.3.2.2 Biodegradable microspheres
There are two types of biodegradable microsphere currently in use:
1.8.3.2.2.1 Starch rnicrospJjeres
Starch microspheres are approximately 40 gm in diameter and have a half-life at 37°C in vitro 
in human plasma of 25 mmutes (Hakansson et al 1997). If sufficient amounts are 
administered via the hepatic artery (mean dose of 835 mg) they are capable of causing 
tr ansient vessel occlusion (Civarelli et al 1994). They are degraded by alpha-amylase which 
is present in normal human serum (Aronsen et al 1979, Hakansson et al 1997).
Co-administration of starch microspheres with cytotoxic drugs does appear to alter the 
pharmacokmetic profile of the administered drug. When compared to intr a-arterial MMC 
alone, the peak systemic plasma concentration of MMC and tlie area under the curve were 
reduced in patients who received intia-arterial MMC m combination with starch 
microspheres (Ensminger et al 1985, Gyves et al 1983).
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Group P atien t
Number
C ytotoxic
A gent
CliemoemboUc
Agent
Response
R ate
Daniels et al, 1992 55 Cisplatin
Dox
MMC
Collagen 34%
Lang et al, 1993 46 Dox Ethiodised Oil CR 17% 
PD 13%
Martinelli et al, 1994 24 5FU+IFN 
versus no 
chemo
Polyvinyl
Alcohol
25%
(both
groups)
Lyster et al, 1993 25 Cisplatin
Dox
MMC
Collagen 85%
Table 1.3 Summary of four studies looking at the effect of 
chemoembolisation on colorectal liver métastasés.
Key:
Dox = Doxorubicin 
MMC = Mitomycin C 
5FU = 5 Fluorouracil 
IFN = Interferon
OR = Complete Response 
PD = Progressive Disease
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This was also seen when BCNU was administered in combination with starch microspheres 
via the hepatic artery (Dakhil et al 1982). The transient occlusion caused by the 
microspheres may also cause a redistribution of blood flow towards the more resistant 
hypovascular lesions found within the liver, which should result in improved delivery of 
cytotoxic agents to these areas (Civalleri et al 1994).
A tlrree-arm, prospective, randomised study of 61 patients compared the effect of 
chemoembolisation using starch microspheres and 5FU with simple hepatic embolisation 
using lypholised dura mater or gelfoam with symptomatic management only. There was no 
statistical difference in survival between each of the three groups. However, for the patients 
within each group who had less than 50% replacement of their liver by tumour (12-13 
patients per group), there was a survival advantage for the chemoembolisation group 
(median of 23.6 months) compared with the other 2 groups (10.2 months and 10 montlis 
respectively) though this did not reach statistical significance (Hunt et al 1990). Study 
numbers were small and the absence of a chemotherapy only arm for comparison, makes 
any conclusion of limited value.
A non-randomised study which demonstrated significant responses in 4 out of 11 patients 
treated witli MMC and degradable starch microspheres who had progressive disease 
following intra-arterial FUDR chemotherapy, was also too small for any conclusion to be 
reached with regard to the efficacy of MMC combined with starch microspheres (Lorenz et 
al 1989).
There is a need for a larger prospective randomised trial to be carried out in this area in 
order to determine whether combining chemotherapy with starch microspheres improves 
antitumour response and survival when compared with standard chemotherapy regimens in 
the treatment of colorectal liver métastasés.
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1.83.2.2 .2  Albumin microsplteres
Biodegradable albumin microspheres are similar in size to starch microspheres (20 - 40gm in 
diameter). In a dose finding study the maximum dose of microspheres which was safely 
administered via the hepatic artery was 350mg, although 4 out of 5 patients tieated at this 
dose developed severe right upper quadrant pain and nausea. Therefore, 300mg of 
microspheres was recommended for further studies (Goldberg et al 1988). The median 
biological half-life of the albumin particles within the liver is 2.4 days (range 1.5 - 11.7 days). 
In some patients it is prolonged in tumour tissue compared with normal liver (Goldberg et al 
1991C). The use of radiolabelled albumin microspheres has also shown that there is no 
significant arteriovenous shunting of microspheres to the lungs following hepatic arterial 
administi'ation, despite the démonstration of arteriovenous malformations within the 
tumour tissue (Goldberg et al 1987).
Co-administration of intra-arterial Angiotensin II (Hemingway et al 1991A, 1991B) has been 
shown to further improve delivery of the microspheres to tumour deposits (Goldberg et al 
1991A, 1991B). This is due to the lack of smootlr muscle in the tumour blood vessels which 
reduces their responsiveness to such vasoactive agents. The administration of Angiotensin II 
therefore results in vasoconstriction of the normal vasculature, resulting in increased blood 
flow to tlie tumour areas, which results in an increased delivery of microspheres ± drug to 
these areas. Initial studies appear to suggest that the regional advantage of 5FU given over 
24 hours can be significantly improved if it is co-administered with Angiotensin II and 
albumin microspheres. This is thought to be due to increased extraction of the drug by the 
tumour (Kerr et al 1991, Goldberg et al 1988,1990).
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1.8.3.2.3 Chemoembolisation toxicity
The side effects of embolic therapy differ from that of infusional therapy. The main toxicities 
are pain (60-100%), fever (50-90%), nausea (40%) vomiting and fatigue. Less commonly, 
cholecystitis (0-5%), gastritis (5-20%), abscess formation (5-10%) and renal failure (0-5%) can 
also occur. Most side effects resolve within 24-48 hours, although fatigue may persist for up 
to 3 weeks (Chuang et al 1982, Allison et al 1990).
1.8.3.2.4 Chemoembolisation using drug delivery systems
Drug delivery systems can be defined as any system which possesses the ability to target 
active molecules to specific sites in the body (Cummings et al 1993A). They allow drugs to be 
re-evaluated, many of which may have been unsuccessful, despite promising preclinical 
data, when given by the normal systemic route. The drug delivery system itself must be 
non toxic, and should not stimulate an immune response because this would prevent its 
repeated administration. It should, if possible, be a relatively non-specific system which 
would potentially allow the incorporation of different agents for the treatment of a variety of 
diseases. The drug delivery system must also be capable of delivering a therapeutically 
effective dose of drug to the target site without leakage or metabolism of the incorporated 
drug (Widder et al 1979). Furtliermore, the formulation and production of the delivery 
system must be practical.
The ideal drug delivery system has yet to be designed, but there are numerous systems 
available which attempt to incorporate some of the above properties into their design. For 
tire purposes of this thesis they can be divided into 2 main groups:
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1.8.3.2.4.1 Vesicular systems
These are drug delivery systems of a more fluid consistency which are given systemically. 
They are manufactured from various products which include liposomes, non-ionic 
surfactant vesicles, polymeric based drug carriers and antibody based therapies but, because 
they do not normally undergo chemoembolisation, they will not be considered further in 
this thesis. (For detailed reviews the reader is referred to Cassidy et al 1993, Cummings et al 
1993A).
1.8.3.2.4.2 Microparticulate systems
These are more rigid drug delivery systems which, following embolisation, release the 
cytotoxic agents which have been incorporated into their structure. They are only suitable 
for use in locoregional tlierapy. The two main types are microcapsules and microspheres.
i) Microcapsules
Microcapsules are vesicular-type structures in which a membrane encloses tire incorporated 
drug. EÜryl cellulose is the most widely used material for the membrane structure (Kato et al 
1980). They are large particles, over lOOprrr irr diameter and tlrey exert their' effect by a 
corrrbinatiorr of vascular embolism and prolonged drug release. Their main advantage is 
that, because of their structure, their level of drug errtrapment is very high (80% W /W  of 
drug). However, this drug load is released fairly rapidly compared to other chemoembolic 
agents and is largely complete witlrin 1-2 hours of microcapsule administration (Goldberg et 
al 1991D).
The microcapsules which have been most commonly utilised are tiiose containing MMC, as 
originally formulated by Kato, using the process of coacervation. This involves dispersing 
2g of MMC into a solution contammg 0.5g ethylcellulose, 0.5g polyethylene and 50mls 
cyclohexane at 80<^ C. The solution is stirred and allowed to cool to room temperature, then
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the microcapsules are washed and allowed to air dry before being sterilised. The 
microcapsules formed by this process have an average diameter of 224pm, and an irregular 
morphology. Approximately 84% of the MMC incorporated into the microcapsules is 
biologically active (Kato et al 1980).
Several clinical studies have been carried out using MMC microcapsules witli some 
promising results. In a study of 56 patients with a variety of tumour types, an overall 
response rate of 77% was obtained in terms of botli tumour reduction and symptom relief 
following locoregional administi'ation (Kato et al 1981). In a study of 30 patients with 
umesectable hepatocellular carcinomas who were treated with MMC microcapsules at a 
dose of 0.5mg MMC/kg, 43% of patients had either a complete or a partial response to 
treatment. Toxicity was minimal and the median survival was 7 montlis with a 36% 1 year 
survival (Audisio et al 1990). In anotlier non-randomised study of 32 patients with 
hepatocellular carcinoma treated with MMC microcapsules alone, a 35% response rate was 
documented (Sugita et al 1986).
Kato has collected data on 1013 patients who have been treated with microcapsules 
incorporating various drugs including MMC and cisplatin. A greater than 50% reduction in 
tumour size in 28% of 427 evaluable tumours was obtained with a median of 1 treatment, 
with MMC producing the best response rate. Systemic toxicity was rare with the most 
serious complications, as expected, being due to remote embolism of the particles. Two 
tliirds of those being treated with microcapsules for intractable pain or haemorrhage were 
noted to have a significant improvement in their symptoms (Kato et al 1996).
Pharmacokinetic analysis comparing 20mg of free intra-arterial MMC with the equivalent 
microcapsule dose was carried out in 6 patients with colorectal liver métastasés. The results 
showed tliat the peak plasma concentration was significantly lower when the MMC was
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given in microcapsules (m /c) compared with free MMC (free): (80±75ng/ml (m/c) v 
812±423ng/ml (free); p<0.05), whereas tlie plasma clearance (140±31 1/hour (m /c) v 46±8 
1/hour (free); p<0.05) and volume of distribution (246±23 1 (m /c) v 33±4 1 (free); p<0.05) were 
significantly higher. The plasma MMC half life was also prolonged (0.39 ± 0.03hours (m/c) v
0.11 ± 0.02 hours (free); p<0.05) in the patients treated with microcapsules. The 
pharmacokinetic results and the lack of systemic toxicity suggested dose escalation of the 
MMC microcapsules was possible (Goldberg et al 1991D, Eley et al 1992).
When a Phase I study was attempted in 15 patients, escalating the dose of MMC to 30 and 40 
mg in microcapsules did not increase systemic toxicity, but one third of the patients treated 
did experience significant local toxicity (3 developed pancreatitis and 2 developed 
gastroduodenal ulceration). This was probably due to local perfusion of these organs by the 
microcapsules (Anderson et al 1991 A).
Both of these studies reported considerable problems in administration of the microcapsules. 
Their tendency to clump together due to their hydrophobic surface properties, combined 
with their large size has made this a very difficult procedure. The local toxicity which was 
documented may have occurred because of backflow as a result of the pressure which was 
required for successful particle injection and this has limited further studies (Anderson et al 
1991A, Goldberg et al 1991D).
ii) Microspheres
Microspheres are solid porous structures which can be prepared by a variety of techniques 
including chemical stabilisation (Wilmott et al 1985), heat stabilisation (Fugimoto et al 
1985A), coacervation (Golumbek et al 1993) and multiple emulsion solvent evaporation 
(Okada et al 1994). The process which is utilised depends not only on the matrix material 
(albumin (Fugimoto et al 1985A, 1985B, Allan et al 1993), gelatin (Narayani et al 1994,1996),
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ti'ansferrin (Chen et al 1988) and chitosan (Nishxoka et al 1992)) but also on the drug which is 
to be encapsulated.
The method of microsphere preparation requires careful assessment in order to ensure that 
the encapsulated drug is not degraded or extensively cross-linked by the encapsulation 
process (Cummmgs et al 1985). When MMC is incorporated into albumin microspheres 
using heat stabilisation rather than chemical cross-linkage with gluteraldehyde, tliere is 
significant degradation of the MMC witlrin the microspheres which is temperature 
dependant, ranging from 37% of the MMC undergoing degradation at 120°C to 82% at 170‘^ C 
(Mehta et al 1988). The use of strong chemical cross-linking agents such as biacetyl can also 
result in complete degradation of the MMC within the microsphere (Mehta et al 1988).
Microspheres normally measure 10-50pm in diameter, their size being dependent on the 
method of preparation used. Selective intia-arterial administration is therefore the only 
practical route of administration as systemic therapy would result in entrapment within the 
lung. Targeting to an individual organ or tissue is referred to as "first order" targeting. In 
vivo studies with doxorubicin labelled microspheres have shown a high degree of "first 
order" targeting with 97% of tlie administered particles trapped in the kidney following 
intrarenal arterial injection and 93% of tlie particles trapped within the liver following 
hepatic arterial administr ation (McArdle et al 1988).
The use of vasoactive agents such as Angiotensin II can improve the degree of selectivity still 
furtlier by targeting microspheres to the actual tumour deposits within the organ. This is 
referred to as "second order" targeting. In a study of 9 patients with hver métastasés, the 
distribution of radiolabelled microspheres was studied botli before and after the 
administration of Angiotensin II. The results showed that prior to the administration of 
Angiotensin II, the number of particles present in the normal liver was greater than in the
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tumour deposits, but this was reversed following the administration of Angiotensin II witlr 
2.8 times the number of particles being found in the tumour compared to the normal tissue 
(Goldberg et al 1991A, 1991B). The use of substances such as Angiotensin II to try to 
hrfluence the pattern of microsphere distribution is referred to as "active" targeting.
1.8.3.2.5 The pharmacokinetic profile of microsphere encapsulated drug
The aim of locoregional therapy is to produce a high concentr ation of drug at the target site 
whilst minimising systemic exposure. This means Ürat microspheres must not only be able to 
target well, but must also be associated with a suitable pharmacokinetic profile. The 
therapeutic advantage of locoregional administration can be defined pharmacokinetically as 
a redistribution ratio (Rd) m terms of the degree of reduced systemic exposure versus the 
increased target organ uptake (Collins et al 1982) and can be expressed as follows:
(AUC target tissue)/(AUC plasma) microspheres
Redistribution = ---------------------------------------------------------------------
Ratio (Rd) (AUC target tissue)/(AUC plasma) free drug
Intra-arterial doxorubicin has been shown to have a therapeutic advantage of 1.5-2 when 
compared to intravenous doxorubicin administration (Eksborg et al 1985). In contrast, when 
doxorubicin-loaded microspheres were compared with free intra-arterial drug, the ratio was 
109 m favour of the microsphere group (Cassidy et al 1993). MMC-loaded microspheres 
administered by direct intiatumoural mjection demonstrated a redistribution ratio of 2,4 
when compared with free drug given by the same route. (Cummings et al 1994).
A pharmacokinetic study, which compared doxorubicin-loaded microspheres (20-40pm 
diameter and 1% w /w  drug loading) with free doxorubicin administered via the renal 
artery, showed a reduced peak plasma concentration with the microspheres compared to the 
free drug (16 ng/m l v 135ng/ml) as well as a reduced plasma AUC (20|xg/ml v 1400]Lig/ml).
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However, 1 hour after administration the renal concentration was greater in the 
microsphere-treated group compared to the free drug group (6.8pg/g v 4.5|ig/g), which 
suggested continued drug release had occurred within the microsphere group (Kerr et al 
1988).
Sprague-Dawley rats bearmg Walker 256 tumour in the liver were tr eated via tire hepatic 
artery witlr either doxorubiciir-loaded albumin microspheres or the free drug equivalent 3 
days after tumour implantation. The arrimais were culled at 7 days post-implantation and 
the tumours weighed arrd analysed. The mearr turrrour weight was found to be significantly 
lower hr tire doxorubicin-loaded microsphere group (0.45 ± 0.08g) compared to the free 
doxorubicin group (0.74 ± 0.12g) and the control group (1.01 ± 0.27g) (p<0.05). Fluorescent 
rrricroscopy demonstrated considerable amounts of doxorubicin remaining hr the liver of the 
microsphere group but not in the free drug group. This suggested that the slow release of 
doxorubicin from the microspheres may have beeir responsible for the improved antitumour 
effect which was seen (Goldberg et al 1992).
Limited pharmacokinetic studies have also been carried out using Mitomycin C- (MMC) 
loaded microspheres. The microspheres were similar in size to the doxorubicin microspheres 
(45± 8gm) with 5% MMC loading. Albino rabbits with VX-2 tumours growing on their hind 
leg were treated with MMC microspheres or tire free drug equivalent, delivered via the 
femoral artery. The half-life of the MMC-loaded microspheres was longer than that of the 
free drug (20 mmutes v 7-10 minutes). The drug was still detectable 6 hours after 
microsphere administr ation, while levels of free MMC were below the limit of detection by 2 
hours. In the corresponding survival studies, 50% of tire animals treated in the microsphere 
group had complete tumour regression, whilst in the free drug and control groups all the 
arrimais had progressive disease and died within 9 weeks of treatment (Fugimoto et al 
1985A).
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When MMC-loaded microspheres were compared with the equivalent dose of free MMC 
administered via the hepatic artery in Wistar rats, the concentration of MMC in the hepatic 
vein was constant for the first 2 hours in the microsphere-treated group, but was 
undetectable in the free drug group by 2 hours, which agam suggested tlrat prolonged drug 
release was occurrmg in the microsphere treated group (Fugimoto et al 1985A, 1985B). 
Histology of the heated livers confirmed that the microspheres had become happed in tlie 
hepatic arterioles and these were still detectable 2 weeks after adminishation. Necrosis in the 
hssue adjacent to tlie happed microspheres was also demons hated in the MMC microsphere 
group, but was not seen in the blank microsphere or free drug groups (Fugimoto et al 1985A, 
1985B).
Similarly, when MMC-loaded albumin microspheres were mjected into the hepahc artery of 
Donryu rats bearing the AH-272 tumour and compared with free MMC and blank 
microspheres, histological analysis confirmed that necrosis was present only in the group 
heated witli the MMC microspheres. The rats heated with the MMC-loaded microspheres 
also survived longer (21.9 days) compared with the group heated with free MMC (13.2 days) 
or the blank microsphere conhol group (9.6 days), though the numbers were small in each 
group (Morimoto et al 1989).
The concenhation of methohexate in the livers of dogs following inha-arterial injechon of 
metlrohexate-loaded albumin microspheres was also found to be greater than that seen 
following free drug adminishahon. Methohexate was shll detectable 20 days following 
adminishahon in the microsphere-heated group (0.2nmol/g), but not the free drug group 
which had undetectable levels of methohexate by tliis time point. Histology again confirmed 
happing of the microspheres within the hepahc arterioles (Feng et al 1993).
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1.8.3.2.6 The effect of microsphere encapsulation on drug disposition
Microspheres are capable of altermg a drug's disposition once it reaches the tumour. These 
observations were first made in the WAB/NOT rat bearmg the syngeneic undifferentiated 
mammary carcinoma Sp-107, following intratumoural injection of doxorubicin-loaded 
microspheres. (Intr atumoural injections are useful because they reproduce in a small animal 
tire effect of chemoembolised particles and permit drug disposition variables to be studied 
without interference from targeting variables.) This study suggested that the antitumour 
effect of the doxorubicin-loaded albumin microspheres was 5 times greater than the 
equivalent amount of free drug (Willmott et al 1987A). Wheir HPLC analysis of doxorubicin 
levels in boür groups was carried out, the concentration of doxorubicin in the micro sphere- 
heated group remained constant over a 72-hour period in conhast to the free drug group 
which showed a 5-fold decrease in doxorubicin concenhahon over the same time period. In 
addition, the microspheres appeared to stimulate bioreductive metabolism within the 
tumour, as determined by the presence of the 7-deoxglycone metabolites of doxorubicin (on 
HPLC analysis). These metabolites became detectable 16 - 24 hours after mjection, increased 
by up to 155-fold at 48 hours and were shll detectable 1 week later (Willmott et al 1987A, 
Cummings et al 1992A). This reachon was minimal in the free drug group and only 
happened in the microsphere group if the drug was actually incorporated into the 
microspheres prior to adminishahon. Free drug co-administered with blank microspheres 
did not stimulate bioreduchve metabolism (Cummings et al 1992A). Enzymahc studies have 
suggested that stimulahon of hie bioreduchve metabolism of doxorubicm is thought to be 
due to hie induchon of hypoxia produced by the microspheres and is mediated through the 
achvity of NADPH cytochrome P450 reductase (Cummings et al 1992B).
Further studies were carried out to determine whether the increased achvity seen wihr the 
doxorubicin-loaded microspheres was due to either hre sustamed levels of parent drug 
within the tumour or the shmulahon of bioreduchve metabolism. The studies showed that it
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was tlie proportion of the drug which was covalently complexed to the albumin matrix of 
the microsphere (via a molecule of gluteraldehyde) and which was slowly released as the 
microsphere was broken down, which was responsible for the enhanced antitumour activity 
(Cummings et al 1991). The bioreductive metabolism of the doxorubicm was shown to 
actually result in drug inactivation (Cummings et al 1992A, 1993B). Thus, although the 
doxorubicin-loaded microspheres have demonstiated greater antitumour activity than the 
equivalent amount of free drug, tliey are unable to take advantage of the hypoxic 
environment which is generated by the microspheres. Bioreductive drugs however might 
benefit from such an environment because it may enhance their activation.
MMC is regarded as the prototype bioreductive drug. Studies carried out by other groups, 
using encapsulated MMC either in microspheres or microcapsules, have demons tiated a 
degree of activity which is greater than for the free drug itself (Kato et al 1980, Fugimoto et al 
1985A, 1995B, Morimoto et al 1989). The method of preparation for these microspheres 
however has not been optimal, as the heat stabilisation process often used in their 
manufacture may result in a significant degree of drug inactivation prior to use (Mehta et al 
1988). Therefore a new method for the preparation of MMC microspheres was developed, 
which was based on a modification of the method used to prepare doxorubicin-loaded 
microspheres. This was carried out at room temperature using gluteraldehyde as the cross- 
linking agent. The resultant microspheres were found to have a mean diameter of 16.9|rm 
with drug loading of 1.2% (w /w ). Drug release was sustained over 20 hours with a burst 
effect (60%) apparent over the first 4 hours of drug release. HPLC analysis confirmed the 
presence of mtact drug with no significant degradation occurrmg as a result of tire 
microsphere preparation process (Allan et al 1993).
The pharmacokinetic parameters of the MMC-loaded albumm microspheres were 
determiired in NMRl mice bearmg the MAC 16 mouse adenocarcinoma of colon and
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compared with free drug given by direct intratumoural injection. Both methods of drug 
administi'ation achieved a similar level of total drug exposure as determined by the tumour 
AUC (46.9pg/ml/hr free MMC v 30.0|ig/m l/hr MMC microspheres). The pharmacokinetic 
profiles were otherwise different. The peak level of MMC in the tumour was lower in the 
microsphere-treated group (20.5|rg) compared with the free drug group (98.4gg). Peak 
plasma levels were also lower m the microsphere-treated group (2.34pg/ml) compared with 
tire free drug group (6.03|ig/ ml) (Cummings et al 1994).
However, anti tumour studies showed that the MMC-loaded microspheres had reduced 
antitumour activity compared with the free drug (The T/C  value (the percentage change in 
tumour volume compared to day 0 of the treated group divided by the percentage change in 
tumour volume compared to day 0 for the control group) for free MMC was 39% compared 
to a T/C value of 8% for the MMC-loaded microspheres). The metabohte 2,7- 
Diaminomitosene (2,7-DM) was used as an indicator of metabolic activation in tumour tissue 
in these studies because this metabolite can only be formed as a result of quinone reduction. 
Levels of 2,7-DM have been demonstr ated to correlate with cytotoxicity in human colon cell 
lines (Siegel et al 1990) and it has been shown to be a necessary prerequisite for the N-7 
alkylation of deoxyguanosines located in the major groove of DNA (Prakash et al 1993). 
There was a 3-fold inhibition of 2,7-DM production in the microsphere-treated group 
compared to the free drug group. This was associated with the production of a different 
spectra of metabolites in tire microsphere-treated group, which included elevated levels of 
the cis- and trans-hydro forms of 2,7-DM (Cummings et al 1994). The 1 electron reductases 
such as cytochrome P450 reductase, xanthine oxidase, and cytochrome b5 reductase result in 
the formation of metabolites such as tire cis- and trans-hydro forms of 2,7-DM, while the 2 
elecb'on reductases such as DT-Diaphorase result in the fornration of 2,7-DM. The altered 
pattern of metabolites seen followmg adminishation of the MMC-loaded microspheres
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suggested an alteration in enzyme activity had occurred which has a negative effect on 
antitumour activity (Cummings et al 1994).
Although MMC is regarded as the archetypal anaerobic bioreductive agent, its hypoxic 
cytotoxicity ratio as indicated previously is low (HCR= 2) (Adams et al 1992). Drugs with 
increased selectivity towards hypoxic cells such as E09 are more likely to benefit from the 
type of hypoxic environment which is generated by the microspheres. E09 is also an 
attractive drug to consider for locoregional therapy, because as indicated previously, it is 
likely that, whilst producing a high concentration of drug at the tumour site, systemic 
exposure and therefore toxicity would be minimised using this approach.
1.9 OUTLINE OF THESIS
The aims of the studies presented in this thesis were therefore to:
1. Encapsulate E09 into albumin microspheres.
2. Characterise the E09-loaded microspheres.
3. Determine the antitumour activity and the pharmacokinetics of the E09-loaded 
microspheres and to compare this with free E09 given by direct intratumoural injection 
in a variety of subcutaneous colon tumours.
4. Develop a clinically relevant method of testing the E09-loaded microspheres.
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CHAPTER 2
The encapsulation of E09 into human albumin
microspheres
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2 Chapter 2
2.1 INTRODUCTION
Microspheres are solid porous particles which can be manufactured from a wide variety of 
matrix materials. These have included proteins such as albumin (Fugimoto et al 1985A, 
1985B, Morimoto et al 1989, Allan et al 1993, Cremers et al 1994A, 1994B, 1994C, Feng et al 
1993), gelatin (Narayani et al 1994, 1996, Nastr'uzzi et al 1994), transferrin (Chen et al 1988) 
and caesin (Jayakrishnan et al 1994); polysaccharides such as starch (Ensminger et al 1985, 
Pfeifle et al 1985, Civalleri et al 1994, Teder et al 1995, Johansson 1996, Carr et al 1997, 
Hakansson et al 1997), chitosan (Nishioka et al 1992) and alginate and synthetic polymers 
such as glycolide and lactide (Ichiliara et al 1989, Dordunoo et al 1995, Hagiwara et al 1996, 
1997, Kumagai et al 1996). The primary function of the matrix is to protect the drug and to 
optimise its pharmacokinetic/pharmacodynamic profile. The material selected is important 
because it will determine the overall size and structure of the microsphere, its surface 
properties of charge and shape and its biodegradability, toxicity and antigenicity. It will also 
influence the mcorporated drug's enti'apment efficiency, release rate and overall stability 
(Chen et al 1994).
Albumin was first used as a matrix in the manufacture of microspheres in 1972 and remains 
the most widely used protein because of its many beneficial properties. These include high 
stability, biocompatability (Ratcliffe et al 1984) and biodegradability (Lee et al 1981), togetlier 
with the ability to tr ap, in a relatively non specific maimer, a wide variety of drugs (Kramer 
et al 1974). In common with tire other proteins, albumm possesses functional groups such as 
COOH and NHz, which form inter-molecular (albumin-albumin) covalent bonds during 
microsphere formulation. Albumm taken from different animal species produces 
microspheres with slightly differing physico-chemical properties (Egbaria et al 1992A,
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1992B). The concenti'ation of albumin used in microsphere preparation is important because 
it influences the final size of the microspheres and affects drug loading characteristics 
(Karunaker et al 1994).
Human albumin was selected for our microspheres because it is the least immunogenic in 
humans (Rhodes et al 1969). Like other types of albumm, it is also readily available, has 
excellent storage properties and can be used in several different types of microsphere 
manufacture.
Of the variety of methods available for microsphere preparation (For review see Yapel 1985, 
Chen et al 1994), émulsification is tire one which is most commonly utilised for the 
preparation of albumin microspheres. It involves the use of a disperse phase (the drug 
suspended in an aqueous polymer solution) emulsified in a water immiscible continuous 
phase (usually an oil) which is then stabilised using a surfactant, followed by cross-linkage 
of the newly formed particles. It is suitable for botli water soluble and insoluble drugs 
providing that the drug can be dispersed in the polymer solution.
Cross-linkage of the microsphere particles can be achieved in a variety of ways using heat or 
chemicals to form the cross-links. It has been shown that increasing the level of cross-linking 
alters the rate of particle biodégradation and the release of core material from the mati’ix 
(Arshady 1990). Heat stabihsation is the most commonly used method. This involves 
heating the albumm molecules to more than 100°C which allows self cross-links to form 
between the reactive groups on the polypeptide side chains of the molecules. The level of 
cross-linkage increases with an increase in the reacting temperature (Arshady 1990). The 
mam problem with this technique is that it can cause significant drug inactivation. This has 
been clearly demonstrated in the work by Mehta (Mehta et al 1988) who showed that heat 
stabilisation used in the manufacture of MMC microspheres actually resulted in degradation
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of the MMC ranging from 37% at 120°C to 82% at 170°C. The use of strong chemicals to 
produce chemical cross-lmkage such as biacetyl however can also result in complete 
degradation of the MMC within the particles (Mehta et al 1988).
Glutaraldehyde is the most commonly used chemical cross-linking agent and is the one 
utilised in our metliod. There is a little uncertainty as to the exact method by which the 
cross-linking occurs, but it would appear to involve tire lysine residues as these are the only 
molecules in the albumin sti'ucture which are actually modified in the presence of 
gluteraldehyde (Peters et al 1977). Agam, the degree of cross-linking, which will affect the 
properties of the microsphere, is directly proportional to the concentration of the 
gluteraldehyde present in the solution (Reddy et al 1990, Rubino et al 1993). This will be 
studied furtlrer during the development of the method for E09-loaded microspheres.
Human albumin microspheres, prepared using the émulsification metliod witli 
gluteraldehyde as the chemical cross-linking agent, have been extensively studied in our 
laboratory where tlie cytotoxic agents Adriamycin and MMC have been successfully 
encapsulated and characterised (Wilmott et al 1988, Cummings et al 1985, 1994, Allan et al 
1993). As discussed previously (Chapter 1.5.4), E09 was considered a rational choice to 
attempt to encapsulate into albumin microspheres. This was based not only on the problems 
associated with systemic administration of E09 (instability and dose limiting systemic 
toxicity), but also because E09 as a known bioreductive drug might demonstrate enhanced 
activity in an environment reduced in oxygen due to the chemo-embolic effect of the 
microsplieres themselves.
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2.1.1 Initial Experiment to Formulate E09 Microspheres
The procedure described by Allan et al 1993, for the formulation of MMC-loaded 
microspheres was used initially to attempt to encapsulate E09 into microspheres. This 
method of E09 microsphere preparation is outlined in Figure 2.1, the principle of which, as 
discussed above, is the cross-lmkage of albumm by gluteraldehyde during émulsification at 
room temperature. However, when this method was employed for E09, two main problems 
were identified:
1. When the microspheres were incubated with trypsin at 37°C, microsphere digestion did 
not occur, making subsequent analysis of the drug content of the microspheres difficult. 
It also raised concerns about how biodegradable the particles would be in vivo, as 
trypsin digestion of microspheres in vitro is thought to reflect in vivo biodegradability. It 
was felt that this might be related to the concentration of gluteraldehyde used in the 
cross-linking step because, the higher the concentration of gluteraldehyde used, the 
greater the degree of cross-links which can occur (Reddy et al 1990, Rubino et al 1993). 
Therefore, microspheres were prepared using a range of concentrations of 
gluteraldehyde and the effect of this examined both in terms of microsphere yield and 
particle biodegradability (using trypsin digestion).
2. The isopropanol wash step following microsphere preparation was associated with pinl< 
discolouration of the supernatant. E09 is pink, suggesting that there was drug loss from 
the microspheres and tlrerefore alternatives to the use of isopropanol as one of the 
washing steps in the preparation of the microspheres were assessed.
This chapter wiU describe the studies performed to investigate and correct these problems 
with the method being described which lead to the successful incorporation of E09 into 
albumin microspheres.
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Human serum albumin Fraction V (200mg) 
and E09 (5mg) were mixed with 900gl of 
5mM sodium phosphate buffer, pH 7.4 
containing 0.1% sodium dodecyl sulphate.
Disperse (aqueous) phase
40mls of cotton seed oil was mixed with 
60mls of petr oleum spir it.
O.Smls of sorbitol monoleate (Span 80) was 
added to aid the émulsification process.
Continuous (oil) phase
The continuous phase was mixed by a Silverson mixer at a speed of 1250 
r.p.m, using the emulsor screen attachment. The disperse phase was 
added to tire continuous phase, followed by lOOpl of a 22% 
gluteraldehyde solution (diluted to the appropriate concentration in 
distilled water) and émulsification carried out for 1 hour at room 
temperature.______________________________________________________
Emulsification Conditions
Washing and Preparation of the Microspheres
The stabilised microspheres obtained from this process were separated 
from the oil phase by centrifugation at 500 r.p.m for 5 minutes
Followmg resuspension in phosphate buffered saline (PBS)/0.5% Tween 
20, the microspheres were filtered through a 63 pm metal sieve (to 
remove any large clumps), allowed to dry at room temperature and tiien 
stored at 4°C. They were resuspended in PBS/0.5% Tween 20 prior to 
use.
The microspheres were washed 3 times in petroleum spirit, and once in 
isopropanol, each time centi'ifuging at 500 r.p.m for 5 minutes.
Figure 2.1 Flow chart outlining the method of Allan et al 1993, for the initial 
encapsulation of E09 into albumin microspheres.
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2.2 MATERIALS
All chemicals used were of the highest grade commercially available. These are listed, 
together with their suppliers m Appendix 1. Water was obtained from a Milli-UlO water 
purification system. All suppliers of the apparatus used throughout are also listed in 
Appendix 1. High Performance Liquid Chromatography (HPLC) analyses were performed 
using a Hewlett-Packard Model 1090 equipped with the following features; a PV5 ternary 
low pressure mixing solvent delivery system, a variable volume (10-250pi) automatic injector 
and autosampler, a heated column compartment and multidiode rapid scanning UV/Vis 
spectrophotometric detector. System control and data evaluation were performed using 
Hewlett-Packard Series 9000 300 "Chemstation" software.
2.3 METHODS
2.3.1 The Analysis of E09 by High Performance Liquid 
Chromatography
The stationary phase was a Li-Chrosorb RP-18 (7pm particle size) HPLC cartridge column 
(column dimensions 25cm x 4mm) and a LiChrospher 100 RP-18 (5pm particle size) 
precolumn (column dimensions 4mrn x 4mm) enclosed in a LiChrocart Manu-fix cartridge 
holder.
The mobile phase consisted of lOmM sodium phosphate buffer, pH 7.5, mixed with 
metlranol in a ratio of 76:24. Elution was isocratic at a flow rate of 1ml per minute with the 
oven temperature mamtained at 40°C. The mobile phase was filtered before use through a 
0.45pm filter for the metlranol and a 0.6pm filter for the sodium phosphate buffer and 
sparged continuously with helium throughout chromatographic analysis.
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Detection using a diode assay detector was at 280nm, close to the absorption maxima of both 
E09 and the hydrolysis product E05A (See Figure 2.2).
2.3.2 Effect of Process Variables on E09-loaded Albumin 
Microspheres
2.3.2.1 Gluteraldehyde concentration
The original method produced microspheres which failed to undergo digestion in the 
presence of tiypsin, making potential assessment of drug content in the microspheres 
difficult and raising concerns about the biodegradability of the particles in vivo (Chapter
2.1.1). This was thought to be related to the concentration of gluteraldehyde used in 
microsphere preparation, so microspheres were prepared as outlined above, but using 
different concentrations of glutaraldehyde in the cross-linking step. lOOpl of 22%, 11%, 
6.25%, 5.5%, and 2.5% gluteraldehyde solutions, prepared as previously described (Figure
2.1), were each compared for their effect on microsphere characteristics, which was 
determined in two ways:
a) The "yield" of microspheres: an approximation of the amount of filterable microspheres 
produced, which was assessed by visual inspection as being high, intermediate or low.
b) Microsphere digestion assessed by visual inspection and microscopy during a timed 
digestion witlr tiypsin using the following method: lOOpl of the final microsphere 
suspension was added to 2ml of 0.4%(w/v) trypsin in PBS solution containing penicillin and 
sti'eptomycin (500 units/ml) to prevent possible drug degeneration occurring as a result of 
bacterial overgrowtlr and incubated at 37°C for 4 and 16 hours. Digestion was graded as 
either complete or incomplete.
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Figure 2.2 Comparison of the UV/Visible absorption spectra of EOS and the 
hydrolysis product E05A.
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2.3.2.2 E 09  loss during the isopropanol wash
It had been noted that the supernatant following the isopropanol wash was pink suggesting 
premature release of E09 from the microspheres. No loss of E09 from the microspheres was 
detected in the preceding petroleum ether washes. In order to evaluate tiiis, HPLC analysis 
(outlined m Chapter 2.3.1) was performed using a 20pl aliquot of the total isopropanol 
supernatant and standard curves used to determine the amount of E09 present.
2.3.2.S Microsphere resuspension
Because of the apparent loss of E09 from the microspheres mto the isopropanol wash, 
experiments were performed where this step was omitted. However, removing the 
isopropanol wash resulted in increased difficulty in resuspending the microspheres prior to 
their use. Alternative metliods of particle resuspension were therefore investigated:
2.3.2.3.1 The effect of freeze drying on microsphere resuspension
The microspheres (both E09-loaded and blank) were manufactured as in Figure 2.1. After 3 
washes with petroleum ether the microspheres were allowed to dry at room temperature. 
They were then reconstituted m 1ml of ice cold PBS, snap frozen using solid carbon dioxide 
and methanol and freeze dried for 12 hours. The vacuum in these conditions results in the 
evaporation of water and solvent from tlie sample which reduces the requirement for 
multiple washes. After reconstitution in PBS/0.5%Tween 20, followed by filtering through a 
63pm sieve, the supernatant from the E09 and blank microspheres was obtained by vacuum 
filtration.
a) A lOOpl aliquot of the supernatent from the reconstituted E09 microspheres was taken 
and subjected to HPLC analysis in order to ensure that the E09 which had been
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mcorporated and subsequently released from the microspheres had not been adversely 
affected by the freeze drying process.
b) lOOpl of the blank microsphere suspension was taken following reconstitution and 
subjected to digestion for 16 hours at 37°C using tiypsin in order to ensure that the 
freeze-drying process had not altered the ability of the microspheres to undergo 
digestion, which may suggest altered particle biodegradability.
2.3.23.2 Reconstitution of the microspheres following freeze drying
a) Microsphere resiispension
Resuspension m PBS/0.5% Tween 20 was assessed as bemg sub-optimal following freeze 
drying. Therefore, other agents were assessed and compared with PBS/0.5% Tween 20. The 
microspheres were resuspended in 4mls of eiüier i) phosphate buffered saline (PBS), ii) 
lOmM sodium phosphate buffer (pH 7.5), iii) PBS with 0.5% Tween 20 or iv) PBS with 0.5% 
Tween 80. They were subsequently vortexed and filtered through a 63pm sieve. The amount 
of residue on the sieve was assessed and the microsphere sample was then analysed directly 
usmg light microscopy to mspect the degree of clumping and aggregation.
h) The ejfect of ultrasonication on microsphere resuspension
To improve microsphere resuspension further, the effect of ultrasonication was studied. The 
suspension of microspheres was divided into 2 aliquots (A and B). Ahquot A was sonicated 
for 3 minutes in an ultrasonic water batli and then filtered through a 63pm sieve. The 
amount of residue on the sieve was assessed and the microsphere suspension tlien mspected 
directly using light microscopy for the degree of clumping and aggregation. The sonicated 
samples were compared directly with microspheres which had not undergone the sonication 
process (Aliquot B).
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2.4 RESULTS
2.4.1 High Performance Liquid Chromatographic analysis of 
Indoloquinone E09
Using the HPLC analytical technique outlined in Chapter 2.3.1, E09 has a retention time of 
23-25 minutes with the hydrolysis product E05A eluting at the earlier time of 16-18 minutes 
(Figure 2.3). Each has a distinct UV/Vis absorption spectra. E09 shows UV absorption 
maxima at 268nm with a shoulder at 313nm and a visible absorption maximum at 505nm. In 
contrast, the spectia of E05A exhibits bathochromic shift (a shift in tire UV/Vis absorption 
spectr a towards longer wave lengths) in UV absorption to maxima at 280 and 321 nm and a 
batlrochromic shift hr the visible absorption maximum to 550nirr (Figure 2.2).
2.4.2 Effect of process variables on E09-loaded albumin microspheres
2.4.2.1 Gluteraldehyde concentration
a) Microsphere yield
A t  22% and 11% glutaraldehyde by volume, the highest yield of microspheres was seen 
(Table 2.1). At the lowest coirceirtiation of 2.5%, the amount of microspheres produced fell 
dramatically. This was accompanied by the presence of a large amount of iroir-filterable 
irraterial on the irrechairical sieve, probably occurrmg as a result of hradequate cross-lmkage 
of the albunrm by the glutaraldehyde, which results in partially formed microspheres and 
aggregated albumin particles.
b) Microsphere digestion
The lower concentrations of glutaraldehyde (2.5%, 5.5% & 6.25% by volume) produced 
microspheres which underwent complete digestion witli ti'ypsm withhi 4 hours at 37^C 
(Table 2.1). Digestion did not occur in the microsphere batches which used 11% and 22%
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Figure 2.3 Standard chromatographs of E09 and the hydrolysis product 
E05A.
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Glulcrnldehyde 
Percentage 
(lOO i^l ijohime)
Microspheie
Yield
Microsphcre tligeslioii after 4 hours 
incuhation ivith tnjpsin at .37*’C
22 +++++ No
11 +++++ No
6.25 +++ Yes
5.5 +++ Yes
2.5 + Yes
Key:
H—h+ +  +  
+ + +
+
high yield 
intermediate yield 
low yield
Table 2.1 The effect of gluteraldehyde concentration on a) Microsphere 
yield and b) Microsphere digestion with trypsin at 37°C.
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gluteraldehyde in their manufacture even after incubation with tiypsin for 16 hours.
The concentration of 6.25% by volume of glutaraldehyde was chosen for the final 
microsphere method because it produced a high yield of microspheres which were amenable 
to digestion with tiypsin.
2.4.2.2 Assessment ofEOQ loss during the isopropanol wash
The HPLC trace obtained from the isopropanol wash showed three apparent peaks with 
retention times of 18.6 mmutes, 20.6 minutes and 24.4 minutes respectively (Figure 2.4). The 
later peak had the same retention time and spectra as the E09 standard. Although the other 
2 peaks had different retention times, they had identical spectra to the E09 standard (Figure 
2.5). It was assumed that this was due to peak splitting of the parent compound as a result 
of the reduced solubility of E09 in tlie isopropanol. On the basis of this assumption, the 
total peak area was used to calculate the amount of E09 present in the isopropanol wash. 
Using a standard E09 curve, this was calculated to be 37% of the total E09 dose. This 
confirmed that significant loss of E09 was occurrmg and the isopropanol wash was 
therefore omitted from subsequent method development.
2.4.2.3 Microsphere resuspension
2.4.2.3.1 The effect of freeze drying on microsphere resuspension
After 12 hours of freeze drying the microspheres, a fine powder was obtained. These 
microspheres resuspended more readily and passed through the sieve more easily than 
those which had not undergone the freeze drying process.
76
EOS
16:
280 nm
2 0
Figure 2.4 Chromatograph of the isopropanol wash produced during the 
preparation of the EOS-loaded microspheres.
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Figure 2.5 Comparison of the UV/Visible absorption spectra of the 3 peaks 
found in the isopropanol wash produced during preparation of 
the EOS-loaded microspheres.
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a) HPLC analysis of the freeze dried E09-loaded microsphere supernatant
HPLC analysis confirmed that the retention times (Figure 2.6) and the spectra (Figure 2.7) of 
tlie E09 obtained from the freeze dried microspheres was identical to that of the freshly 
prepared E09 sample. A small amount of the hydrolysis product, E05A, was also identified 
but there was no evidence of any E09 metabolites. Assessment of the purity of the E09 peak 
obtained from the freeze dried microspheres using the Hewlett Packard "Chemstation" 
software confirmed a maximum possible purity factor of 1000. This was calculated by 
overlying the spectr a taken from different points on the chromatographic peak of the sample 
and comparing it with the original parent compound (Figure 2.8).
b) Biodegradability of the freeze dried blank niicrospheres
Complete digestion of tire freeze dried, blank microspheres occurred in the presence of 
trypsin at 37°C. HPLC analysis of the blank digest mixture was identical to that obtained 
using freshly made blank microspheres (Figure 2.9), which suggested that freeze drying had 
not affected microsphere cross-links or structure.
Freeze drymg also proved to be a suitable method for preparing the microspheres for long­
term storage. The microspheres were stored in this form at 4°C for up to 6 weeks. HPLC 
analysis of the supernatant of the resuspended E09-loaded microspheres confirmed that the 
drug payload remamed chemically intact throughout this period.
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Figure 2.6 Comparison of the chromatograph of the E09 standard with the 
E09 obtained from the freeze dried microspheres. In addition to 
E09, a small amount of the hydrolysis product, E05A, is 
identified in the microsphere sample.
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Figure 2.7 Comparison of the UV/Visible spectra of the E09 standard 
(MDGES.D) with the E09 obtained from the resuspended freeze 
dried microspheres (EOMSP009.D).
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Figure 2.8 The peak purity assessment of the E09 peak produced from the 
resuspended freeze dried microspheres. The peak is at the 
maximum purity level detectable by the HPLC "Chemstation” 
software.
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Figure 2.9 Chromatographs of albumin microspheres digested overnight 
with trypsin. Identical chromatographs are obtained for freshly 
prepared (A), and freeze dried microspheres (B).
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2.4.2.3.2 Reconstitution of the microspheres following freeze drying
a) Microsphere resuspension
Following freeze drying the microspheres resuspended poorly in PBS and phosphate buffer. 
There was increased residue on the sieve and a greater degree of aggregation seen on dhect 
microscopy. The two solutions which incorporated Tween products (PBS/0.5% Tween 20, 
PBS/0.5% Tween 80) produced improved microsphere resuspension with less residue on the 
sieve and less aggregation on direct microscopy, presumably because Üie Tween products 
help to emulsify any residual oil left on the microsphere surface. This experiment however 
failed to detect any difference between the two Tween products (Table 2.2 and Figure 2.10).
b) The effect ofultrasonication on microsphere resuspension
The effect of ultrasonication on microsphere particles resuspended in PBS/0.5%Tween 20 
and PBS/0.5%Tween 80 showed that tlie microspheres that had been sonicated for 3 minutes 
resuspended more easily, gave less residue on the filter and were less aggregated on direct 
microscopy tlian the unsonicated microspheres (Table 2.2, Figure 2.IOC and D, Figure 2.11).
The PBS/0.5%Tween 80 solution was found to be better than PBS/0.5% Tween 20 in 
resuspending the microspheres when sonication was used as part of the resuspension 
process.
2.4.3 Final Method of E09 Albumin Microsphere Preparation
The final method of E09-loaded albumin microsphere production, based on the above 
results, is outlined in Table 2.3. The characteristic appearances of blank and E09-loaded 
microspheres, which were prepared using this method, are identical under light microscopy 
and are shown in Figure 2.11B.
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iiesuspetuHug Agent Res iline on 
the sieve
Degree, o f nggregation 
On direct microscopxf
Degree o f  
aggregation post 
sonication
Phosphate Buffered 
Saline (PBS)
+++ +++++ nd
Sodium Phosphate 
Buffer (lOmM, pH 7.5)
+++++ +++++ nd
Phosphate Buffered 
Saline/0.5% Tween 20
-t- +++ ++
Phosphate Buffered 
Sahne/0.5% Tween 80
+ +++ +
Key;
+ + + + +
+ + +
+
nd
large residue/aggregation 
moderate residue/aggregation 
minimum residue/  aggregation 
not determined
Table 2.2 The effect of various resuspending agents and ultrasonication 
on microsphere resuspension.
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Figure 2.10 Direct comparison using light microscopy of freeze dried
microspheres resuspended in A) Phosphate Buffered Saline,
and B) 10mm Sodium Phosphate buffer (pH 7.4).
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Figure 2.10 Direct comparison using light microscopy of freeze dried
microspheres resuspended in C) PBS/0.5% Tween 20, and D)
PBS/0.5% Tween 80.
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Figure 2.11 Direct comparison using light microscopy of freeze dried
microspheres resuspended in A) PBS/0.5% Tween 20, and B)
PBS/0.5% Tween 80 after 3 minutes of ultrasonication.
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S tep M eth o d
1 200mg of human serum albumin (fraction V) and 5mg of E09 
were added to 900^1 of 5mM sodium phosphate buffer, pH 7.4 
containing 0.1% sodium dodecyl sulphate as the disperse phase
2 The continuous phase consisted of 40ml of cotton seed oil 
mixed with O.Smls of Span 80 (sorbitol monoleate) and 60mls of peti oleum
ether
3 The disperse phase was added to the continuous phase and émulsification 
carried out at 1600, 2000 or 2500r.p.m for 1 hour at room temperature. 
Stabilisation of cross-links was achieved by the addition of 100ml of a 6.25%
gluteraldehyde solution
4 The resulting microspheres were washed three times in petroleum ether, 
centrifuging each time at SOOr.p.m for 5 mmutes
5 The microspheres were vacuum filtered and allowed to air dry. They were 
then resuspended in 1ml of ice cold PBS and freeze dried for 12 hours 
before being stored at 4^ C^
6 Prior to use, the microspheres were resuspended in PBS/0.5% Tween 80, 
sonicated in a waterbath for 3 minutes and then filtered through a 63pm
metal sieve
Table 2.3 Final method for the production of E09-loaded albumin 
microspheres.
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2.5 DISCUSSION
The aim of this chapter was to develop a method for the successful encapsulation of E09 
into human albumin microspheres. The method previously developed m our laboratory for 
the encapsulation of MMC was used initially, not only because it has been well 
characterised, but also because it avoids tire use of heat or sti'ong chemicals for cross-linkage 
(Allan et al 1993). This is likely to reduce the risk of drug inactivation as a result of the 
encapsulation process which is important when chemically unstable drugs such as E09 are 
being considered for encapsulation.
When this method (Allan et al 1993) was adopted with substitution of MMC by E09, it was 
found to be sub-optimal and modifications were required in order to successfully 
encapsulate the E09. In retr ospect, this was perhaps not an unexpected outcome because 
E09, although a bioreductive drug and pharmacologically similar to MMC, has different 
chemical properties. Furthermore, the method of MMC encapsulation was itself derived 
from the original method used to encapsulate the anthracyline, Adriamycin, which 
suggested tlrat some modification would also be required for E09 (Wilmott et al 1988).
Trypsin is a very proteolytic enzyme which digests albumin into well characterised 
fragments. Incubathrg tire albumin microspheres with trypsin in vitro will therefore provide 
the best possible environment for microsphere digestion to occur. Failure of trypsin to 
digest the microsphere particles under these conditions suggests that the particles will be 
poorly biodegradable in vivo. Trypsin digestion is also useful as a means of preparing 
microspheres in a form which is amenable to analysis by HPLC. The use of HPLC in this 
situation will not only allow the chemical integrity of the drug to be assessed, but it will 
potentially also allow the total amount of drug which has been incorporated into tire
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microspheres to be determined. Incomplete digestion of the microsphere system is likely to 
result in inaccurate analysis of total drug content.
The inability of trypsin to digest the original microsphere particles was thought to be due to 
the high concentration of gluteraldehyde (12.5%) used in the cross-linking step. This was 
confirmed in subsequent experiments which assessed the effect of varying concentrations of 
gluteraldehyde on microsphere production and digestion. The highest concentration of 
gluteraldehyde did produce the highest microsphere yield, but failed to allow digestion of 
the microspheres by trypsin. Reducing tire gluteraldehyde concentration resulted m fewer 
microspheres being produced, but allowed digestion to occur, thus making HPLC analysis 
possible (Table 2.1). The final concentration of gluteraldehyde which was chosen (6.25%) for 
future experiments was therefore a comprise between tlrese 2 factors. It produced the 
highest yield of microspheres which underwent digestion in the presence of trypsin, thus 
allowing potential information on total drug content to be determined.
Isopropanol is important as one of the washing steps during microsphere preparation 
because it is miscible with both water and solvents and therefore provides a useful 
mtermediate step between the solvent and water-based washes. The problem with this step 
was that resuspending the microspheres m the isopropanol turned the isopropanol "pink" 
which suggested that there was rapid release of the E09 from tire microspheres into the 
isopropanol. This had not been a significant problem with the MMC-loaded microspheres, 
presumably because MMC is more water soluble than E09. HPLC analysis of the 
isopropanol wash confirmed this observation (Figure 2.4).
The isopropanol wash was removed from the method, which benefited the microspheres in 
terms of reducing the amount of drug lost during preparation (37% total E09), but resulted 
in significant problems in microsphere resuspension prior to mechanical filtering. It proved
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to be impossible to filter the microspheres when they had been resuspended in either 
petroleum etirer or PBS. This aggregation of particles may, in part, be caused by the presence 
of residual aromatic hydrocarbon chains from the petroleum ether on tire surface of the 
microspheres. Alternative methods of resuspendmg the microspheres were investigated.
Freeze drying was one of the first methods to be studied because freezing the particles in the 
presence of a vacuum may allow evaporation of the residual aromatic hydrocarboir chains 
pres err t on the microsphere structure. It was easy to carry out aird did not appear to have 
any adverse effect on either the E09 (Figures 2.6, 2.7 and 2.8) or the microspheres (Figure 
2.9). In addition to improving particle resuspension, it also proved to be a very useful means 
of preparmg the microspheres for storage. It was possible to store microspheres prepared in 
tliis way for at least 6 weeks at 4^0 without any loss of E09 activity.
Despite the improvement produced as a result of the freeze drying process, the microspheres 
still had a greater tendency to aggregate than when the isopropanol wash was included in 
microsphere preparation. Various resuspending agents were compared and the effect of 
ultrasonication compared on the most efficient agents. The most effective reconstitution was 
produced by the combination of resuspension m detergent in tire form of PBS/0.5% Tween 
80 (presumably because the Tween component helps to emulsify any residual hydrocarbon 
chains from the pet ether which may still be present on the surface of the microspheres) and 
3 mmutes of vigorous mechanical resuspension using ultrasonication (Table 2.2 and Figures 
2.10 & 2.11).
As a result of these experiments (summarised in Table 2.4), a new method for tire successful 
preparation of the E09-loaded microspheres has been developed and is outlined in Table 
2.3. The characteristics of these new microspheres, which will influence both drug activity 
and particle disposition, are described hr the next chapter.
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Problem Solution
Failure of microsphere 
Digestion using trypsin
Reduce Gluteraldehyde 
Concentration to 6.25%
Loss of E09 into Isopropanol wash Miss out Isopropanol wash
Aggregation of particles following 
Washing steps
Freeze Drying of 
particles
Aggregation of particles prior 
To utilisation
Resuspend in PBS/0.5% Tween 
80 combined with ultrasonication
Table 2.4 Summary of steps Involved in methods development of E09 
microspheres.
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CHAPTER 3
The characterisation of E09-ioaded 
albumin microspheres
9 4
3 Chapter 3
3.1 INTRODUCTION
In Chapter 2 the development of a metlrod for the successful encapsulation of the 
indoloquinone E09 into human albumin microspheres was described. The aim of the 
experiments which are discussed in this chapter is to study some of the characteristics of tire 
E09-loaded microspheres.
Microsphere characteristics are important because they not only influence the disposition of 
tire particles withitr the body, but they can also significantly affect the activity of the drug 
which has been incorporated (Chen et al 1994, Wilhnott et al 1987B). The microsphere 
properties which we considered to be importairt and which will be studied in this chapter 
can be summarised as follows:
1. Microsphere size.
2. Drug incorporation (drug payload).
3. Drug release rate.
4. Microsphere biodegradability.
5. The percentage of eircapsulated drug released from tire microspheres.
6. The retention of chemical integrity of the drug durmg and after the encapsulation 
process.
There are many inter-dependent factors which exert a significant influence on microsphere 
characteristics. These include the nature of the matrix material, the method of microsphere 
preparation, the physico-chemical nature of the drug and the ratio of drug to matrix 
material. It is not the place of this introduction to review each of these features in detail, as 
some of these factors are pre-determined, but they are summarised in relation to each of the 
above characteristics together with appropriate references in Table 3.1.
95
IO) 4-1yi
I
II i
Ibo
bo
bo
a  
B <
CD
8
■'g
1
2ra
JZo
î
JZ
wo
I
45
<U
O
bnj
E
E3(/}
<
CO
0)
.Qm
3.1.1 Microsphere Size
The size of tlie microsphere particles is important because following administi'ation their 
final location will, to a large extent, be determined by their size. This is shown in Table 3.2 
which relates microsphere size to final destination after intr avenous administration (adapted 
from Tomlinson et al 1983). Thus, in order to be suitable for locoregional administration via 
the hepatic artery, the particles need to be larger than 12pm so that they will remain trapped 
within the liver irr the first capillary bed they encounter and not pass into the systemic 
circulation. Size will also influence the particles' biodegradability and the release profile of 
the encapsulated drug. Passive targeting, which relies on inherent microsphere properties, is 
also heavily dependent on this particular characteristic.
One of the most important factors in determining the size and the size distribution of the 
microspheres (in addition to the matrix material which is utilised and the nature of the drug 
being encapsulated) is the method by which the microspheres are actually prepared (Table 
3.1). The émulsification process used in our method produces droplets, the size of which, 
will determine the size and range of the final particles which are produced. The size of the 
droplets is likely to be significantly influenced by the stirring speed of the mixer used in the 
émulsification method.
3.1.2 Drug Incorporation
The amount of drug which can be encapsulated into microspheres is usually expressed as 
tlie amount of drug per lOOmg of microspheres (w /w ). The aim in microsphere preparation 
is to tiy to encapsulate as high a drug content as possible in an attempt to maximise drug 
delivery to the tumour site. This is particularly important because there would appear to be 
physical limitations to the amount of microspheres which can be administered.
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Microsphere Size 
(/nn)
Destinntion
0.05 Spleen and bone marrow
0.1 -  2.0 Cleared from tlie blood str eam by the 
reticuloendothelial system
2.0 -  12 Trapped in the liver, lung and spleen
>12 Lodge in the first capillary bed 
encountered (chemoembolisation)
Table 3.2 The relationship between microsphere size and final destination 
following intravenous administration. 
(Adapted from Tomlinson 1983)
98
A dose of 350mg of blank albumin microspheres given via the hepatic artery was found to 
cause significant right upper quadrant pain in 85% of the patients treated, making 300mg the 
recommended maximum dose (Goldberg et al 1988). This clearly limits how much of the 
encapsulated drug the tumour site can receive and therefore, the higher the drug load, the 
more favourable the microsphere system is likely to be.
As expected, there are a number of factors which can influence drug loading, many of which 
are inter-related with other microsphere characteristics. Therefore, altering the drug loading 
capability of the microsphere system is Likely to result in an alteration in other characteristics 
such as the drug's release pattern and the stability, size and structure of the microsphere 
particles (Table 3.1).
3.1.3 Drug Release Rate
The rate at which the drug is released from the microsphere system affects tire concentration 
over time profile or exposure of the tumour cells to drug, which in turn influences the drug's 
overall effect. In vitro release of incorporated drug from microspheres is characteristically 
described as biphasic, with a fast initial release of drug known as the burst effect, followed 
by a slower second phase. It has been suggested by several groups that the initial burst 
effect of the drug may be the result of drug held loosely on the surface of the molecule being 
released and that the sustained release comes from particles which are trapped deeper 
within the microsphere (Gupta et al 1986, Reddy et al 1990). In the case of doxorubicin, a tri­
phasic model has been devised to represent its release profile from albumin microspheres. 
Firstly, native drug which is superficially located and loosely attached accounts for the initial 
burst effect which is seen in vitro. Secondly, native drug which is strongly, but not 
covalently bound to the microsphere matrix using forces such as ionic bonds, is slowly 
released by dissociation and is responsible for the sustained release seen in vitro. Thirdly,
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there is drug which is covalently bound to the albumin molecule via a molecule of 
gluteraldehyde. This is only released when the molecule undergoes biodégradation in vivo. 
Increasing the cross-links will therefore result in more drug being physically associated with 
the matrix material, thus resulting in a reduction in the burst effect and an increase in the 
drug available for release in the slower second phase (Chen et al 1994).
3.1.4 Microsphere Biodegradability
The biodegradability of the microsphere system influences the in vivo stability of the 
particles in terms of drug release rate as well as affecting the clearance of the microspheres 
from the body. For microspheres which are made of protein, the rate of biodegradability is a 
function both of the type of protein used for the matrix material and the incorporated drug, 
as well as the ratio of protein to drug and the amount of cross-linking agent used. Increasing 
the cross-linkage wül increase the length of time tlie particles remain intact in vivo, which 
will also influence the release rate of the encapsulated drug (Davis et al 1987).
3.2 MATERIALS
All reagents, equipment and suppliers used are listed in Appendix 1.
3.3 METHODS
3.3.1 Microsphere size measurement
The mean diameter of the microsphere preparations was determined using a Malvern 
Particle Sizer; Series 2600C witli a 63mm focal length and a 14.3 mm beam length. The 
instrument was calibrated with latex particles of known diameter prior to use. The freeze 
dried microsphere preparation was prepared and reconstituted using the final metliod
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outlined in Table 2.3, A small amount of filtered suspension was then added to 10ml of 
degassed PBS and placed in the cell of the particle sizer for analysis. Each sample was 
analysed 3 times. The sample data recorded included the particle size distribution and the 
50% size average. These recordings were determined for both E09-loaded and blank 
microspheres manufactured at 3 different Silverson mixer speeds (1600, 2000, 2500r.p.m). 
There were 4-6 samples analysed within each group and the average result for each group 
was determined. Statistical analysis was carried out using the unpaired students t-test.
3.3.2 The Assessment of Drug Content in E09-ioaded Albumin 
Microspheres
3.3.2.1 Trypsin digestion o f albumin microspheres
In order to determine the total amount of drug incorporated into the microsphere system, a 
known weight of microspheres were digested with üypsin as outlined in Chapter 2.3.2.1.b. 
lOOpl of tlie digest mixture which was obtained from each sample was then subjected to 
HPLC analysis using the method previously described in Chapter 2.3.1. The E09 
microsphere digest was compared with the blank microsphere digest.
3.3.2.2 Timed trypsin digestion o f E09-ioaded albumin microspheres
Preliminary HPLC results (section 3.4.2.1) failed to identify any E09 in the digest mixture, 
Üiough the hydrolysis product E05A was identified. The breakdown and hydrolysis of E09 
could either be the result of the microsphere preparation procedure or the digestion process. 
In order to determine during which of the two procedures E09 breakdown and hydrolysis 
was occurring, a timed trypsin digest was performed. lOOpl samples of a known weight of 
resuspended E09 microspheres were taken at 0, 30, 100, 150 and 240 minutes during the 
digestion procedure (section 2.3.2.1b), as well as at 24 hours, filtered if necessary (required 
during the early part of the procedure due to incomplete digestion) and then subjected to
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HPLC analysis as described in 2.3.1. The amount of E09 present at each time point was 
determined using previously constructed standard curves. Blank microspheres were 
compared with E09-loaded microspheres.
3.3.2 3 Factors affecting trypsin digestion o f E09-loaded albumin 
microspheres
The previous experiment (for results, see section 3.4.2.2) confirmed tlrat the encapsulated 
E09 underwent breakdown and hydrolysis as a result of the trypsin digestion procedure 
rather than as a result of the encapsulation process. In order to determine which of tire 
factors in the trypsin digest procedure were responsible for the hydrolysis and loss of E09 
tire following set of experirrrents were performed.
3.3.2.3.1 The effect of 37°C temperature on E09 stability
Img of E09 was dissolved in 10ml of phosphate buffered saline containing penicillin arrd 
streptonrycirr (500units/ml) to preveirt possible drug degeneration occurring as a result of 
bacterial overgrowth arrd placed in arr incubator at 37°C. lOOpl samples were taken at 0, 2, 4, 
6 arrd 18 hours, diluted 1 in 10 arrd lOOpl of the diluent subjected to HPLC analysis as 
outlined in 2.3.1. This was compared with an iderrtical sample placed at 4°C over the same 
time period.
3.3.2.3.2 The effect of gluteraldehyde on BOB stability
5mg of E09 was dissolved in 900pl 5mM sodium phosphate buffer containing 0.1% sodium 
dodecyl sulphate arrd irrcubated at 37°C with lOOpl of a 6.25% gluteraldehyde solution. lOOpl 
sarrrples were takeir at 0, 2, 4, 6 and 18 hours, diluted 1 in 100 hr the above buffer and lOOgl 
of the dilueirt subjected to HPLC analysis as outlirred in 2.3.1. This was compared with E09 
hrcubated under the same corrditions without gluteraldehyde.
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3.3.2.3.3 The effect of trypsin on E09 stability
Img of E09 was added to 2mls of phosphate buffered saline witli penicillin/streptomycin 
(500units/ml) containing 0.4% trypsin and the sample incubated at 37°C. Samples were 
taken and processed as outlined above (3.3.2.3.2) and compared witli E09 incubated under 
the same conditions without trypsin.
3.3.3 In vitro Release of E09 from Microspheres and Assessment of 
Drug Loading
In order to generate a release profile of tire incorporated E09 from intact microspheres and 
to examine its chemical integrity, a continuous "flow-through" system was employed 
(Cummings and Wilmott 1985). A known weight of freeze dried microspheres were 
resuspended in 4 mis of PBS/0.5% Tween 80 and immobilised on glass wool (2.0g) in a glass 
column (20cm x 3cm internal diameter). The column was eluted witli phosphate buffered 
saline, pH 7.4 at a flow rate of 7.0mls per hour using a LKB Broma 2120 Varioperspex 
Peristaltic pump. Fractions were collected at 30 minute intervals for 6 hours using a LKB 
7000 Ulti'orac Fraction Collector, HPLC analysis was carried out on a lOOpl aliquot from 
each fraction to detect and quantify E09 and E09 metabolites.
The amount of E09 in each sample was determined using previously constiucted standard 
curves to generate a drug release profile. Blank and drug-loaded microspheres prepared at 
mixer speeds of 1600, 2000 and 2500r.p.m were analysed and compared with free E09. Six 
samples of blank and E09-loaded microspheres were analysed for each mixer speed and the 
mean result and standard deviation calculated for each group. Statistical analysis was 
carried out using the unpaired students t-test.
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The entrapment efficiency, calculated as the amount of drug eluted through the column (in 
milligrams) in comparison to the original drug weight used and expressed as a percentage, 
was determined for each sample. The mean and standard deviation were again determined 
for each group.
The mean drug loading for each group was also calculated, being defined as the amount of 
drug present (mg) per lOOmg of freeze dried microspheres.
3.4 RESULTS
3.4.1 Microsphere Size Measurement
As discussed previously, the desired size for microspheres which could be potentially useful 
for hepatic arterial embolisation is greater tlian 12pm, so that they will remain trapped 
wiüiin the liver and not pass into the systemic circulation (section 3.1.1, Table 3.2). The 
median size of the E09-loaded microspheres manufactured at the lower mixer speed of 
160Or.p.m. was 19.9 ± 5.5pm (mean estimate of 50% particle size ± SD). This was 
significantly larger than the median size of the microspheres produced at tlie higher speeds 
of 2000r.p.m. (11.5 ± 0.8pm) and 2500r.p.m. (11 ± 1.6pm) (p < 0.05) (Figure 3.1, Table 3.3.). 
There was no significant difference in size between the particles produced at 2000r.p.m and 
2500r.p.m. Both of these speeds (2000 and 2500r.p.m) produced microspheres of which more 
than 50% were smaller than required and therefore will not be considered furtlier.
The addition of E09 to the microspheres did not appear to affect microsphere size. No 
significant difference was detected between the blank and the E09-loaded microspheres at 
each of the three mixer speeds.
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1.6 B 1.6 E 2.0 8  2.0 E 2.5 B 2.5 E
Mixer Speed o f  E 09  and blank microspheres ( x 1000 r.p.m.)
Figure 3.1 The effect of mixer speed (1600, 2000 and 2500r.p.m) on 
microsphere size. Comparison of the mean median size (±SD) of 
blank (B) and E09-loaded (E) microspheres. The E09-loaded 
microspheres produced at IGOOr.p.m were significantly larger 
(p<0.05) than the E09-loaded microspheres produced at 2000 
and 2500r.p.m.
1 0 5
Mixer Speed Microsphere
Type
Mean Median 
Size ±  Standard 
Deviation (/jm)
Mean Population 
Range (10-90%) 
±  Standard 
Deviation (um )
IbOn RPM 
(n=4)
Blank
Microspheres
17.8± 2.2 5.31 1.8 - 38.2± 7.4
1600 RPM 
(n=6)
E09-Ioaded
Microspheres
19.9± 5.9 5.912.1-41.9112.2
2000 RPM 
(n=4)
Blank
Microspheres
12.8± 1.3 5.01 2.1 - 25.81 9.2
2000 RPM 
(n=4)
E09-loaded
Microspheres
11.5± 0.8 3.81 0.6 - 20.413.3
2500 RPM 
(n=4)
Blank
Microspheres
14.1± 4.7 4.211.5 - 31.2111.5
2500 RPM 
(n=4)
E09-loaded
Microspheres
10.7±1.6 3.01 0.3 - 25.5110.1
Table 3.3 The effect of mixer speed on the size and population range of 
E09-loaded and blank albumin microspheres. (The results 
shown are the mean and standard deviation for each group 
where n = 4 or 6).
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All tliree mixer speeds produced a wide range of particle sizes with a biphasic disti'ibution 
(Figures 3.2 and 3.3). The peak at the smaller particle size appeared similar for all three 
speeds and is probably accounted for by partial cross-linkage of albumin particles as well as 
microsphere degradation products.
At 1600r.p.m approximately 70% of microspheres formed were larger than 12pm. Slower 
mixer speeds might be anticipated to give a greater yield of larger microspheres, but when 
this was attempted increased aggregation of the microspheres occurred which made them 
impractical for further use.
3.4.2 The Assessment of Drug Content in E09-loaded Albumin 
Microspheres
3.4.2.1 Trypsin digestion o f albumin microspheres
Comparison of tire chromatograms comparing 16-hour tiypsin digests of E09-loaded 
microspheres with blank microspheres (Figure 3.4) showed that the digests for each were 
virtually superimposable, except for a peak on the E09 microsphere digest at 20.52 minutes. 
The retention time and spectra of this peak was not that of E09, but the hydrolysis product 
E05A. Hence, there was no evidence of native E09 in the digest mixture foliowmg 
overnight incubation with trypsin. Repeated experiments confirmed this result which 
suggested that E09 was undergoing hydrolysis and breakdown either as a result of the 
encapsulation process or the digestion procedure. Subsequent experiments were performed 
in order to clarify the reason for the E09 breakdown and hydrolysis.
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Figure 3.4 Comparison of blank microsphere (A) and EOS-loaded 
microsphere (B) digests using HPLC analysis.
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3.4.2.2 Timed trypsin digestion of E09~loaded albumin microspheres
In order to determine whether intact E09 was present within the microspheres as digestion 
began, timed trypsin digests of E09-loaded microspheres were carried out. The results 
showed tiiat the amount of E09 present m the filtrate increased initially, being maximal 30 
mmutes into the digestion process, but thereafter drug levels began to fall and were absent 
by 24 hours (Figure 3.5). The fall in the amount of E09 was associated with the appearance 
and then increase in the hydrolysis product E05A (Figure 3.5).
The amount of E09 present within tlie digest at each time point was maximal at 30 minutes 
(Table 3.4). This could be considered a conservative estimate of the total amount of E09 
present in one batch of microspheres (approximately 1.25mg/100mg microspheres) because 
digestion of microspheres was incomplete at 30 mmutes and the formation of the E05A  
metabolite was already identified.
This experiment also confirms that free E09 present in the digest mixture was hydrolysed to 
E05A over time.
3.4.2.3 Factors affecting trypsin digestion o f E09-loaded albumin 
microspheres
The following experiments were carried out in an attempt to determine what factor in the 
digestion process was likely to be responsible for the hydrolysis and breakdown of the E09 
which had been observed in the previous experiments.
I l l
30 min
240 min 
24 hr
40’
30
2 0 E09
IV E05R V I
20 25
Figure 3.5 HPLC analysis of timed trypsin digestion of E09-loaded albumin 
microspheres which shows the loss of E09 and the appearance 
of E05A as digestion proceeds.
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T huefoilow iiig  commencement o f  
microsphere digestion using trypsin  
(minutes)
Total E 09  (mg^OOnig microspheres) 
determined from  the digest mixture 
using HP!.C analysis
0 0.60mg
30 1.25mg
1 0 0 1 .1 2 mg
150 0.74mg
240 0 .6 6 mg
24 hours O.Omg
Table 3.4 Assessment of the total amount of E09 present (mg) in the EOS- 
loaded microspheres as determined from HPLC analysis of the 
trypsin/microsphere digest mixture. (This is a representative 
sample from duplicate experiments).
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3.4.2.3.1 The effect of temperature (37°C) on E09 stability
The chromatogranis shown in Figure 3.6 confirmed tliat incubation in digestion solution 
(mmus trypsm) at 37°C resulted in the formation of a significant amount of the hydrolysis 
product E05A in comparison to mcubation at 4PC, whose chromatogram was similar to that 
obtained at 0 hours at 37°C. After 18 hours mcubation the amount of E09 had fallen to less 
than 50% of its original value (ti/2 = ~14 hours), with a simultaneous mcrease in tire amount 
of E05A present. No other significant degradation products were detected.
3.4.2.3.2 The effect of gluteraldehyde on E09 stability
When incubated at 37°C in phosphate buffer and 0.1% sodium dodecyl sulphate witli added 
gluteraldehyde, E09 did undergo hydrolysis to E05A, but the rate of hydrolysis was not 
mcreased compared to incubation at 37°C m phosphate buffer and 0.1% sodium dodecyl 
sulphate alone (Figure 3.7). Gluteraldehyde therefore did not significantly increase E09 
hydrolysis. No other degradation products were identified and there was no evidence of 
E09 complexation in the presence of the gluteraldehyde.
3.4.2.3.3 The effect of trypsin on E09 stability
The results showed that the amount of E09 fell significantly during an 18 hour incubation 
with trypsin at 37°C and that this was again associated with the formation of the hydrolysis 
product E05A (Figure 3.8), In comparison to incubation at 37"C alone (outlined in 3.4.2.3.1), 
in tire presence of trypsm, breakdown and hydrolysis appeared to occur more rapidly (ti/2  = 
~10 hours) with E05A being present at detectable levels as early as 2  hours compared to 6 
hours in the previous experiment.
114
16i BOB
14-
12 -
10 -
18hr
6hr
TimeO
0 5 15 2510 2 0 30
Figure 3.6 The effect of Incubation at 37°C on E09 stability as assessed by 
HPLC analysis at 0, 6 and 18 hours.
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Figure 3.7 The effect of gluteraldehyde on E09 stability at 37°C as 
assessed by HPLC analysis at 0, 6 and 18 hours.
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Figure 3.8 The effect of trypsin on E09 stability at 37°C as determined by 
HPLC analysis. Comparison at 0, 6 and 18 hours.
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These experiments demonstrated that tiypsin digestion of the E09-loaded microspheres was 
unlikely to be useful in accurately determining the drug content of the microspheres because 
the prolonged exposure at 37°C, in the presence of tiypsin, resulted in significant breakdown 
and hydrolysis of E09. Therefore, an alternative method of quantification of drug loading 
was required.
3.4.3 In vitro Release of E09 from Microspheres and Assessment of 
Drug Loading
The rate of drug release may vary between microspheres of different size and therefore, 
release profiles for the microspheres produced at 3 different mixer speeds were determined, 
together with the profile for free E09 (Figure 3.9). These data showed that there must be 
rapid release of E09 from the microspheres on washing, regardless of size, as the speed of 
transit of E09 through the column from the microsphere samples was not statistically 
significantly different from the free drug samples (p<0.05). E09 appeared to have been fully 
eluted from the column by 6 hours. HPLC analysis of the samples confirmed tliat tlie E09 
was chemically intact following it's release from the microspheres (Figure 3.10). E05A can 
be identified in low concentration in the samples, but there was no other evidence of 
significant drug degradation.
Entrapment efficiency (E09 eluted from column/ original weight of E09 used in 
microsphere preparation) was similar for each of tire mixer speeds; 36 ± 7% for 1600r.p.m, 35 
± 2% for 2000r.p.m, and 34 ± 3% for 2500r.p.m (Table 3,5). Drug loading (E09 eluted from 
the column/ weight of microspheres applied to column) was also similar for the 
microspheres manufactured at 1600r.p.m and 2500r.p.m at 1.24 ± 0.2mg/100mg and 1.4 ±
0.12 mg/lOOmg freeze dried microspheres respectively (Table 3.5).
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80
60
lâOOr.p.m. microspheres 
2000r.p,in. microspheres 
2500r.p.ni. miorospheres 
Free E09
40
20
0
0 100 200 400300
Time (minutes)
Figure 3.9 The cumulative release (mean ± SD, n = 6) of E09 from drug- 
loaded microspheres manufactured at 1600, 2000 and 2500 
r.p.m. Comparison with free E09.
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Figure 3.10 HPLC analysis of E09 released from the drug-loaded 
microspheres (B). Comparison with blank microspheres (A) and 
free EOS (C).
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SiivcrsoH Mixer 
Speed (R.PM ) 1600 2 0 0 0 2500
Eiitrapmenl 
Efficiency (%) 36 ± 7 35 ± 2 34 ±3
Drug Loading 
(tfig/1 OOwg microspheres) 1.24 ± 0.2 Nd 1.4 ± 0.12
Table 3.5 The entrapment efficiency (%) and drug loading (mg/100mg 
microspheres) of EOS-loaded albumin microspheres 
manufactured at 3 different mixer speeds (mean ± SD, n=6).
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3.5 DISCUSSION
The properties which are considered to be important in any drug delivery system and which 
require detailed consideration witii regard to the E09-loaded microspheres have already 
been outlined (see section 3.1) and include the following:
1. Microsphere size.
2. Drug incorporation (drug payload).
3. Drug release rate.
4. Microsphere biodegradability.
5. The percentage of encapsulated drug released from the microspheres.
6 . The retention of chemical integrity of the drug during and after encapsulation process.
3.5.1 Microsphere Size
The size and the size disti'ibution of the microspheres is significantly influenced by the 
method of microsphere production. Thus, the stirrmg speed of the mixer used in the 
émulsification process is likely to be important in determining the final size of the particles. 
This was confirmed in our experiments when microsphere sizes at three different mixer 
speeds (1600, 2000 and 2500r.p.m) were compared. The results showed tliat increasing the 
mixer speed did result in the production of statistically smaller microspheres (Table 3.3, 
Figures 3.1, 3.2 & 3.3). This agrees with others who have also shown an inverse relationship 
between mixer speed and microsphere size (Morimoto et al 1985, Reddy et al 1990, 
Anderson et al 1991B, Zeng et al 1994B).
No statistical difference was detected between the blank and E09-loaded microspheres for 
each of the mixer speeds which suggested that tire incorporation of this amount of E09 did 
not significantly affect particle size (Table 3.3, Figure 3.1). This corresponds with previous
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work carried out in our laboratory, looking at MMC-loaded microspheres, which detected 
no significant size difference between MMC-loaded and blank microspheres (Allan et al 
1993). It does however, contradict the work of Tomlinson and Zeng (Tomlinson et al 1985, 
Zeng et al 1994A) who found that drug incorporation did influence microsphere size. 
Perhaps this effect is related to the nature or the amount of the drug which is being 
incorporated rather than a general effect.
The amount of drug incorporated into the microspheres may influence the final particle size, 
especially if the amount approaches the limit of drug solubility in the disperse (aqueous) 
phase. In general, increasing drug loading tends to increase the overall size of the particles 
(Tomlinson et al 1985, Zeng et al 1994A). This was not investigated in our experiments but, 
if the amount of E09 was increased in an attempt to improve drug loading, the particles 
would need to be resized.
As indicated earlier (3.1.1), in order to be suitable for locoregional administration via the 
hepatic artery, the particles need to be greater than 1 2 pm in diameter so that tlrey will 
become trapped within the liver in tire first capillary bed they encounter. A study in a rabbit 
model, using 99mTc labelled doxorubicin-loaded albumin microspheres which were 15- 
40pm in diameter, confirmed that 97% of the microspheres were trapped in the kidney after 
renal artery injection and that 93% were retained in the liver after hepatic artery injection 
(Kerr et al 1988, McArdle et al 1988). A furürer study in Hooded Lister rats which looked at 
the administration via the gastroduodenal artery of radiolabelled albumin microspheres 
with mean sizes of 12,5, 25 & 40pm respectively, confirmed that the best tumour to hver ratio 
was produced by the larger microspheres, athough increasing size resulted in increased 
difficulty in administration (Anderson et al 1991 A). The E09-loaded microspheres produced 
at 1600r.p.m have a mean median size of 19.9pm and an 80% population range of 5.9 - 
38.2pm with approximately 70% of particles being greater than 12pm in diameter, which
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makes them the most suitable of all the E09-loaded microspheres produced using the 
present technique, for locoregional administration (Table 3.3).
3.5.2 Drug incorporation
The amount of drug which can be encapsulated into microspheres (drug payload) is 
important because of the physical limitations with regard to the maximum amount of 
microspheres which can be administered (Section 3.1.2, Goldberg et al 1988).
There were problems in attempting to determine the level of drug loading in our 
microspheres. The origmal plan had been to utilise a method which had been used 
previously in our laboratory to determine the drug content of MMC-loaded microspheres 
(Allan et al 1993). This involved digesting the drug-loaded particles at 37°C with tiypsin and 
then subjecting the digest mixture to HPLC analysis in order to determine the drug content. 
Unfortunately, when this method was applied to the E09-loaded microspheres, HPLC 
analysis failed to detect any E09 in the digest mixture (Figure 3.4).
Subsequent studies carried out to establish the fate of the encapsulated E09 showed that 
altliough E09 was initially present at high levels, it underwent hydrolysis and breakdown 
fairly readily (Figure 3.5 & Table 3.4). This was shown to be due to a combination of 
temperature (37°C) and the tiypsin itself (Figures 3.6 and 3.8).
The lack of stability of E09 at 37°C meant that this digestion method could not be used to 
determine the drug payload of the microspheres. The timed digest however, did produce an 
estimate for the amount of E09 present (1.25mg/100mg of microspheres). This is likely to be 
inaccurate botli because of incomplete digestion of the particles at this early stage (30 
minutes) and the development of tire hydrolysis product E05A which, in the absence of an 
available standard, is not quantifiable.
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An alternative approach to determining tire drug payload was to calculate tire amount of 
drug released hr each sample obtahred from the "flow through" system (see section 3.3.3). 
This method has the advantage of being carried out at room temperature which will 
mhrimise the degradation associated with higher temperatures. It will only give an 
indication of the amount of free drug present in the system, so it may still therefore be, in 
real terms, an underestimate because it will fail to detect any E09 complexed (if such 
complexes exist) to the albumin matrix which may become available in vivo when the 
microspheres are digested. HPLC analysis of tlrese samples confirmed that the released 
drug was chemically intact with very little in tire way of degradation being observed (Figure 
3.10). Therefore the "flow through" system, despite its problems, was felt to be more 
accurate than the previous method and was used to calculate the drug payload of the 
various E09 microspheres which were produced.
The drug payload did not seem to be significantly affected by the mixer speed with loading 
of 1.24 ± 0.2mg/100mg and 1.4 ± 0.2 m g/100 mg microspheres at speeds of 1600 and 
2500r.p.m. respectively (Table 3.5). These results were noted to be similar to those obtained 
usmg the previous digestion method (1.25mg/100mg microspheres).
E09 has not been encapsulated by any other group, tlrerefore direct comparison of the drug 
loading obtained using our method with others is not possible. As mentioned previously, 
our result does not take into account any drug which may be complexed to the albumin 
matrix, which may be important as this has been shown to occur when doxorubicin is 
encapsulated into albumin microspheres (Cummings et al 1991). The values obtained 
however are comparable to results obtained by other groups using a similar method. Allan 
obtained drug loading of 1 .8  ± 0 .1 1 % (w /w ) with an average entrapment efficiency of 2 0 % 
for MMC-loaded albumin microspheres (Allan et al 1993) and Chen obtained drug loading 
of 0.9 ± 0.28% (w /w ) for doxorubicm-loaded albumin microspheres (Chen et al 1988).
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MMC-loaded albumin microspheres prepared using a heat dénaturation method produced 
microspheres of 45 ± 8 pm with an increased drug loading of approximately 5% (Fugimoto et 
al 1985A & 1985B). Otirer MMC albumin microspheres formed by various heat dénaturation 
methods also lie within the slightly higher range of 1.7 - 4.6% (Natsume et al 1990). Although 
the drug loading of these MMC microspheres is higher, in vitro studies carried out to 
determine drug release using dialysis tubing and sonication showed that only 1 0 % of the 
incorporated drug was actually released in the first 24 hours and only 20% of the total 
mcorporated drug was released in the first 3 days (Fugimoto et al 1985A). The in vivo 
picture obviously may be slightly different with drug being released as the microspheres are 
biodegraded although studies using these microspheres have shown that they remain intact 
within the liver parenchyma up to 2 weeks following intrahepatic administration (Fugimoto 
et al 1985A & 1985B). This would imply that the actual amount of drug released is small and 
occurs over a prolonged time period. It should also be remembered that this method of 
microsphere preparation results in significant levels of drug inactivation (Mehta et al 1988).
Thus, although the level of drug loading calculated for the E09 microspheres is low when 
compared to other drug-loaded microspheres, it does represent the amount of chemically 
intact free drug which is actually released from the microspheres.
As mentioned previously, the payload is important because it will determine the maximum 
amount of drug which can be made available to the tumour due to the physical limits on the 
amount of microspheres which can be administered (300mg is the maximum recommended 
dose (Goldberg et al 1988)). Thus, if drug loading is in the region of 1-1.5%, it means the 
maximum amount of drug which can be given is 3-4.5mg. This is exemplified by 
doxorubicin-loaded albumin microspheres which have a payload of about 1 %, resulting in 
the maximum administration of 3mg of doxorubicin, a dose which is 20-40 times less than 
the normal systemic dose (Kerr et al 1991). The drug payload may be less important
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however if the drug disposition, as a result of the encapsulation process, is altered in favour 
of the microsphere system. Studies have shown that encapsulated doxorubicin undergoes 
altered metabolism due to the stimulation of quinone reduction which is probably a result of 
the hypoxia induced by the microsphere system (Willmott et al 1987A, Cummings et al 
1992A & 1992B). Unfortunately this has a negative effect on doxorubicin activity but, for 
bioreductive drugs such as E09, this effect may be beneficial and may result in increased 
activity despite lower levels of the drug being present.
In our method, because of time consti'aints, we only studied the drug loading obtained when 
one weight of E09 (5mg) was used in the preparation of the microspheres. It would be 
useful to know, particularly if tlie microspheres have antitumour activity, whether the drug 
payload could be increased if tire amount of E09 used in the initial stages was increased. 
This would mean more E09 could be administered for the same weight of microspheres. 
Re-characteristion of the microspheres in terms of particle size and drug release rate as well 
as tire level of drug loadmg would be required.
3.5.3 Drug Release Rate
The release of E09 from the loaded microspheres was also assessed using the "flow 
through" system outlmed in section 3.3.3. It has two main advantages over the normal 
dialysis method used by others: it offers haemodynamic features which are closer to the 
physiological situation in the body and it generates a differential release profile unlike 
conventional methods, thus revealing the iirti'hrsic release characteristics of the sustained 
release system.
Results from this study are similar for tire microspheres manufactured at the three different 
speeds. There is rapid drug release from the microspheres (Figure 3.9) with no significant
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difference between the microsphere samples and the free E09 samples. The release is 
therefore presumably predominantly a "burst" effect, which suggests that most of the drug 
is present at or near the surface of the microsphere and that there is little in the way of any 
binding to the matrix material.
By comparison with other microsphere systems, the E09 appears to be released more 
quickly from our microspheres. A similar system used by Allan for MMC-loaded 
microspheres showed that 60% of the encapsulated drug was released in the first 3 hours as 
an initial "burst" effect, followed by sustained release of the remaining drug over the next 17 
hours (Allan et al 1993). The difference seen may be due to tire different physico-chemical 
natures of the 2  drugs combined with the fact that less gluteraldehyde was utilised in the 
preparation of the E09-loaded microspheres.
In the manufacture of MMC microspheres using heat dénaturation methods, only 20% of tire 
encapsulated drug was actually recoverable aird this was shown to be slowly released in vivo 
in comparison to administration of free drug (Fugimoto et al 1985A). MMC is more water 
soluble than doxorubicm and has 3 chemically reactive groups which are unstable at acid 
pH. The high level of drug degradation which occurs using this method of manufacture 
(Mehta et al 1988) nray account for the low level of drug which was recovered.
HPLC analysis of the samples which were obtahred confirmed that the E09 which was 
released from the microspheres was chemically intact and that it remaiired so until release 
was complete. This compares well witlr MMC-loaded microspheres where 90% of the 
released drug released was chemically intact, with the remaining 1 0 % accounted for as the 
cis- and trans-hydroxy metabolites of MMC (Allan et al 1993).
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E09 is a drug whose mechanism of action is thought to involve cross-linking of DNA, single 
stiand breaks and the generation of reactive species capable of causing cellular damage 
(Bailey et al 1994, Walton et al 1991). Taking tliis proposed mode of action into account, the 
best way to utilise E09 is to maximise the peak concentiation of the drug rather than aim for 
prolonged delivery of a low dose of the drug as this is the method most likely to result in 
maximum cell damage. Prolonged release of small amounts of drug is unlikely to achieve 
tire same response because exposure of the cell to inadequate levels of the drug is likely to 
occur, particularly iir view of the unstable nature of E09. This is in contrast to doxorubicin, 
whose mode of activity involves the mhibition of tire enzyme Topoisomerase II. Continuous 
exposure of the cell to low doses of this drug is more likely to increase its activity because it 
will result hr prolonged enzyme hrhibition.
The E09 microspheres therefore appear to release the drug in a maimer which is more 
appropriate for the drugs' proposed mechanism of action and are more likely to produce an 
antitumour effect tlran if the drug was released in lower doses over a prolonged time period. 
This would appear to be confirmed in the recent clinical tiials which compared weekly 
schedules with higher dose, 3 weekly schedules of E09. The 3 weekly schedule had a 
significantly higher level of stable disease, than the weekly schedule, aitlrough it was 
associated with an increase in systemic toxicity (Pavlidis et al 1996).
3.5.4 Microsphere Blodegradabililty
The length of time the microspheres remain chemoembolised could potentially affect the 
drug release pattern, especially if part of the drug load is covalently attached to the mati'ix 
material, because this will be released as the microspheres are broken down. This is known 
to occur witlr doxorubicin-loaded albumin microspheres. Initial studies using these 
microspheres suggested that they had 5 times the level of activity of free drug and that
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active drug metabolism was still being recorded 1 week after their administration. Free drug 
given with blank microspheres did not have this effect. The use of radiolabelled doxorubicm 
revealed that it was the covalently bound fraction of the drug within the microspheres which 
was responsible for their sustained release properties. This fraction was slowly being 
released from the microspheres as they underwent biodégradation. The effect was shown to 
be dependent both on the amount of cross-linkage and the type of mati'ix material used 
(Cummings et al 1991).
It is difficult to determine from our studies whether any E09 is actually covalently bound to 
die matrix material, but it is thought that from the nature of the microspheres, any such 
levels would be low. Regardless of this however, tire chemoembolic effect of the 
microspheres remains important for a number of reasons:
Firstly, chemoembolism, by causing a reduction in blood flow is more likely to retain the 
drug at the required site of action, which should reduce the risk of systemic overflow and 
therefore toxicity. This has been shown using doxorubicin-loaded microspheres given into 
tire renal artery. When compared with free drug given by the same route, the drug-loaded 
microspheres had a reduced peak plasma concentration aird AUC aird air iircrease m the 
local renal drug concentr ation (Kerr et al 1988). This is likely to be of benefit for E09 as it 
nrearrs that the local drug corrceirtration will be iircreased without increasing the systemic 
drug concentratioir, which will minimise systemic toxicity.
Secoirdly, chemoembolism may also hrduce an hypoxic environment. This has beerr shown 
using doxorubicin-loaded albumin nricrospheres where stimulation of anaerobic quinone 
reductiorr has beerr denronstrated (Willmott et al 1987A, Curnmürgs et al 1992A & 1992B). 
This type of errvirorrmeirt is likely to be ideal for bioreductive drugs such as E09 where the 
preserrce of hypoxia could poterrtially increase the drugs' antitumour activity.
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CHAPTER 4
The antitumour activity of E09-ioaded 
albumin microspheres
131
4 Chapter 4
4.1 INTRODUCTION
E09 has been successfully encapsulated, chemically intact, into human albumin 
microspheres and these drug-loaded microspheres have now been formally characterised. 
The aim of this chapter is to assess the antitumour activity of the microspheres.
Several studies have been carried out using E09 which have demonstrated significant 
antitumour activity against a wide variety of solid tumour cell lines (Fitzsimmons et al 1996, 
Phillips et al 1992, Robertson et al 1994, Smitskamp-Wilms et al 1994, Walton et al 1992A). 
These studies have suggested that in aerobic conditions, cell lines which are high in the 
activity of the 2 electron reducing enzyme DT-Diaphorase are more sensitive to E09 than 
cell lines which have low levels of enzyme activity (Collard et al 1995, Fitzsimmons et al 
1996, Plumb et al 1994A, Smitskamp-Wilms et al 1994, Walton et al 1992A).
The role of hypoxia in the activation of E09 has also been studied by several groups. These 
studies have shown that cells with low levels of DT-Diaphorase activity demonstrate an 
increase in sensitivity to E09 under hypoxic conditions. Cell lines which have high levels of 
enzyme activity do not demonstiate tire same degree of hypoxic enhancement (Bando et al 
1995, Plumb et al 1994B, 1994C, Robertson et al 1994).
However, the information obtamed from the in vitro studies does not seem to translate 
directly into the in vivo situation. Both enzyme activity levels and antitumour activity 
appear to be different when the cells are grown as xenografts and treated with either 
intravenous or intr'aperitoneal E09. These studies have suggested that the correlation
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previously determined in vitro between antitumour activity and enzyme activity levels does 
not hold in vivo (Bibby et al 1993A, Collard et al 1995).
In view of these data, it was thought to be important to assess the drug-loaded microspheres 
in an in vivo tumour model rather than in vitro, because an in vivo method was likely to 
provide more relevant antitumour data. In vivo techniques are also a better way of assessing 
the activity of any potential drug delivery system.
The antitumour activity of the microspheres was therefore assessed in vivo in mouse models 
bearing four different tumour types. The microspheres were given by direct inti’atumoural 
injection rather than by the preferred intra-arterial administration because the size of the 
mice rendered intra-arterial administration impossible. Their antitumour effect was 
compared to that of the equivalent amount of free drug which was also administered 
intratumourally.
4.2 MATERIALS
All reagents, equipment and suppliers used are listed m Appendix 1.
4.2.1 Animal Models
4.2.1.1 Murine Tumour Models
The murine tumour model used was tire inbred NMRI mouse and the subcutaneously 
growing murine adenocarcinomas of the colon, MAC 16 and MAC 26 (original tumours and 
breeding pairs kindly supplied by Professor J.A. Double and Dr M.C. Bibby, Clinical 
Oncology Unit, University of Bradford, Bradford, U.K.). The mice were kept under standard 
laboratory conditions of heating and lighting, fed a standard mouse diet (RM3(E)) and were 
given access to water ad lib. The MAC tumours were maintained by passaging 1-3 mg of
133
viable tumour via a ti'ochar needle to animals weighing 25-30g. When tumours reached 
0.02-0.Icm^ (after 2-3 weeks), the animals were either randomised for experimental studies 
or sacrificed as a source of tumour material. Regular histological analyses of the tumours 
during their passage were carried out to confirm the consistency of their pathology.
4.2.1.2 Human xenograft tumour models
The xenograft model used was the N u /nu  mouse (originally bred at Imperial Cancer 
Research Fund (ICRF), London, supplied by Harlan UK Ltd or the ICRF Unit at Clare Hall, 
London) and the subcutaneously implanted human adenocarcinomas, HT29 and BE, 
established m-house from their respective cell lines. The BE cell line was kindly supplied by 
Dr Neil W. Gibson, Pfizer Inc, Crouton, USA via Dr Jane Plumb, CRC Department of 
Medical Oncology, Glasgow, UK. The N u /nu  mice were housed in Morden isolators, fed on 
RM3 (E) mouse diet tieated by irradiation and given free access to water. The xenografts 
were maintained by serial subcutaneous passage of 1-3 mg of viable tumour via a trochar 
needle to animals weighing between 20-25g. When tumours reached 0.02-0.1cm3 (after 4 
weeks for the HT29 and 6 weeks for tire BE), the animals were either randomised for 
experimental studies or sacrificed for collection of tumour material. Regular histological 
analyses of the tumours during their passage were carried out to confirm their pathology.
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4.3 METHODS
4.3.1 Dose Finding Studies to Determine Tumour Sensitivity to E09
4.3.1.1 Murine tumour model
MAC 16 bearing NMRI mice were randomised into 6 groups, each containing 7 or 8 animals, 
which were then treated by direct mtratumoural injection with 200pl of PBS/0.5% Tween 80 
containing 50, 75,125 or 250jig of free E09. The two contr ol groups were treated with either 
200pl of PBS/0.5% Tween 80 alone or received no treatment. Measurement of the tumours 
was carried out every second day for a total of 14 days. Tumour volume was determined by 
caliper measurement and calculated using the formula: 0.5 x length x widtlP. The animals 
were sacrificed once the study was complete.
Antitumour activity or growtlr delay, was calculated as the percentage increase/decrease in 
tumour volume compared to day 0:
Tumour volume (cm )^ Day X
--------------------------------------------  X100%
Tumour volume (cm )^ Day 0
The nrean, standard deviation and standard error were tlren calculated for each group, and 
results compared using the unpahed students t-test.
4.3.1.2 Xenograft tumour model
HT29-bearing N u /nu  mice were randomised into four groups, each containing seven 
animals, which were then treated as above with 200pl of PBS/0.5 % Tween 80 containing 
125pg, 250pg or 500pg of E09. The conti'ol group was treated with PBS/0.5% Tween 80 
alone. Measurements and antitumour activity were carried out and determined as above.
135
4.3.2 Assessment of the Antitumour Activity of E09-loaded Albumin 
Microspheres
4.3.2.1 Murine tumour model
MAC 16 and MAC 26 bearing NMRI mice were each randomised into six groups containing 
6-8 animals. The groups were heated as outlined in Table 4.1 by direct inhatumoural 
injection with 200pl of PBS/0.5% Tween 80 containing 250pg E09 (based on data from the 
dose finding studies (section 4.4.1)), E09-loaded microspheres containing the equivalent of 
125pg, 250|.ig or 500pg E09 (the amount of microspheres used calculated from the 
previously described drug loading studies (chapter 3.4.3)) blank microspheres or PBS/0.5% 
Tween 80 only. The microspheres were prepared as described in Table 2.3, but each batch 
was reconstituted in a different amount of PBS/0.5% Tween 80 so that tire E09 dose given 
did not affect the overall injection volume. Measurements were carried out and antitumour 
activity determined as described previously hr 4.3.1.1. Following completion of the study, 
selected tumours were removed for histological assessment as outlmed below (4.3.3).
For comparative purposes, the antitumour activity of E09 was also expressed as a 
percentage of the mean antitumour activity of the drug heated group/mean anhtumour 
activity of the conhol group (T/C) on day 14 (tire hme taken for approximately 3-4 tumour 
doublings (Double et al 1989)). The anhtumour achvity of 250pg of free E09 and the 
equivalent dose of E09-loaded microspheres were compared. The conhol groups for the 
free E09 and the E09 microspheres were PBS/0.5% Tween 80 and blank nricrospheres 
(resuspended hr PBS/0.5% Tween 80) respechvely. T/C eshmahon gives a "point" eshmate 
with no assessment made of the confidence in that eshmate and therefore its significance. In 
an effort to address this, the T /C  values were determined using three meürods which were 
then compared.
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Control Group rree E 0 9  ipg) L09-toadcd  
Micro spheres 
(Equivalent free E09)
PBS/0.5% Tween 80 125pg
250pg 250pg
Blank microspheres 500pg
Table 4.1 Outline of the treatment and control groups used to determine 
the antitumour activity of free E09 and E09-loaded 
microspheres when given by direct intratumoural injection in the 
murine and xenograft models. The injection volume in each 
group was 200pl and the vehicle was PBS/0.5% Tween 80.
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Method 1
The first method took the mean of tire treated group (T) and divided it by the nrean of the 
coirti'ol group (C) oir day 14,
Method 2
In air attempt to try to obtam more iirformatioir about the variability of the data, the means 
and standard deviations of each of the tieated and coirti'ol groups were calculated and then 
used to sinrulate 10000 irorirrally distributed T values and 10000 normally distributed C 
values usirrg the Minitab Release 11 programme. T/C  values and their confidence intervals 
were calculated from these. The results obtained for each group were then compared using 
the unpaired students t-test.
Method 3
In the third method, because there is no correlation between the treated groups and tire 
control groups and therefore no reason to divide any one T by any one C, the percentage 
tumour volumes from each of the treated group were taken and divided by each of tire 
tunrour volumes from the corrtrol group. This produced a larger sample of T/C values and 
a set of data from which the mearr, mediair and standard deviation could be obtained. The 
data however, were not normally distributed, so the results obtained for each group were 
compared using the Mann-Whitney test,
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4.3.2.2 Xenograft Tumour Model
4.3.2.2.1 BE xenograft
BE-beariiig N u /nu  mice were randomised into six groups each containing 5 or 6 animals. 
Each group was then treated as outlined in Table 4.1. Measurements were carried out and 
antitumour activity determined as above (4.3.2.1), except tliat the experiment was continued 
until day 21 (the time taken for 3-4 tumour doublings) before the animals were sacrificed. 
Histological analysis was carried out as outlined in 4.3.3, below.
4.3.2.2.2 HT29 xenograft
HT29-bearing N u/nu  mice were randomised into six groups containing 6 or 7 mice and 
treated as shown in Table 4.1. Measurements were carried out and antitumour activity 
determined as outlined previously (4.3.2.1). The animals were sacrificed at 21 days. 
Histological analysis was carried out as outlined in 4.3.3 below.
The experiment was repeated in this tumour type witlr identical controls, but using lower 
doses of free E09 and tlrerefore E09-loaded rnicrospheres, in an attempt to try to determine 
whether there was any difference in antitumour activity between the free drug and the 
nricrospheres. The doses used were 30pg and 60|.ig in the second experiment, and 75pg and 
lOOpg of E09 or the microsphere equivalent in the third experiment. Antitumour activity 
was measured in these experiments for 30 days, following which, the animals were 
sacrificed.
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4.3.3 Histological Preparation of Tumours Treated with E09-loaded  
Microspheres
Tumours were randomly selected from animals treated with the E09-loaded microspheres at 
the end of the previous experiments and following removal were fixed in 4% 
paraformaldehyde solution and then embedded in paraffin wax ready for sectioning. 
Tumour sections of approximately 3pm thickness were cut, mounted on non-coated glass 
slides and then stained with Haematoxylin and Eosin. Sections were examined using a Leitz 
Ortholux 11 microscope equipped with Leitz 10, 25, 40 and 100 objectives. Photographs 
were taken witlr a Wild Photoautomat MPS 45 camera and Fujichrome Velvia Daylight füm.
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4.4 RESULTS
4.4.1 Dose Finding Studies to Determine Tumour Sensitivity to E09
4.4.1.1 Murine tumour model
This experiment contained two possible control groups: a group which received no 
treatment and a group which received the corrtrol vehicle PBS/0.5% Tweeir 80. Although 
sorrre variability irr growth activity was seerr between the two groups, it was rrot statistically 
sigrrificarrt (p<0.05) (Figure 4.1). The PBS/0.5% Tweerr 80 group was choserr as the conhol 
for all future experimerrts because it was the vehicle which was used to resusperrd the 
microspheres prior to their use.
The growth curves using different doses of E09 are shown irr Figure 4.2. They suggest 
increasing arrhtumour achvity with irrcreasmg E09 dosage.
Wherr corrrpared with the corrhol group, usirrg the students unpaired t-test, there was 
sigrrificarrt growth delay at all hme points in tire group heated with 250pg of E09 (p<0.005).
The growtlr of the tumour in the group heated with 250pg E09 was also sigrrificantly 
delayed throughout the time course of the experiment when compared witlr the other 
heahnerrt groups of 125pg, 75pg arrd 50pg E09 (p<0.05). No sigrrificant differerrce in growtlr 
was detected between the groups treated with 125pg, 75pg arrd 50pg E09 and Hre conhol 
group durirrg the experimerrt.
The dose of 250pg of E09 was choserr for future experimerrts because this produced 
significarrt growth delay hr comparison to the conhol group.
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Figure 4.1 Comparison of control groups treated with either intratumoural 
PBS/0.5% Tween 80 or no treatment, on the subcutaneously 
growing MAC 16 tumour in NMRI mice. Each time point denotes 
the mean ± standard error (SE) for the group.
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Figure 4.2 Dose finding study to determine the antitumour activity of E09 
given by direct intratumoural injection, on the subcutaneously 
growing MAC 16 tumour in NMRI mice. Each time point denotes 
the mean ± standard error (SE) for the group.
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4.4.1.2 Xenograft tumour modei
The growtlr delay profiles for the different doses of E09 used in the experiment with the 
HT29 xenograft are shown in Figure 4.3. This shows that the three doses utilised all had 
significant antitumour activity in comparison to the control group. The highest dose of E09 
(SOOpg) produced the most significant results (p<0.0005 from day 7 onwards). The 125)ig 
and 250pg doses of E09 produced similar results which were statistically significant from 
day 11 onwards (p<0.05), when compared to the control group.
The growth delay profile in this experiment was different to that seen in the previous study. 
The initial increase in size of the treated tumours may be related to the extensive necrosis 
and formation of non-tumoural scar tissue which occurred following intiatumoural injection 
with E09 in this tumour type.
The dose of 250pg of free E09 was again chosen for future experiments because it resulted in 
a growth delay, which was significantly different from the control group during the 
experiment. It also allowed for comparison to be made with the murine tumour model.
4.4.2 Assessment of the Antitumour Activity of E09-loaded Albumin 
Microspheres
4.4.2.1 Murine tumour model
4.4.2.1.1 MAC 16 tumour
As for all the tumour types, no significant difference in growth delay was seen between the 
two control groups of PBS/0.5% Tween 80 and the blank microspheres resuspended in 
PBS/0.5% Tween 80 (Figure 4.4).
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Figure 4.3 Dose finding study to determine the antitumour activity of E09 
given by direct intratumoural injection, on the subcutaneously 
growing HT29 tumour in Nu/nu mice. Each time point denotes 
the mean ± standard error (SE) for the group.
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Figure 4.4 Comparison of the antitumour activity of the control groups 
(PBS/0.5% Tween 80 and blank microspheres) with free E09 
(250^g) and E09 (SOOpg)-loaded microspheres given by direct 
intratumoural injection, on the subcutaneously growing MAC 16 
tumour model in NMRI mice. Each time point denotes the mean 
± standard error (SE) for the group.
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In comparison to the contiol groups significant growth delay was detected in tlie free E09 
group (250pg) from day 7 onwards (p<0.05), which compares well with the initial dose 
finding study outlined in Section 4.4.1.1. The E09 microsphere group containing the 
equivalent of 500pg of E09, demonstrated significant growth delay from day 10 onwards 
(p<0.05) when compared to the contr ol groups. No significant growth delay was seen in the 
group treated with the equivalent of 125pg or 250|ig E09 in microsphere form.
There was a significant difference in antitumour activity detected between 250pg of free E09 
and tire E09-loaded microspheres containing 250pg E09 in favour of tire free drug at days 3, 
7 & 10 (p<0.05) (Figure 4.5). There was no significant difference however, at any time point 
between the airtitumour activity of free E09 (250pg) and the microsphere group containing 
tire equivalent of 500pg E09 (Figure 4.4).
These results suggest that the E09 microspheres do have antitumour activity and that the 
ti'end is towards increased activity as the dose of E09 in the microspheres mcreases (Figure 
4.6). However, in this model system, a higher dose of E09-loaded microspheres is required 
to produce an equivalent anti tumour effect to free E09.
4.4.2.1.2 MAC 26 tumour
The growth delay results for the MAC 26 tumour show that in comparison to the control 
group, free E09 (250pg) produced antitumour activity which reached statistical significance 
from day 7 onwards (p<0.05) (Figure 4.7). The equivalent dose of E09 (250pg) in the 
microsphere group failed to produce any significant antitumour effect. The higher dose of 
E09-loaded microspheres (500pg) had statistically significant activity detectable only at the 
end time point of the study (p<0.05).
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Figure 4.5 Comparison of antitumour activity of 250|ig free E09 with the 
equivalent dose of E09-loaded microspheres given by direct 
intratumoural injection, on the subcutaneously growing MAC 16 
tumour in NMRI mice. Each time point denotes the mean ± 
standard error (SE) for the group.
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Figure 4.6 Comparison of the antitumour activity of different doses of E09 
(125pg, 250pg, SOOpg) loaded albumin microspheress given by 
direct intratumoural injection, on the subcutaneously growing 
MAC 16 tumour in NMRI mice. Each time point denotes the 
mean ± standard error (SE) for the group.
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Figure 4.7 Comparison of the antitumour activity of free E09 (250|ig) with 
E09 (500|ig) loaded microspheres given by direct intratumoural 
injection, on the subcutaneously growing MAC 26 tumour in 
NMRI mice. Each time point denotes the mean ± standard error 
(SE) for the group.
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These results suggest that the free E09 has significant antitumour activity in relation to the 
MAC 26 tumour, but tliat tliis activity appears to be reduced when the drug is encapsulated 
into the microspheres.
4A.2.2 Xenograft tumour model
4.4.2.2.1 BE xenograft
There was a significant growth delay associated with the administi'ation of free E09 
compared to the control group from day 10 onwards (p<0.05) in the BE tumour (Figure 4.8). 
However, there was no significant difference in antitumour activity between the control 
group and either the 250pg or the SOOpg E09 microsphere group in this experiment.
These results demonstrate that free E09 also has significant antitumour activity in the BE 
tumour. However, when the drug is encapsulated into the microspheres this activity 
appears to be reduced.
4.4.2.2.2 HT29 xenograft
The initial experiment, which compared 250pg of free E09 with the equivalent of 250pg and 
125jLig of E09-loaded microspheres, showed significant antitumour activity in all three 
groups in this tumour type when compared with the control groups (p<0.005 at days 19 and 
21) (Figure 4.9). No significant difference however, could be detected between the free drug 
and the drug-loaded microsphere groups. Again, as in the dose finding study, there was an 
initial increase in tumour size in those groups treated with the E09 due to the necrotic effect 
of the drug on the tumour.
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Figure 4.8 Comparison of the antitumour activity of free E09 (250^ig) with 
E09 (SOOfig) loaded microspheres given by direct intratumoural 
injection, on the subcutaneously growing BE tumour in Nu/nu 
mice. Each time point denotes the mean ± standard error (SE) 
for the group.
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Figure 4.9 Comparison of the antitumour activity of 250|ig of free E09 with 
the equivalent dose of 125|ig and 250 i^g in E09-loaded 
microspheres given by direct intratumoural injection, on the 
subcutaneously growing HT29 tumour in Nu/nu mice. Each time 
point denotes the mean ± standard error (SE) for the group.
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The experiment was tlrerefore repeated using lower doses of botlr free and microsphere- 
loaded E09 m an attempt to try to determine the form in which tire drug was most active.
At mtratumoural doses of 30pg and 60pg of free E09 and tire equivalent dose of E09-loaded 
microspheres, no sigrrificarrt antitumour activity was detected throughout the time course of 
tire experimerrt when compared to the corrtrol groups (Figure 4.10).
At higher doses (75|iig and lOOpg) of free E09 arrd the equivalerrt dose of E09-loaded 
microspheres a definite arrtitumour effect was agahr seen (Figure 4.11). Wherr compared to 
blarrk microspheres, both tire free drug and tire E09-loaded rrricrospheres (75pg and lOOpg) 
derrronstrated sigrrificarrt arrtitunrour activity from day 7 orrwards (p<0.05), with the level of 
sigrrificarrce irrcreasmg towards the errd of the study. There was rro statistically significarrt 
difference be tweeir the free drug and its microsphere equivalerrt. There was also no 
sigrrificarrt differerrce hr arrtitumour activity betweerr the two doses (75pg and lOOpg) for 
either free drug or the microsphere equivalerrt.
These results show that the HT29 tumour is the most sensitive tumour type to E09. There 
was rro sigrrificarrt differerrce betweerr the free drug and tire equivalent amouirt given hr 
microspheres hr terms of arrtitumour activity.
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Figure 4.10 Comparison of the antitumour activity of 30^g and 60^g of free 
E09 with the equivalent dose of E09-loaded microspheres given 
by direct intratumoural injection, on the subcutaneously 
growing HT29 tumour model in Nu/nu mice. Each time point 
denotes the mean ± standard error (SE) for the group.
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Figure 4.11 Comparison of the antitumour activity of 75^g and lOO^g of free 
E09 with the equivalent dose of E09-loaded microspheres given 
by direct Intratumoural Injection, on the subcutaneously 
growing HT29 tumour model In Nu/nu mice. Each time point 
denotes the mean ± standard error (SE) for the group.
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4.4.2.3 Assessment o f antitumour activity using T/C (Tumour/Controi) 
estimates in each o f the tumour types
Method 1
The results of the T /C  estimates calculated from the mean percentage tumour volumes of 
tlie treated groups (250pg free E09 and the equivalent dose of E09-loaded microspheres) 
divided by tlie mean percentage tumour volumes of the control groups (PBS/0.5% Tween 80 
and blank microspheres) for each of tire tumour types are shown in Table 4.2. These results 
suggested that tire order of sensitivity of the tumour types differed between the free drug 
and the microsphere groups. In the case of the free drug, HT29 appeared to be the most 
sensitive (15%), followed by the BE tumour (27%) and the MAC 16 tumour (33%), with the 
MAC 26 tumour being the least sensitive (60%). In the microsphere groups, tire HT29 
tumour agam appeared to be the most sensitive (29%) followed by the MAC 16 tumour 
(58%) and the MAC 26 tumour (74%) with the BE tumour being the least sensitive (79%). 
The major difference between the two groups therefore appeared to be the change in the 
rankiirg of tire BE tumour. In addition, the E09-loaded microspheres appeared to be less 
active tiran the free E09 hr all four tumour types. The main problem with this method 
however is tirat the results do not give any indication of tire confidence intervals of these 
estimates, which made it difficult to determine whether the results held any real significance 
hr relation to each other.
Method 2
The results obtained using a method which simulated T/C values from 10000 T and 10000 C 
results based on the mean and standard deviation of each of the treated and control groups 
are outlined in Table 4.3. The simulated T and C values were normally distributed and the 
results from the students t-test show that when comparing the microspheres with free drug 
hr each of the tumour types, there was a significant difference only in the BE tumour 
(t=24.09; p<0.0001) in favour of tire free drug.
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Tuiiiour type A ntiiuw our acLivity (l/C) 
TrceEOQ
Antitum our activ ity  (1/C) 
E 09 microspheres
HT29 15% 29%
BE 27% 79%
MAC 16 33% 58%
MAC 26 60% 74%
Table 4.2 Comparison of antitumour activity T/C values (tumour/control 
volumes) for free E09 and E09-loaded microspheres in each of 
the 4 tumour types, calculated by dividing the mean percentage 
tumour voiume of the treated group with the mean percentage 
tumour volume of the control group.
(For the free E09 the control group is PBS/0.5% Tween 80. For the 
EOQ-ioaded microspheres the control group is blank microspheres 
resuspended in PBS/0.5% Tween 80).
158
Tumour FreeF.09 E 0 9  Microspheres
Type Mean Median ‘ s m ^  m Mean Median STM
HT29 6 14 17 I p 33.1 29.8 0.4
BE 34.4 27.4 1.9 W 81 78.5 0.5
MAC 16 30.9 27 8.2 € 53.9 40.6 17.2
MAC 26 104 58 ...... -153 74 242
Table 4.3 Comparison of antitumour activity (T/C values) of free and E09- 
loaded microspheres using the simulated data based on the 
mean and standard deviation of each of the treated and control 
groups for each of the tumour types. The number of simulations 
in each group is 10000.
(SEM = standard error of the mean)
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There was no significant difference between each of tire tumour types treated with the free 
drug using the unpaired students t-test. In comparmg the effect of the drug-loaded 
microspheres, there was a significant difference in activity only between the HT29 and the 
BE groups in favour of the HT29 group (t=-68.62; p<0.0001). However, several of the 
standard deviations for the means which were used for the simulation, particularly the MAC 
26 microsphere group, were large, which gave huge distributions for simulated T /C  values 
and in the case of the MAC 26 microsphere group, a negative simulated mean value. 
Therefore, meaningful statistical analysis of tlrese results was probably not possible.
Method 3
The results outlined in Table 4.4, produced a series of T/C  values by dividing each of the 
treated values by each of the control values in each group. These T /C  estimates were not 
normally distributed so data could not be compared using the students t-test. Therefore the 
Mann-Whitney test was employed. This showed a significant difference in results when 
comparing the free drug with the microspheres in both the BE tumour and the MAC 16 
tumour, in favour of the free drug (p<0.05). Similarly, when comparing the effect of free 
E09 between each of the four tumour types, there was significantly increased antitumour 
activity in the HT29 tumour compared with the MAC 26 tumour (p<0.05), the MAC 16 
tumour compared to the MAC 26 tumour (p<0.05), and the BE tumour compared to the 
MAC 26 tumour (p<0.05). In the case of the E09-loaded microspheres, there was a 
significant difference between the HT29 and all the other tumour types (p<0.05) in favour of 
the HT29 tumour, but not between any of the other groups. These results were similar to 
those obtamed using the first method, in that when free E09 was used tire MAC 26 tumour 
was much less sensitive than the other three tumour types and when the E09 microspheres 
were used, HT29 was much more sensitive than the other three tumour types.
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Tfiinoiir Tree E 09 E 09  Microsphejvs
Type Median Number in 
Sample
Median Number in 
Sample
HT29 23.2 24 229 49
BE 31.7 20 78.1 20
MAC 16 31.4 35 109.3 35
MAC 26 63.1 15 70.4 15
Table 4.4 Comparison of the antitumour activity (T/C) values for free E09 
and E09-loaded microspheres in each of the tumour types 
obtained by dividing each of the treated values by each of the 
control values in each group.
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The results obtained with the simulated data were compared with the results outlined in the 
previous paragraph and plotted in a boxplot which used the median values with 25% 
percentiles on either side of the median value (Figure 4.12). This plot shows that there is a 
good similarity between the 'real' data and the simulated data when the median values are 
compared, except in the MAC 16 microsphere group.
4.4.3 Histological Preparation of Tumours Treated with E09-loaded  
Microspheres
The results were similar for each of the 4 tumour types and therefore only the HT29 and BE 
tumours are shown (Figures 4.13 and 4.14). In comparison to the tumours treated with 
PBS/0.5% Tween 80, an increase in the number of inflammatory cells and str omal tissue was 
seen m the tumours treated with the E09-loaded microspheres which was particularly 
pronounced in tire FIT29 tumour. The microspheres were still clearly visible 2 weeks 
following the intratumoural injection in botlr tumour types. Some disruption of the normal 
architecture of the tumour was also seen witlr loss of tumour cells in the areas of the tumour 
which were adjacent to the microspheres.
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Figure 4.12 Boxplots of simulated T/C data compared with the “real” data 
from Method 3 for free E09 and E09-loaded microspheres in 
each of the four tumour types.
(M = E09-loaded microspheres, F = free drug, S = simulated data,
D = real data)
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Figure 4.13 Comparison of the histology of the HT29 tumour grown 
subcutaneously in the Nu/nu mouse, 14 days following 
intratumoural injection of 200|il of A) PBS/0.5% Tween 80 and B) 
250pg E09-loaded albumin microspheres. The microspheres are 
clearly visible in the upper half of Slide B.
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Figure 4.14 Comparison of the histology of the BE tumour grown
subcutaneously in the Nu/nu mouse, 14 days following
intratumoural injection of 200|il of A) PBS/0.5% Tween 80 and B)
250|ig EOS-loaded albumin microspheres. The microspheres 
are clearly visible on the left hand side of Slide B.
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4.5 DISCUSSION
The aims of the studies described in this chapter were to investigate the anti tumour potential 
of the E09-loaded microspheres and to compare the effect of these drug-loaded 
microspheres with the equivalent amount of free drug when given by direct intratumoural 
mjection.
The models which have been utilised in this study are the well-established murine 
adenocarcinomas of colon, MAC 16 and 26 and tlie human colonic xenografts HT29 and BE. 
These were particularly useful models to study because some information was already 
available usmg E09 m these tumour types both in vitro and in vivo, thus allowing for 
comparison of our results. They were also appropriate because of the potential clinical use 
of tlie microspheres as a locoregional treatment hi the management of liver metastasis from 
colorectal cancer.
The MAC tumours have been well described by others (Cowan et al 1980, Double et al 1978, 
1989, Bibby et al 1988, 1989). They are similar to human colon tumours m that they exhibit 
varying histological characteristics and are active mucin producers. The spectrum of 
cheinosensitivity of these tumours has also shown good correlation with the response rates 
to standard tlierapeutic agents in colon cancer (Ball et al 1975, Double et al 1975). MAC 26 is 
well differentiated, well vascularised and has a relatively slow doubling time of around 4.5 
days. MAC 16, on the other hand, is poorly differentiated, poorly vascularised and necrotic 
and its growth usually associated with marked cachexia and weight loss in the host. MAC 
16, probably due to its poorer blood supply, is usually less responsive to cytotoxic therapy 
(particularly alkylating agents), than the MAC 26 tumour (Double et al 1989).
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Less information is available with regard to the HT29 and BE xenografts, particularly the BE 
xenograft, which were both established in-house as subcutaneous xenografts from their 
respective cell lines.
The intratumoural route for delivery of drug or microspheres was the chosen method of 
administi'atioir for these experiments. This method has previously been successfully 
employed m our laboratory (Cummings et al 1991, 1992A, 1992B, 1993B, 1994, Chirrey et al 
1995, Willmott et al 1987A). It was chosen because in small rodents it reproduces as closely 
as is technically feasible, chemoembolised particles and tlrus allows a study of drug 
disposition parameters to be made without mterference from targeting variables (Cassidy et 
al 1993). Furthermore, previous studies which have used systemic E09 have failed to detect 
E09 or metabolites within the treated tumour (Workman et al 1992C). This may be related 
to the known instability and short half life of the drug, which makes it difficult to determine 
whether the tumour has actually been exposed to adequate doses of the drug before it is 
metabolised. Therefore direct mti'atumoural injection should ensure that the tumour is 
exposed to the drug and should allow for detection of both drug and metabolites in 
subsequent pharmacokinetic studies (See following chapter).
Dose finding studies in the MAC tumours and the xenografts were carried out prior to the 
formal antitumour studies so that a dose of E09 would be utilised in these experiments 
which would allow for the observation of either an increase or decrease in response when 
the microspheres were compared with free drug. To account for any change which could be 
caused by the general distension and cellular destruction of the tumour as a result of the 
mjection volume, the same volume of the vehicle, PBS/0.5 Tween 80, was chosen as the 
control group for each of the studies.
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The HT29 tumour, as expected, was the most sensitive to both free drug and drug-loaded 
microspheres with significant anti tumour activity being detected at lower drug 
concentrations tlran in the other tumour types. It was also the only tumour to show no 
significant difference in anti tumour activity between free E09 and the equivalent dose of 
E09-loaded microspheres, which suggested that the tumour was equally sensitive to both 
methods of drug presentation. MAC 16 was also found to be sensitive to both free drug and 
microspheres. However, a higher dose of the microspheres was required to produce a level 
of anti tumour activity which was comparable to that of the free E09, which suggested that 
tire microspheres were less active than the free drug in this tumour type. In the MAC 26 
tumour, free E09 demons tinted statistically significant antitumour activity from day 7 
onwards. No significant antitumour activity was detected with tire equivalent dose of 
microspheres, although the higher dose (500pg) of microspheres did demonstiate activity by 
the end of the study. This suggested that the drug-loaded microspheres were again less 
active than the free drug hr this tumour type. Significant antitumour activity was only 
detected hr the BE tumour when free E09 was utilised, but not at any of tire microsphere 
doses which were admhristered.
The degree of sensitivity of each of the tumour types to E09 was also expressed as a 
percentage of the mean drug treated tumour volume/mean control tumour volume (T/C ). 
To facilitate statistical comparison, three methods were used to calculate T/C. The simplest 
method, which divided the mean of the treated group by the mean of tire control group, 
results of which are outlined hr Table 4.2 for both free drug and drug-loaded microspheres, 
suggested that the degree of sensitivity to E09 depended on the method of presentation of 
the E09. In the case of the free drug, the HT29 tumour was the most sensitive (15%) with the 
MAC 26 tumour being the least sensitive (60%). The HT29 tumour also appeared to be the 
most sensitive (29%) to the E09-loaded microspheres with the BE on tlris occasion appearing 
tire least sensitive (79%). However, tlrese results gave no indication of the degree of
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confidence which could be placed in this data, especially as the spread of the results in all 
the groups was known to be wide. The otirer two statistical methods were therefore 
employed to try to take this into account.
The second metliod, which took the mean and standard deviation of the treated and contr ol 
groups and simulated 10000 T and C values, allowed comparisons between the groups to be 
made usmg the unpaired students t-test. These results suggested that in each tumour type 
there was no statistically sigirificant differeirce m anti tumour activity between 250jLig of the 
free drug and tire equivaleirt dose of E09-loaded microspheres, except iir the BE tumour 
where ti'eatiirg with the microspheres appeared to result hr a loss of antitumour activity. It 
also suggested that there was no real difference in airtitumour activity between each of the 
tumour types wlreir free drug activity was compared following intratumoural 
administration. When the drug-loaded microspheres were compared in each of the tumour 
types, tire only difference in activity was between the BE and HT29 tumours hr favour of 
increased antitumour activity in the HT29 tumour. However, the simulation of 10000 values 
gave huge distributions of T /C  values and therefore meanhrgful statistical analysis was 
probably not achieved.
In the third method, where all measured T values were each divided by all measured C 
values, the data were not normally distributed and therefore had to be analysed usmg the 
Mamr-Whitney test. This showed that, as for the simulated data, there was a significant 
difference hr activity in the BE tumour between the free drug and the microspheres in favour 
of tire free drug. It also showed that there was a difference hr activity hr the MAC 16 tumour 
agam m favour of the free drug. These data also suggested tlrat there was a sigirificant 
difference hr activity between the MAC 26 tumour and the other three tumour types when 
the free drug was adnriiristered with the MAC 26 being less sensitive to E09. Wlreir the 
drug-loaded microspheres were administered, the difference between the HT29 and the 3
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other tumour types was significantly in favour of the HT29. These results are similar to 
tiros e obtained when tire mean of tire treated group was divided by the mean of the control 
group (Method 1), but have the advantage of statistical confidence.
E09 has been shown previously to have activity in both MAC tumour types in vivo as well 
as in vitro. Although our experiments have used a differeirt method of drug administration, 
our work agrees with that of others, in that activity in the usually less drug responsive MAC 
16 tumour was greater than that seen in the MAC 26 tumour (Workman et al 1990B, Walton 
et al 1992A). This was the case for both free drug and drug-loaded microspheres.
Our results however, differ to tliat previously seen in HT29-bearing N u /n u  mice where little 
activity was seen following systemic administiation of E09 at its maximum tolerated dose of 
6m g/kg given intravenously on four consecutive days. This documented lack of activity 
was thought to be either the result of inadequate levels of drug reaching the tumour or an 
alteration in the levels of metabolising enzyme levels within the tumour compared to the in 
vitro model (Collard et al 1995). Taking our results into account, which indicate that the 
tumour remams very sensitive to E09 in vivo, this documented lack of activity is more likely 
to be related to the mability to target adequate doses of the drug into the tumour.
The chemosensitivity of the BE xenograft has, to the best of our knowledge, not been 
described previously. The fact that antitumour activity with free drug is detected in this 
tumour type, known to lack the 2 electron reductase DT-Diaphorase (DTD), suggests a role 
for the other reductase enzymes in the drug activation process.
The differences which were detected in T /C  values between the free drug and tire 
microsphere group were different to those which had been anticipated. The enzymology of 
E09, as mentioned previously, is extremely complex, hi vitro studies had suggested tlrat
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under normoxic conditions there was a sti'ong correlation between tumour levels of DT- 
Diaphorase and sensitivity to E09 (Walton et al 1992A, Robertson et al 1992,1994, Plumb et 
al 1994A, 1994C, Smitskamp-Wilms et al 1994). The HT29 tumour was shown to be 15 to 30- 
fold more sensitive tiran the BE tumour and the MAC 16 tumour 28-fold more sensitive tiran 
the MAC 26 tumour (Walton et al 1992A). This has been confirmed in vivo using the MAC 
tumours where a correlation was seen between the levels of DTD and sensitivity to E09 
when the drug was given systemically (Workman et al 1990B, Walton et al 1992A). This 
correlation however, has not been borne out hr other in vivo studies. The influence of otirer 
cell types which may be present within the tumour, together with the presence of cell debris, 
may result in an maccurate estimation of the tumour's actual DT-Diaphorase levels (Collard 
et al 1995).
Previous work within our laboratory had estimated the levels of both 1 and 2 election 
reductase enzymes present in each of tire tumour types in vivo (Table 4.5) (Spanswick 1996). 
These results coirfirm that the highest level of DT-Diaphorase is present within the HT29 
tumour and that the BE tumour lacks any active DT-Diaphorase. The level of DT- 
Diaphorase was also found to be greater in the MAC 16 tumour when compared to tire MAC 
26 tumour, which is in agreement with the results of others (Workman et al 1990B, Walton et 
al 1992A).
Based on these results and taking into account the in vitro studies mentioned previously, we 
would have expected the HT29 and tire MAC 16 tumours to be the most sensitive to free 
E09 with the MAC 26 and BE tumour being the least sensitive. What we found was that in 
botlr the HT29 and MAC 16 tumours free E09 did show significant antitumour activity 
when compared to the MAC 26 tumour, but that in the BE tumour similar antitumour 
activity was seen to that in the HT29 and MAC 16 tumours.
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The activity seen in the BE tumour was unexpected because of its known lack of active DT- 
Diaphorase and caimot be fully explained. The activity seen must be due to the other 
reductive enzymes present within the tumour.
There is a known difference in the reductive capacities of human and murine reductases. 
Murine DT-Diaphorase has been shown to be less effective than its human equivalent (Lewis 
et al 1994). This difference may also apply to the one election reductases which might help 
to explain the anti tumour activity which was seen in the BE tumour.
The role of hypoxia in E09 activation has also been extensively investigated in vitro (Bando 
et al 1995, Plumb et al 1994A, 1994B, 1994C, Robertson et al 1994). In a panel of cell lines in 
hypoxic conditions, there was a greater increase in the level of sensitivity of cell lines which 
were low in DT-Diaphorase compared to cells which had high levels of the enzyme, with a 
significant inverse correlation bemg found between levels of DT-Diaphorase and hypoxic 
sensitivity to E09 (r=0.93) (Plumb et al 1994B). In the case of the BE cell hne, this resulted in 
a 1000-fold mcrease m sensitivity compared to HT29 which only showed a 2 to 5-fold 
increase in sensitivity (Plumb et al 1994C). The sensitivity of the EMT6 mouse mammary 
tumour cell line has been shown to increase 3-fold in the presence of hypoxia (Hendriks et al
1993) and an increase in sensitivity has also been documented in the V79 and KHT ceU lines 
under hypoxic conditions (Adams et al 1992). This suggests that the other reductases 
present in the cell take on a more prominent role in low oxygen conditions (Plumb et al 
1994A, 1994B, Robertson et al 1994).
Previous work, looking at doxorubicin-loaded microspheres, suggested tlrat the 
microspheres appeared to induce hypoxia when given by direct intiatumoural injection. 
This was based on the fact that stimulation of anaerobic quinone reduction of doxorubicin by 
cytochrome P450 reductase to its 7-deoxyglycone metabolite was increased by up to 155-fold
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ill tumour tissue following intiatumoural injection of doxorubicin-loaded microspheres 
(Cummings et al 1992A). In addition, studies using magnetic resonance spectaoscopy have 
suggested that intratumoural injection of the microspheres results in tlie induction of a 
hypoxic environment lasting approximately 20 minutes (Spanswick, personal 
communication). Based on this and takhig into account the results of the in vitro work 
mentioned above previously, it was anticipated that the tumour types which were lower in 
DT-Diaphorase (MAC 26 and BE) would show some enhancement of activity when treated 
witli the encapsulated form of E09 compared to treatment witli free E09. The opposite 
effect was in fact seen to occur in that the tumour types which had least DT-Diaphorase were 
found to be even less sensitive in the presence of the encapsulated drug, i.e. a reduction in 
response compared with the free drug. These results are in agreement with previous studies 
carried out in our laboratory, which investigated the metabolism of E09 in tumour 
homogenates of each of the four tumour types in vitro under aerobic and hypoxic conditions. 
No enhancement of activity was seen under hypoxic conditions in those tumours which 
were low in DT-Diaphorase (Spanswick 1996). The reason for this difference was unclear, 
but it may be related to the degree of hypoxia which was present. The microspheres 
probably induce a relative degree of hypoxia rather tlian absolute hypoxia or anoxia. In the 
case of the in vitro data, the hypoxic conditions described suggest that anoxia rather than 
hypoxia may have occurred (Plumb et al 1994A, 1994B, 1994C). Perhaps there needs to be a 
much lower level of oxygen present than we were able to produce for augmentation of 
activity to be seen.
The blood supply to each of the tumours will also be important when assessing tumour 
sensitivity. The MAC 26 tumour, as mentioned previously, is known to have a good blood 
supply and therefore the drug is likely to be cleared more quickly than in a necrotic tumour 
such as MAC 16. In addition, m a well-vascularised tumour, a reduction m relative oxygen 
concenti'ation to levels which are significant will be more difficult to achieve. The poorly
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vascularised MAC 16 tumour on the other hand, is more likely to have hypoxic regions 
present within the tumour. The poorer blood supply may also mean that a higher 
concentration of the drug is retained witlr in the tumour, which may have significant 
implications m determining antitumour activity. The increase hr antitumour activity seen by 
Bibby et al hr the MAC 26 tuirrour following co-admhristiation of hydralazhre was 
postulated to be the result of hypoxia, because hydralazine had been shown to cause an 80% 
vascular shutdown hr MAC 26 tumours. In fact, the effect may be due to more E09 behrg 
retahred withiir the tumour as a result of the reduced blood flow, rather than, or as well as, 
the presence of hypoxia (Bibby et al 1993B). This issue will be addressed in greater detail in 
the next chapter, when pharmacokinetic studies will be performed in each of the tumour 
types.
A further reason for the reduction in the antitumour activity of tire microspheres may be the 
rate of presentation of the drug to the tumour. Although the release of E09 from the 
microspheres is kirown to occur rapidly (see Chapter 3.4.3), the drug will be presented at a 
different rate to the tumour compared to the administration of free drug. E09 is thought to 
act by producing single strand breaks in DNA (Walton et al 1991) as well as DNA cross- 
linkage (Bailey et al 1994), so perhaps it is the peak concentration of the drug rather than 
prolonged drug release (which may attenuate the peak), which is important for maximum 
DNA damage to be achieved. This contrasts with doxorubicin-loaded microspheres where, 
as discussed previously (Chapter 3.5.4), studies have suggested that the observed 5-fold 
increase m activity is the result of slow release of the doxorubicin, covalently bound to the 
albumin of tlie microspheres ratlier than the production of tlie 7-deoxyglycone metabolites 
which is thought to result in drug hiactivation (Cummings et al 1991, 1992A). Doxorubicin 
is known to produce its antitumour effect by inliibition of Topoisomerase II and therefore 
slow release of tlie drug will be the more effective method of administration because it will
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produce prolonged enzyme inliibition. Again, this will be considered in more detail in the 
next chapter.
The data presented in this chapter is in contrast to previous work witli MMC-loaded 
albumin microspheres where the encapsulation process appeared to result in complete loss 
of activity (Cummmgs et al 1994). However, these experiments were incomplete in that only 
one tumour type was examined (MAC 16) and only one dose of microspheres was compared 
with the free drug equivalent. As noted from our results, increasing the dose of E09-loaded 
microspheres resulted in significant antitumour activity in the MAC 16 tumour and it would 
be mteresting to know whether this would also have been the case for the MMC- 
microspheres (Cummmgs et al 1994).
In conclusion, the E09-loaded microspheres have demonstrated anti tumour activity in the 
HT29 xenograft and the MAC 16 murine adenocarcinoma, but not in the BE xenograft or the 
MAC 26 murine adenocarcinoma. This contrasts with the free drug which shows significant 
antiturnour activity in all the tumour types when given by direct intratumoural injection. 
These results therefore do not support the use of E09-loaded microspheres as a method of 
mcreasing the drug's activity in this type of tumour model.
However, intratumoural injection of the E09-loaded microspheres is unlikely to be the best 
method of determining the relative activity of the microspheres compared witlr free drug. 
Intratumoural injection of the free drug might be the optimal way to treat a tumour but is 
not practical in the majority of cases. Cytotoxic drugs are usually given systemically by the 
intravenous route. The result of this is that the drug may only be transiently in contact witlr 
the tumour. A further problerrr witlr E09 is that its instability meairs that not only is it 
ti’airsieirtly in coir tact with the tumour when given intraveirously, but it is also uirlikely to 
reach the tumour iir any significairt concentration as a result of its rapid metabolism or
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hydrolysis, a problem previous studies have identified (Workman et al 1992C). This may 
well conb'ibute to its lack of activity. Therefore, the advantage of the microspheres is that 
tlrey not only have the potential to deliver a high local concentration of the drug if tlrey are 
administered via tire tumour's arterial blood supply, but they may also help to physically 
retain the drug at the tumour site. A better model of studying the microspheres needs to be 
devised in order to obtain a more clinically relevant picture of the microsphere activity. This 
will be discussed further in Chapter 6, where a model will be developed which will allow 
tire comparison of inti'a-arterial admmistiation of free E09 and E09-loaded microspheres 
with free E09 given by the intravenous route.
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CHAPTER 5
Pharmacokinetic studies with E09 
loaded aibumin microspheres
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5 Chapter 5
5.1 INTRODUCTION
In Chapter 4, the antiturnour activity following intiatumoural injection of free E09 or the 
equivalent dose of E09-loaded albumin microspheres in the HT29, BE, MAC 16 and MAC 26 
tumour types was presented. The results showed that the administration of free E09 was 
associated with anti tumour activity in all four tumours and tlrat the HT29 xenograft was the 
most sensitive of the four tumour types which were studied. When the E09-loaded 
microspheres were compared to free drug, only the HT29 tumour demonstrated antitumour 
activity at a dose of microspheres equivalent to that of free drug. The MAC 16 tumour 
required an E09 dose of 500pg in microsphere form to produce an equivalent antitumour 
response to 250pg of free drug. No significant antitumour activity was demonstrated by any 
dose of microspheres in either tlie MAC 26 or BE tumours.
The aim of the experiments described in this chapter was to determine whether the variation 
seen in antitumour activity between the four different tumours and between the free drug 
and the microsphere treated groups in the same tumour type could be explained by 
pharmacokinetic differences. In particular, the metabolism of E09 was studied to see 
whether any metabolites could be identified which may correlate with the differences which 
were observed.
Previous studies within our laboratory studying MMC-loaded microspheres in the MAC 16 
tumour had suggested that although there was similar drug exposure compared to the free 
drug studies (30.0|ig/ml x hr (microsphere group) v 46.9|Lig/ml x hr (free drug group)), the 
half life and absolute tumour concentrations in the microsphere treated group were 
different. Encapsulating tlie drug resulted in a prolonged ti/2 of 600 minutes hi the
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microsphere group compared to 70 minutes in the free drug group, with generally lower 
MMC concentiations in the microsphere group at the early time points in the study (Allan 
1994). A significant reduction in plasma MMC concentration in the microsphere-treated 
group was also detected (Cummings et al 1994).
In addition to the change in the pharmacokinetic profile when the microspheres were used, 
MMC metabolism was also altered. 2,7-diaminomitosene (2,7-DM) is thought to be the 
principal indicator of MMC metabolic activation in tumour tissue because it is only found 
after quinone reduction and levels correlate in vitro with cytotoxicity. It was tire main 
metabolite found after mtiatumoural injection of free MMC, but was present in much lower 
levels following intiatumoural injection of MMC-loaded microspheres, suggesting possible 
inhibition of its formation in the microsphere heated group. An addihonal four mitosane 
metabolites were detected in the group heated with tire microspheres. The encapsulahon of 
MMC mto microspheres was associated with reduced anhtumour achvity, so that the level 
of 2,7-DM which was detected in vivo was thought to be an important indicator of 
anhtumour achvity (Cummings et al 1994).
An alterahon in the metabolism of doxorubicin has also been demonshated when the drug is 
encapsulated mto microspheres. This results hr the shnrulation of anaerobic quinone 
reduchon of the doxorubichr to 7-deoxyglycone metabolites by a factor of up to 155-fold 
when compared to the free drug (Willmott et al 1987A).
E09, as mdicated previously, is known to be very uirstable witlr a short half-life. There are 
very little data available on the generahon of reachve intermediates and metabolite 
formahon in vivo. This is due m part to the presumed instability and short half-life of the 
metabolites. Previous in vitro work in our laboratory ushrg E09 has been carried out in the 
four tumour types menhoned above hr an attempt to identify potenhal metabolites which
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may act as indicators of tumour sensitivity (Cummings et al 1998). HPLC analysis of tumour 
homogenates was carried out following incubation with E09 under aerobic or hypoxic 
conditions. Three main metabolites were identified in addition to E05A that had retention 
times between 4.2 - 4.4 minutes, 5.4 - 6.2 minutes and 7.5 - 8 minutes. They were present in 
all four tumour homogenates and their formation appeared to be unaffected by tire presence 
or absence of oxygen. No correlation was identified between any of these metabolites and 
tumour sensitivity in vivo, nor was there any correlation with these metabolites and levels of 
the major bioreductive enzymes, DT-Diaphorase, Cytochrome P450 reductase and 
Cytochrome b5 reductase (Cummings et al 1998). The experiments in this chapter will 
determiire whether these metabolites are also present in vivo and, if so, whether the 
encapsulation of drug into microspheres alters metabolite formation.
Pharmacokitretic analysis has been carried out previously m vivo following i.v. injection of 
E09. At the maximum tolerated dose in C3H/He mice (12mg/kg) the ti/z was 1.9 minutes 
witli a peak plasma concentration of 1.8pg/ml. E09 and E05A were identified in the
plasma along with several other potential metabolites. No E09 or metabolites were 
detectable in the tumour or any of the tissues examined during die course of the experiment. 
No parent drug was detected in the urine but, 20% of the total E09 dose was detectable in 
the urine as either E05A or other hydrophilic metabolites which, as yet, have not been 
formally characterised. This absence of E09 m both the tissues and urine suggested diat 
there was rapid metabolism and clearance of the drug (Workman et al 1992C). 
Pharmacokinetic studies which were performed during die Phase I trial of E09 detected 
E09 and E05A in the plasma, but minimal amounts of each in the urine (Schellens et al
1994).
No work, to the best of our knowledge, has been performed in vivo to look at E09 
metabolism in tumour dssue. The direct intiatumoural injection of E09 should maximise
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tlie chance of detecting any metabolites which may be formed and will allow a diiect 
comparison with tlie metabolism of E09 incorporated into the microspheres which may, as 
indicated previously alter the tumour environment and thus, drug metabolism.
5.2 MATERIALS
All reagents, equipment and suppliers used are listed in Appendix 1. The High Performance 
Liquid Chromatography (HPLC) analyses were performed using a Waters Alliance System 
equipped witli the following features: a 996 Photodiode Array detector, a 2690 Separations 
module which included a variable volume automatic injector and autosampler and a heated 
column compartment. System control and evaluation were performed by a Millermium 
software package run on a standard PC.
5.3 METHODS
5.3.1 Pharmacokinetic Studies
5.3.1.1 Comparison of free E 09  with E09-loaded albumin microspheres 
administered by direct intratumoural injection
MAC 16- and 26-bearing NMRI mice and HT29- and BE-bearing N u/nu  mice were 
randomised into groups of three animals per time point and injected intratumour ally with 
200|il of PBS/0.5% Tween 80 contaming either 250pg of E09 or the equivalent dose of freshly 
prepared E09-loaded microspheres. Following injection, the animals were killed using CO2 
asphyxia at the following time points; 0, 5, 10, 15, 30, 45, 60 minutes and 2, 4, 6, 18 and 24 
hours following drug administration. Blood samples were immediately collected by open 
cardiac puncture, centrifuged (2000r.p.m for 10 minutes at 4°C) and the separated plasma 
then placed in liquid nitrogen. The tumours were excised and immediately placed in liquid 
nitrogen. Both plasma and tumour samples were stored at -80‘^ C prior to analysis.
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5.3.1.2 Preparation o f pharmacokinetic samples using Solid Phase 
Extraction (SPE) for HPLC analysis
a) Plasma
The plasma was allowed to tliaw at room temperature and kept on ice. The total volume 
was determined and lOOpl of the plasma sample was then added to 800pl of 20mmol sodium  
phosphate buffer, pH 8.0 and lOOpl of the internal MMC standard (lOOpg/ml). The Icc C18- 
OH Bond Elut solid phase extraction columns were activated with 1ml of metlianol and 
washed witli 1ml of the above buffer. The sample was placed on the colunm and washed 
witli a further 1ml of buffer. The column was allowed to vacuum dry for 20 minutes and the 
sample eluted in 0.5ml of methanol. This was dried down in a stream of nitiogen and then 
reconstituted in 300pl of a methanol: buffer (25:75 ratio) mixture. The reconstituted sample 
was passed through a syringe filter and a lOOpl ahquot was injected onto the HPLC column.
b) Tumour
The tumour was thawed slowly on ice and weighed. Buffer was added to the whole tumour 
in a ratio of 2 buffer: 1 tumour and the tumour homogenised. To the volume of tumour 
homogenate, lOOgI of the internal MMC standard (see above) was added and additional 
buffer to make a fmal volume of 2.6mls. The sample was then spun at 2500r,p.m for 10 
minutes at 4°C, following which, the supernatant was immediately removed and kept on ice. 
A 3cc C18-OH Bond Elut column was activated with 2.5mls of methanol and washed with 
2.5mls of buffer. The sample was then placed on the column and the column and sample 
were washed with a further 2.5 mis of buffer. The column was allowed to vacuum dry for 20 
minutes and the sample then eluted from the column in 1ml of methanol. This was dried 
down in a stream of nitiogen and then reconstituted in 300gl of the buffer: metlianol mixture 
as outlined above. It was then passed through a syringe filter and a lOOgl aliquot was placed 
in the HPLC column for analysis.
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5.3.1.3 HPLC analysis o f tumour and plasma pharmacokinetic samples
HPLC analysis was carried out under identical conditions to tliose previously described in 
Chapter 2.3.1. The HPLC equipment which was used was the Waters system rather than the 
Hewlett Packard system and is described earlier in this chapter. Extracted standards were 
analysed on a daily basis to ensure reproducibility of results.
5.3.1.4 Pharmacokinetic data analysis
The chromatograph obtained for each sample was carefully analysed, botli to determine the 
amount of E09 present in the sample (based on the height of the E09 peak) and also to look 
for potential E09 metabolites.
The total E09 (gg) from each tumour and the plasma E09 concentration (gg/m l) were 
determined for each sample using previously constructed standard curves. The mean (and 
standard error) and median of the total E09 obtained following analysis of tire 3 samples at 
each time point were then calculated and plotted against time. The results following 
mtratumoural injection with free drug were compared with the results obtained from 
tumours treated with tire equivalent dose of drug-loaded microspheres. Individual time 
points were tlren compared using the unpaired students t-test.
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5.3.2 Timed Histological Assessment of Tumours following Direct 
Intratumoural Microsphere Injection
In order to try and establish how long the microspheres remained within the tumour, MAC 
16- and 26-bearing NMRI mice and HT29- and BE-bearing N u /n u  mice (previously 
described in Chapter 4,2) were mjected inti’atumourally with 250gg blank albumm 
microspheres resuspended in 200gl PBS/0.5% Tween 80. The control group were treated 
with 200gl PBS/0.5% Tween 80 only. There were seven animals in each group, which were 
sacrificed at the following time points: 0 ,1 , 2, 4, 7,10 and 14 days. The final tumour volume 
was determined and the tumours removed and prepared for histological assessment as 
discussed previously in Chapter 4.3.3.
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5.4 RESULTS
5.4.1 Pharmacokinetic Studies: Comparison of Free E09 with E09- 
loaded Microspheres
5.4.1.1 HT29 xenograft model
a) Tumour
After injection of free E09 and E09-loaded microspheres into the tumour, analysis of 
samples collected immediately after injection and sacrifice (to) showed that the mean tumour 
E09 content at this time point was 12.8gg (5% of the original total of free E09) and 28.2gg 
(11% of the original total of E09 microspheres). These results were not significantly 
different. Following injection of free drug, E09 was detected in the tumour for up to 24 
hours, although only a small amount (< 0.2% of the total E09 injected into the tumour) was 
present after tire 2 hour time point. When the E09-loaded microspheres were used, drug 
was also detected in the tumour up to 24 hours following injection, with less than 0.2% of the 
total E09 which had been injected into the tumour being present after 6 hours (Figure 5.1).
Significant variation was present in the three replicates obtained at each time point in both 
groups which made statistical analysis of the data difficult e.g. m the free drug group at to 
tumour E09 content was 30.6gg, 7.4gg and 0.2gg respectively with a mean of 12.8 ± 15.9gg. 
No statistical difference between the two sets of data, apart from one isolated time point at 
60 minutes (p<0.05) in favour of the microsphere treated group, were detected (Figure 5.1).
In an effort to eliminate the impact of tlris variability and exclude outliers the median values 
from each set of data were compared. This suggested that the rate of drug loss from the 
tumour was slower in the microsphere group than in the free drug group (Figure 5.2). This 
implied that retention of E09 withm the microsphere treated tumours may be occurrmg 
compared to the group treated with free drug.
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Figure 5.1 The effect of time on the concentration of E09 following direct 
Intratumoural injection of 250pg free E09 or the microsphere 
equivalent in the HT29 xenograft grown subcutaneously in the 
Nu/nu mouse. The E09 concentration at each time point, 
expressed as the total drug content (pg) per tumour is the mean 
result ± standard error of 3 animals. No statistical difference 
was detected between the two sets of data except for an isolated 
time point at 60 minutes in favour of the microsphere group 
(p<0.05).
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Figure 5.2 The effect of time on the concentration of E09 following direct 
intratumoural injection of 250^g free E09 or the microsphere 
equivalent in the HT29 xenograft grown subcutaneously in the 
Nu/nu mouse. The E09 concentration at each time point, 
expressed as the total drug content (pg) per tumour is the 
median result from 3 animals.
188
However, when the experiment was repeated these results were not reproducible. When 
free E09 was injected in the second experiment it was detected m the tumour throughout 
tire 24 hour period, but when the E09-loaded microspheres were used, E09 was only 
detected in the tumour over the first 6 hours (Figure 5,3).
When the results of both these experiments were combined and the administration of E09 
and E09 microspheres were compared using the unpaired students t-test, no statistical 
difference was detected between the two sets of data (Figure 5.4). This suggested that there 
was no difference in drug concentration over time within the HT29 tumour followmg tire 
adnrinisti'atioir of free drug or drug-loaded microspheres. The variability which was seen in 
these experiments could be due to the metlrod of drug administration which may result in 
peritumoural as well as intratumoural administr ation of the drug.
b) Plasma Concerrtratiorr
In the first experiment, E09 was detected in the plasma 5 mmutes following intratumoural 
injection of free drug but was undetectable after 15 minutes. When the drug-loaded 
microspheres were used E09 was again detected after 5 mmutes but, remained detectable 1 
hour later in all three samples and in 1 out of the three samples at 2 and 6 hours respectively. 
Although highly variable, this did initially suggest that retention of E09 occurAd in the  ^
tumours of mice treated with microspheres, resulting in tire prolonged detection of drug m 
the plasma. This was more apparent when the median values from each group were 
compared (Figure 5.5). However, tlrese results again were not confirmed in the repeat 
experiment which failed to detect E09 in the plasma of either group at any time point, thus 
further demonstr ating the lack of reproducibility.
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Figure 5.3 The repeated effect of time on the concentration of E09 
following direct intratumoural injection of 250^g free E09 or the 
microsphere equivalent in the HT29 xenograft grown 
subcutaneously in the Nu/nu mouse. The E09 concentration at 
each time point, expressed as the total drug content (^g) per 
tumour is the mean result ± standard error of 3 animals.
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Figure 5.4 The combined effect from two identical experiments on the 
concentration of E09 foilowing direct intratumourai injection of 
250^g free E09 or the microsphere equivalent in the HT29 
xenograft grown subcutaneousiy in the Nu/nu mouse. The E09 
concentration at each time point, expressed as the totai drug 
content (^g) per tumour is the mean result ± standard error for 6 
animals. No statistical difference was detected between the two 
sets of data (p<0.05).
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Figure 5.5 The effect of time on the piasma concentration (M-g/mi) of E09 
following direct Intratumoural injection of 250pg free E09 or the 
microsphere equivalent in the HT29 xenograft grown 
subcutaneously in the Nu/nu mouse. The E09 plasma 
concentration at each time point is the median result for 3 
animals.
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5.4.1.2 BE xenograft model
a) Tumour
After injection of free E09 and E09-loaded microspheres into the tumour, analysis of "to" 
samples demonstr ated that the mean E09 tumour content at this time point in each group 
was again much less than 100% (27%: free E09 and 13.2%: E09 microspheres). This was not 
statistically significantly different. E09 was detected in both groups of tumours throughout 
the 24 hour time course of the experiment but tumour drug content had fallen to less than 
0.2% after 2 hours in the free drug group (except for the 18 hour sample and this result 
appears to be an outher suggesting mislabelling) and to less than 0.2% after 6 hours in the 
microsphere tieated group (Figure 5.6). Variability in drug content was again seen at each 
time point, making analysis of the results difficult, e.g. in the microsphere ti'eated group E09 
values of 3.5pg, 22.6pg & 73.3pg were obtained at to. When the median values for each 
group were compared the rate of drug loss from the tumour m the microsphere group 
appeared slower than in the free drug group (Data not shown).
However, when the experiment was repeated, the results were not reproducible. Drug was 
again detected in both groups throughout the 24-hour time period. In this experiment 
however, tlie amount of drug was greater than 0.2% 6 hours after injection for both the free 
drug and the microspheres (Figure 5.7). The results were significantly different and in 
favour of the free E09 group at 15 minutes and 2 hours following intratumoural injection 
(p<0.05).
When the results of both experiments were combined and the free E09 group compared 
with the E09 microsphere group, no statistical difference was detected in drug concentration 
during the time course of the experiment.
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Figure 5.6 The effect of time on the concentration of E09 following direct 
intratumoural injection of 250|ig free E09 or the microsphere 
equivalent, in the BE xenograft grown subcutaneously in the 
Nu/nu mouse. The E09 concentration at each time point, 
expressed as the total drug content (^g) per tumour is the mean 
result ± standard error for 3 animals. No statistical difference 
was detected between the two sets of data (p<0.05).
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Figure 5.7 The repeated effect of time on the concentration of E09 
following direct intratumoural injection of 250^g free E09 or the 
microsphere equivalent in the BE xenograft grown 
subcutaneously in the Nu/nu mouse. The E09 concentration at 
each time point, expressed as the total drug content (^g) per 
tumour, is the mean result + standard error for 3 animals. No 
significant difference was detected between the two sets of data 
except at 15 minutes and 2 hours in favour of the free E09 group 
(p<0.05).
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This experiment therefore failed to detect any significant difference in tumour E09 levels 
between the free drug and tlie microsphere group in the BE tumour, a result similar to that 
obtained in the HT29 xenograft.
b) Plasma Concentr ation
In both the experiments E09 was detected in the plasma up to 15 minutes following 
administration of the free drug and up to 10 minutes following administration of the 
microspheres (Figure 5.8). No statistical difference was detected between the two sets of 
results. There was no suggestion of prolonged plasma concentration of drug in the 
microsphere group.
5.4.1.3 MAC 16 tumours growing in NMRI mice
a) Tumour
After injection of free E09 and E09-loaded microspheres into the tumour, sample analysis at 
"to" demonstrated that the mean E09 content of the tumour was 5.5% (free E09) and 11.4% 
(E09 microspheres) immediately after injection. These were not statistically significantly 
different. Following the intratumoural injection of free E09, drug was detected above 0.2% 
of the starting dose at 6 hours but was undetectable by 24 hours. When the drug-loaded 
microspheres were mjected E09 was still detectable at 24 hours, although levels had fallen to 
less tlran 0.2% by 2 hours (Figure 5.9). No statistically significant difference was detected 
between drug levels in the tumours treated with free drug compared to those treated with 
the microspheres.
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Figure 5.8 The effect of time on the plasma concentration (pg) of E09 
following direct intratumoural injection of 250|ug free E09 or the 
microsphere equivalent in the BE xenograft grown 
subcutaneously in the Nu/nu mouse. The E09 plasma
concentration at each time point is the mean result + standard 
error for 3 animals. No statistical difference was detected 
between the two sets of data (p<0.05).
197
40 “I
30 i E09 Microspheres 
Free E09I j
a  2 0  " 
%
3
o\ ^
O
m 10 -
300 350 400100 150 200 2500 50
Time (minutes)
Figure 5.9 The effect of time on the concentration of EOS following direct 
intratumoural injection of 250^g or the microsphere equivalent 
in the MAC 16 tumour grown subcutaneously in the NMRI 
mouse. The EOS concentration at each time point, expressed as 
the total drug content (^g) per tumour is the mean result ± 
standard error for 3 animals. No statistical difference was 
detected between the two sets of data (p<0.05).
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c) Plasma Concenti'ation
When the plasma E09 mean concentiations were compared, E09 was detected throughout 
the time course of the experiment in the microsphere treated group, but only up to 2 hours 
in the free drug group (Figure 5.10). The results were statistically significant after 45 
minutes suggesting continued release of drug from the tumour into the plasma in the 
microsphere-treated group.
5.4.1.4 MAC 26 tumours growing in NMRI mice
a) Tumour
After injection of free E09 and E09-loaded microspheres into the tumour, sample analysis at 
"to" demonstrated tliat the mean E09 tumour content immediately after mjection was 11.8% 
(free E09) and 2.7% (E09 microspheres) and these were not statistically different. E09 was 
detected in the tumour up to 24 hours following intratumoural mjection of the free drug, but 
only up to 2 hours following mtratumoural microsphere mjection (Figure 5.11). No 
statistically significant difference could be detected between the two groups during the first 
two hours of the analysis due to the variability of results within each group.
b) Plasma Concentr ation
When the mean E09 plasma levels were studied, E09 was not detected in any of the free 
plasma samples at any of tire time points. E09 was present in the microsphere-tieated group 
up to 4 hours following the intratumoural injection. The result in the free drug group 
suggests a technical problem hr the airalysis of the samples which irrakes airy comparison 
betweeir the two groups difficult and requires the experimeirt to be repeated.
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Figure 5.10 The effect of time on the plasma concentration ( i^g/ml) of E09 
following direct intratumoural injection of 250pg free E09 or the 
microsphere equivalent in the MAC 16 tumour grown 
subcutaneously in the NMRI mouse. The E09 plasma 
concentration at each time point is the mean ± standard error for 
3 animals. The results were statistically significant in favour of 
the microsphere treated group after 45 minutes (p<0.05).
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Figure 5.11 The effect of time on the concentration of E09 following direct
intratumoural injection of 250fig free E09 drug or the 
microsphere equivalent in the MAC 26 tumour grown 
subcutaneously in the NMRI mouse. The E09 concentration at 
each time point, expressed as the total drug content (|ig) per 
tumour, Is the mean result ± standard error for 3 animals.
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5.4.2 Chromatographic Analysis Comparing Free E 09 with E09-loaded 
Microspheres
Detailed chromatography was only available for the human xenograft tumours (HT29 and 
BE) and tlrerefore only these data will be discussed. As standards are not available for E05A  
and potential metabolites of E09, the results can only be descriptive and comparative rather 
tlran quantitative.
5.4.2.1 HT29 xenograft
5.4.2.1.1 Chromatographic analysis of the HT29 tumour foilowing 
intratumoural administration of free E09
In comparison to the chromatography of the contiol tumour (Figure 5.12), after
intiatumoural injection of free E09, 4 otlier peaks were identified in addition to E09 and the
hydrolysis product E05A (with retention times of 24.4 and 17.5 minutes), at 5.8 minutes
(Peak If), 6.6 minutes (Peak Ilf), 11.9 minutes (Peak Illf), and 14.7 minutes (Peak I Vf)
respectively (Figure 5.13 and Table 5.1).
E09 and E05A were both present throughout the time course of the study. The peak at 5.8 
minutes (Peak If) was present for tire first 2 hours. The peak height increased in tlie first 15 
minutes, and began to fall after 1 hour. It had a UV spectrum similar to E05A. The peak at 
6.6 minutes (Peak Ilf) was present from to with peak height falling by 10 minutes and it was 
absent by 45 mmutes. On UV specti'al analysis it did not resemble tlie spectra of E09 or 
E05A suggesting that it was unlikely to be an E09 related product (Figure 5.14). The peak 
at 11.9 minutes (Peak Illf) was a broad peak present from to at low level and absent after 4 
hours. It had a UV spectrum similar to E05A. Peak IVf was another broad peak present 
from to at 14.7 minutes. It was not detected after 2 hours and had a UV spectrum similar to 
E05A.
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Figure 5.12 HPLC analysis of untreated (control) HT29 tumour homogenate 
which shows the internal MMC standard (100p.g/ml).
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Figure 5.13 HPLC analysis of HT29 tumour homogenate at a) t = 0, b) t = 15 
min, and c) t = 24 hours, following intratumoural administration 
of 250)ig free E09. In addition to the hydrolysis product E05A, 4 
additional peaks were identified at 5.8 min (Peak If), 6.6 min 
(Peak Ilf), 11.9 min (Peak Illf), and 14.7 min (Peak IVf).
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Figure 5.14 Spectral analysis of E09, E05A and Peak Ilf in the HT29 tumour 
homogenate following intratumoural administration 250|ig free 
E09. The retention time (in minutes) for each peak is shown on 
the graph.
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5A.2.1.2 Chromatographic analysis of the HT29 tumour following 
administration ofEOQ microspheres
E09 and tlie hydrolysis product, E05A, were present throughout the time course of the 
study. The E05A level remained fairly constant for the first 2 hours and tlien began to fall, 
although more slowly than the E09, so that tire proportion of E05A relative to E09 
increased. By 18 hours, unlike the free drug group, the height of the E05A peak was greater 
than the E09 peak. In addition to the E09 and E05A peaks, definite peaks were also 
detected at 3.4 minutes (Peak Im ), 6.2 minutes (Peak I lm ) ,  11.7 minutes (Peak H im ) and 13 
minutes (Peak IVm) when compared to the control sample (Figures 5.12 & 5.15 and Table 
5.1). Although the peak at 3.4 minutes (Peak Im) was present at a relatively constant level 
over tire 24 hours of the study, it remained small. On UV spectral analysis, it was not similar 
to either E09 or E05A (Figure 5.16) and was not present in tire analysis of the tumour 
treated with free drug. The peak at 6.2 mmutes (Peak Ilm) was also present from t o .  It 
remamed at a constant level for tire first hour and then its height began to fall relative to the 
MMC peak (internal standard). It was not detectable after 6 hours. The UV spectrum of this 
peak was similar to tire spectra of E05A (Figure 5.16). The broad peak detected at 11.7 
minutes (Peak Him) was present from t o  but was irot detected after 30 minutes. It had an 
identical UV spectrum to that of E05A and was similar to Peak Illf in the free drug group. 
By 4 hours a further broad peak (Peak IVm) had developed at 13 minutes which was present 
throughout the remaining time points. This again had a UV spectrum identical to that of 
E05A.
5.4.2.1.3 Chromatographic analysis of HT29 plasma following administration 
ofE09 and E09 microspheres
Hr both the free drug group aird the microsphere group, only E09 and E05A were identified 
at low concentrations iir the plasma.^,
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Figure 5.15 HPLC analysis of HT29 tumour homogenates at: a) t = 10 min, b) 
t = 2 hr, and c) t = 24 hr, following intratumoural administration 
of 250^g E09 in albumin microspheres. In addition to E09 and 
the hydrolysis product E05A, 4 additional peaks were identified 
at 4.2 min (Peak L), 6.2 min (Peak IL), 11.7 min (Peak ML) and 13 
min (Peak IVm).
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Figure 5.16 Spectral analysis of E05A, Peak Im and Peak Ilm in the HT29 
tumour homogenate following intratumoural administration of 
250|ag E09 in albumin microspheres. The retention time (in 
minutes) for each peak is shown on the graph.
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5A.2.2 BE xenograft
S.4.2.2.1 Chromatographic analysis of the BE tumour following administration 
of free E09
E09 and E05A were present throughout the 24 hour time course of tlie experiment (Figure 
5.17). Their retention times occurred earlier than for the HT29 tumours, at 20.1 and 15.6 
mmutes respectively. This was likely to be related to the age of the column used for the 
HPLC analysis as retention times are known to shorten as the column ages. The ratio of E09 
to E05A remamed similar throughout the time course of the experiment and was similar to 
that seen in tlie HT29 tumour ti’eated witli free drug. In addition to the E09 and E05A, 
further peaks were identified at 4 minutes (Peak If), 6 minutes (Peak 2f) and 12.5 minutes 
(Peak 3f) (Figure 5.17 and Table 5.2). The peak at 4 minutes (Peak If) was detected from 5 
minutes onwards and was present up to 1 hour. It remained a very small peak at all time 
points. Spectral analysis showed that it was not similar to E09 or E05A (Figure 5.18). The 
peak at 6 minutes (Peak 2f) was present from to and present for the first 6 hours of the study. 
Its peak height was greatest m the first 15 minutes of the study and fell thereafter. Its 
spectrum was similar to but not identical to that of E09. The peak at 12.5 minutes (Peak 3f) 
was present from 15 minutes but absent after 6 hours. Its spectrum was different to that of 
E09 or E05A, having no absorption present in the visible spectrum range (Figure 5.18). This 
peak had not been previously identified m the HT29 tumour treated with E09.
5A.2.2.2 Chromatographic analysis of the BE tumour following administration 
of E09 microspheres
E09 and E05A were present throughout the analysis with retention times similar to the free 
E09 study at 20 minutes and 15.7 mmutes respectively.
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Figure 5.17 HPLC analysis of BE tumour homogenates at a) t = 5 min, b) t = 
1 hr, and c ) t  = 18hr, following intratumoural administration of 
250|ig free E09. In addition to E09 and the hydrolysis product 
E05A, 3 additional peaks were identified at 4 min (Peak If), 6 min 
(Peak 2f), and 12.5 min (PeakSf).
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Figure 5.18 Spectral analysis of E09, Peak 1r and Peak 3f in the BE tumour 
homogenate following intratumoural administration of 250pg 
free E09. The retention times (in minutes) for each peak are 
shown on the graph.
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The peak height of E05A remained fairly constant over the first 6 hours of the study and 
then began to fall but more slowly tlian the E09 peak, with the result that, as for the 
microsphere-treated HT29 tumour, the ratio of E05A increased relative to the E09. Further 
consisterrt peaks were identified at 4 rnins (Peak Im), 6.4mms (Peak 2m)/ 12 mms (Peak 3m) 
and 23.5 rrrirrs (Peak 4m) (Figure 5:19 and Table 5.2). The peak at 4 minutes (Peak Im) was 
detected from t o  until 6 hours. Spectral analysis confirmed it to be identical to Peak If in the 
free drug study (Figure 5.20). The peak at 6.4 minutes (Peak 2m) was present from t o  until 4 
hours. Like the free drug study it was present at its maximum height for the first 15 mmutes 
and therr the peak height fell. Its spectr um was identical to the spectrum of Peak 2f in the free 
drug study suggesting tliat it was an E09 related product (Figure 5.20). The peak at 12 
minutes (Peak 3m) was detected at 15 and 30 minutes only. Its peak height remamed very 
small, with a spectrum similar to that of E05A. The broad peak at 23.5 minutes (Peak 4m) 
was detected from 30 mmutes and was present until the end of the study. Spectral analysis 
also confirmed tliis to be similar to E05A.
S.4.2.2.3 Chromatographic analysis of BE plasma following administration of 
E09 and E09 microspheres
The only peaks identified in the plasma of botli the free drug and the microsphere treated 
tumours were E09 and E05A, an identical result to that seen in the HT29 xenograft.
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Figure 5.19 HPLC analysis of BE tumour homogenates at: a) t = 0, b) t = 30 
min, and c) t = 18 hr, following intratumoural administration of 
250|ig E09 in albumin microspheres. In addition to E09 and the 
hydrolysis product E05A, 4 additional peaks were identified at 4 
min (Peak Im), 6.4 min (Peak 2m), 12 min (Peak 3m), and 23.5 min 
(Peak 4m) (Peakim and 2m on chromatograph c corresponds on 
spectral analysis to the control peak at 5 minutes and the MMC 
peak on chromatographs a and b respectively. This is due to 
the earlier retention times of these peaks on chromatograph c).
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Figure 5.20 Spectral analysis of E09, E05A, Peak 1m and Peak 2m in the BE 
tumour homogenate following intratumoural administration of 
250|ig E09 in albumin microspheres. The retention times (in 
minutes) for each peak are shown on the graph.
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5.4.3 Timed Histological Assessment of Tumours following Direct 
Intratumoural Mlcrosphere Injection
The results for each of the tumour types were similar and tlierefore only the MAC 26 tumour 
will be discussed. As indicated previously (Chapter 4.5), the MAC 26 tumour is a well 
differentiated, well vascularised tumour. This was clearly seen throughout the time course 
of tlie study in both the microsphere treated and the control group (Figure 5.21). The 
microspheres could be detected tliroughout the 14 days of the study, and do not appear to 
undergo rapid breakdown and digestion by the inflammatory cells present within the 
tumour.
Immediately following the intratumoural injection of the microspheres disruption of the 
architecture of the tumour is seen (Figure 5.21 A). This was followed by the rapid 
accumulation of inflammatory cells both around and within the site of the microspheres 
within the tumour (Figure 5.21B). An increase in stromal tissue around the microspheres 
then developed which suggested that tlie inflammatory cell component was attempting to 
"wail off" the microspheres from the tumour tissue (Figure 5.21C). No changes were seen in 
the tumour following the intratumoural injection of PBS/0.5% Tween 80 (Figure 5.21D), 
which suggested that the changes which were seen relate to the microspheres ratlier than the 
intiatumoural injection process itself.
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Figure 5.21 Timed histological assessment of the MAC 26 tumour following 
the in vivo Intratumoural administration of blank albumin 
microspheres. Comparison of tumour at A) Time 0 and B) Day 2. 
The microspheres are clearly visible on the left side of slide A 
and in the centre of slide B.
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Figure 5.21 Timed histological assessment of the MAC 26 tumour following 
the in vivo intratumoural administration of blank albumin 
microspheres. Comparison of tumour at C) Day 14 and, 
D)PBS/0.5% Tween 80 control Day 14. The microspheres are 
still clearly visible on the left side of slide C.
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5.5 DISCUSSION
The aim of the studies presented in this chapter was to compare the pharmacokinetics of free 
E09 and E09-loaded microspheres in vivo following intratumoural injection in each of the 
tumour types in order to determine whether encapsulating the drug into microspheres 
altered the pharmacokinetic profile. The presence of any potential E09 metabolites during 
the study were also assessed to see if there was any relationship between metabolite 
formation in vivo and antitumour activity.
The results from the pharmacokinetic studies show that the experiments failed to detect any 
significant difference in drug levels within the tumour between the free drug and the 
microspheres. This was found in all four tumour types. These results therefore suggest that 
the antitumour activity which was seen was independent of the amount of E09 which was 
detected within the tumour. This would be in keeping with previous in vitro studies which 
have shown that only very low levels of the drug are actually required for antitumour 
activity (Hendriks et al 1993, Workman et al 1992C).
There was also no evidence of significantly sustained drug release in the tumours treated 
with the microspheres, despite the persistence of the microspheres within the tumour (5.4.3). 
This agrees witlr the in vitro characterisation work in Chapter 3.4.3 where the drug was 
found to undergo rapid release from the microspheres. Since it is the peak concentration of 
drug which is thought to be important for its mode of action, as discussed in Chapter 4.5, 
this characteristic is perhaps less important.
The results which were obtained in tlrese studies were much more variable than those 
obtained in previous antitumour studies (Cummings et al 1994, Spans wick 1996, Willmott et 
al 1987A). These previous studies had, however, involved relatively stable drugs such as
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Adriamycin and MMC. E09's known instability may therefore be an important factor in 
explaining some of the variability in the results which were obtained. In this respect, care 
was taken at all stages in the study to try and maintain as stable an environment as possible 
for the drug, both in terms of storage and in preparation for analysis.
Several problems were identified during this study which require further discussion. One of 
the most consistent features in each of the experiments was that although 250pg of E09 was 
injected directly into each tumour, a mean of only 4.8 ± 2.9 % of the original dose of E09 was 
actually detected at to on tumour analysis. There was no significant difference between 
tumours treated with free drug or with drug-loaded microspheres.
One factor which may have contributed to this low result was the fact that t o  was not an 
immediate sample. T o  refers to the earliest time point at which plasma and tumour could be 
sampled. Drug was injected, the mouse killed by CO2 asphyxia and subsequently bled by 
open cardiac puncture. The tumour specimen was then removed. Clearly a finite amount of 
time (approximately 2-3 minutes) will have passed from the intratumoural injection before 
sample collection is completed. This short delay may allow time for rapid metabolism of the 
drug to occur, such that by the time the tumour has been removed, the majority of the drug 
has been metabolised. This would be in agreement with previous in vivo studies using E09 
where rapid drug loss following systemic administration was demonstrated both in 
C3H/He mice ( t i / 2  of 1.9 minutes) and Sprague-Dawley rats ( t i / 2  of 3.0 minutes). No drug 
was detected in the tissues of either animal following systemic administration of E09, 
presumed to be the result of rapid drug metabolism (Workman et al 1992C). Similarly, in 
tire phase I study, rapid drug metabolism was thought to occur based on the short, though 
variable ti/2  of 0.8-19 minutes (Schellens et al 1994, Smitskamp-Wilms et al 1996).
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However, previous studies using intratumoural drug injections of MMC and MMC-loaded 
microspheres have shown equally low results (Cummings et al 1994, Spanswick 1996) which 
suggests that this may be a feature of the technique rather than being simply due to rapid 
drug metabolism or instability, although in the case of E09, this will certainly be a 
contributory factor. One of the potential reasons for the low level of drug detection may be 
related to the inti'atumoural injection technique itself. It is not possible to know following the 
injection how much of the drug has actually been injected intratumourally and how much 
has been placed peritumourally. This will be of particular relevance in small and necrotic 
tumours. Although a defined tumour size was used in all the experiments to try and 
minimise this effect, it is still likely to be important. Perhaps attempting to analyse the 
surrounding tissues as well as the tumour following the E09 injection may give some idea of 
how much drug is lost in this way.
The inti'a-group variation seen at each time point was often large, which made comparison 
of the results difficult. An alternative approach which was tried was to plot the median 
results from each group in order to see if any definite pattern emerged, although of course, 
no statistical analysis of these results could be attempted.
In the human xenograft tumours each experiment was repeated to try to determine whether 
the results seen in the first experiment were reproducible. Unfortunately this was not the 
case witli the repeat experiments producing different results, which were again not 
statistically significant due to the intra-group variation.
The results from experiments 1 & 2 were then combined so that in essence there were six 
animals per time point rather than tlrree, in order to determme whether by increasing the 
number of animals at each time point any pattern emerged. The presence of large error bars 
again meant that only large differences in drug levels would be detected, so tliat the
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combined results still failed to demonstrate any significant difference between the free drug 
and the microspheres in both types of tumour.
These results are different to those seen using MMC-loaded microspheres (Cummings et al 
1994). Because of the wide variability in the results obtained in these experiments, it was 
impossible to calculate any pharmacokinetic parameters such as haif-life (tVi) or area under 
the curve (AUC). Studies with the MMC microspheres showed that although the level of 
drug exposure was similar for both free drug and microspheres, the pharmacokinetic profile 
was quite different (Cummings et al 1994). However, the characteristics of the MMC and 
the E09 microspheres are different. In particular, as can be seen in Chapter 3.4.3, the rate of 
drug release from the E09 microspheres occurs much more rapidly than from the MMC 
microspheres (Allan et al 1993). Therefore, one might anticipate that there may not be such a 
great difference in the pharmacokinetic profile between the free E09 and the E09-loaded 
microspheres compared to the MMC study where the microspheres did demonstrate more 
of a sustained release characteristic. Despite concerns about the variabihty and 
reproducibility of the studies, it was felt that given the characteristics of the E09 
microspheres, a difference in tumour pharmacokinetic profile between the free drug and the 
microspheres might not have been anticipated.
The results obtained from plasma analysis are also difficult to assess because, Hke the 
tumour results, they are not consistent. There is the suggestion tliat the microsphere treated 
groups may have more sustained plasma levels than the free drug groups in the HT29 and 
MAC16 tumours. This is m contrast to the results obtained with the MMC microspheres 
where lower levels of MMC were seen in the plasma of the microsphere-treated MAC 16 
group (Cummings et al 1994). No relationship was seen between plasma levels and blood 
supply. One might have expected that tliose tumours witlr the better blood supply, such as 
the MAC 26 tumour, would have higher levels of drug detectable in the plasma compared to
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the more necrotic MAC 16 tumour, as has been shown in previous in vivo studies using 
MMC (Spanswick 1996).
Analysis of the chromatographic data produced during the pharmacokinetic study is 
limited. This is because of the lack of any available data for the metabolites including E05A, 
in terms of both standard curves and extraction efficiencies. Previous in vitro studies have 
also failed to detect any metabolites which may be indicative of E09 activation (Cummings 
et al 1998).
In addition to E09 and the hydrolysis product E05A, four other peaks were identified in the 
HT29 tumour treated with free E09 (I-lVf) and four peaks in the HT29 tumour treated with 
E09-loaded microspheres (I-IVm). Similarly in the BE tumour, three additional peaks were 
identified in the tumour treated with free E09 (l-3f) and four peaks in the tumour treated 
with E09-loaded microspheres (l-4m). It was noted that in both tumour types the 
microsphere-treated groups had some peaks which were detected over a longer time course 
(24 hours) compared with the free drug treated groups (4-6 hours). Some of these peaks 
were common to 2 or more of the groups, though each group had at least 1 peak which was 
not seen in any other groups. The UV spectra of these individual peaks were often similar 
suggesting that, although not identical, they were related. The properties of these peaks 
were summarised in Tables 5.1 and 5.2.
On analysis of these peaks, Peak Im in the HT29 microsphere treated group was similar but 
not identical to Peaks If and Im (which were identical) in the BE free drug and microsphere- 
h'eated groups, with retention times of 4.2 and 4.0 minutes respectively. This peak was not 
identified in the free drug treated HT29 tumour. Peaks 2m and 2f were also identical in the 
BE microsphere and free drug treated groups with retention times of 6.4 and 6.0 minutes 
respectively. No similar peaks were identified in the HT29 treated tumours.
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The remaining peaks in all the tumours except the BE free drug group peak at 12.5 minutes 
have spectra identical to that of E05A. Some of these peaks were present for 24 hours in the 
microsphere-treated groups but were only detected for up to 6 hours in the free drug 
groups.
When these results were compared witlr the in vitro studies mentioned previously 
(Cummings et al 1998), several similarities were noted. In addition to E05A, the peak at 4 
minutes in the in vitro study appeared to correlate in spectral analysis, with peaks Im, If and 
Im (in the microsphere-treated HT29 tumour and the microsphere and free E09 treated BE 
tumour) in our study. The peak in vitro at 8 minutes appeared to be similar to Peaks 2f and 
2m (in the free E09 and microsphere-tieated BE tumour) in our study. The other peaks 
identified in vivo were not seen in vitro.
Based on the spec ha and retention times of the peaks which were identified together with 
information obtained from previous in vitro work in tumour homogenates and using pulse 
radiolysis (Spanswick 1996), the possible identities of some of the peaks can be discussed. 
Peaks Im, If and Im are possibly drug-protein adducts based on the fact that protein has an 
absorption maxima similar to that of tlrese peaks. The lack of visible absorption may be a 
consequence of tire absorption spectrum of the protein masking that of the adducted E09 
metabolite. Peaks 2m and 2f hr the BE studies may be hrtermediate products based on the 
fact tlrat they are only preseirt in tire first part of each study. The specti'uirr, while similar in 
part to E09, lack any visible absorption which has beeir demonstrated to be characteristic of 
certain hydroqumoire intermediates (Cunrmhrgs et al 1998), and suggests that they may be 
hydroquinoire adducts. All the other peaks have spectra identical to E05A which is 
characteristic of an open aziridine ring product. The variation in retention times seen for 
these peaks suggests variation in the water soluble nature of the aziriduryl adducts which 
are formed. It should also be remembered that these products are formed by tire process of
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hydrolysis rather than by ti'ue E09 metabolism and that in this study they form the majority 
of the peaks which are seen.
It would be interesting to try to formally identify these metabolites but this is likely to be 
difficult and may not yield any further information on E09's activity. High Performance 
Liquid Mass Spectroscopy has been used to try to identify the metabolites of E09 following 
pulse radiolysis (a technique which allows controlled drug reduction to occur without the 
requirement for enzymes and cofactors (Salmon et al 1993), but this has been unsuccessful 
because tire majority of E09 errded up as products which were not detectable on analysis 
(Spanswick 1996).
In conclusion, these results show tlrat no one metabolite can be identified which is related to 
E09 activation, which is in agreement with previous z'u vitro studies (Cummings et al 1998) 
and no significant difference in tumour pharmacokinetics could be detected between those 
treated with the free drug and those treated with the microspheres.
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CHAPTER 6
The development of a relevant tumour model to study 
the i n  v i v o  antitumour effects of E09-loaded albumin
microspheres
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6 Chapter 6
6.1 INTRODUCTION
Previous studies have shown (Chapter 4.4.2) that in the HT29 tumour, the intratumoural 
injection of 250jrg of free E09 was equivalent in activity to the same dose of E09 
administered in microspheres. However, in the MAC 16 tumour twice the E09 dose was 
required in microsphere form to give the same effect as free drug. In the MAC 26 and tire BE 
tumours, despite antitumour activity being demonstrated with free drug, no activity was 
seen following the administration of E09 microspheres. This suggested that, apart from in 
the HT29 tumour, encapsulation of E09 into microspheres lead to a reduction rather than 
the desired enhancement of the drug's antitumour activity. The pharmacokinetic analyses, 
described in Chapter 5, failed to provide an explanation for the differences which were seen, 
both between tumour types and between the free drug and the microsphere-treated 
tumours.
A major concern with regard to the antitumour studies was that they compared the 
antitumour effect of free drug and microspheres once they were physically at the tumour 
site. The direct intratumoural injection of a drug such as E09 will maximise its antitumour 
effect while at the same time wül minimise tire problems associated with its systemic 
administration. However, direct intratumoural injection may not be the best method of 
assessing the antitumour effect of a potential drug delivery system such as the microspheres.
It has been suggested that the lack of antitumour effect following systemic administr ation of 
E09 m the Phase II studies (Dirix 1996, Pavlidis et al 1996) was due to the drug's instability 
and resultant short half-life. Renal toxicity prevented the dose of E09 from being increased 
to overcome this problem (Schellens et al 1994, Verweij et al 1994). E09's instability meant
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tliat following systemic administration the amount of drug reaching tlie tumour would be a 
fraction of tlie administered dose. This has been confirmed by in vivo studies where 
following intravenous administration of 12m g/kg of E09 in C3H /He mice, no drug could 
be detected in the tumour by HPLC analysis (Workman et al 1992C). Systemic 
administration of 6m g/kg of E09 on four consecutive days in nude mice also failed to 
produce an antitumour effect in tlie HT29 tumour model (CoHard et al 1995) in comparison 
to the studies of intratumoural administration where, the HT29 tumour was found to be 
sensitive to E09 (Chapter 4.4.2.2.2). This difference in effect is clearly related to the method 
of drug administration.
The rationale for encapsulating E09 into microspheres was to administer the drug 
locoregionally so that, unlike conventional intravenous administiation, E09 would reach the 
tumour in high enough concentration to have an antitumour effect whilst minimising 
systemic exposure to the drug and tlius toxicity. The possible induction of hypoxia as a 
result of the administration of microspheres (as previously discussed: Chapter 1.8.3.2.6) may 
further eniiance the drug's activity due to E09's bioreductive activation.
Therefore, the microspheres should be assessed in a model system where they can be 
admhiistered in a cHnically relevant way. The rat has been used previously in studying the 
effects that the administiation of drug and drug delivery systems given via the hepatic 
artery can have on tumour deposits within the hver. These studies have, amongst others, 
looked at tlie antitumour activity of MMC-loaded albumin microspheres (Fugimoto et al 
1985A, 1985B, Morimoto et al 1989), Adriamycm loaded microspheres (McArdle et al 1988) 
and degradable starch microspheres (Teder et al 1993, 1995), as well as the relationship 
between tumour blood flow and microsphere administration (Anderson et al 1991B, 1992). 
The rat model was considered particularly useful in view of the potential for administration
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via the hepatic artery mimicing the likely eventual clinical use, i.e. of intrahepatic arterial 
administration for liver métastasés.
It was initially intended to use a rat colon tumour, WB2054M (a dimethylliydracin induced 
colonic rat adenocarcinoma), which was established in vivo in the Wistar rat (University of 
Edinburgh) from its cell line, which was obtained from the European collection of animal 
cell cultures. However, spontaneous regression of the tumour within tire Ever in this 
particular strain of Wistar rat meant the model had to be abandoned. It was therefore 
decided to use a rat model system which was well established elsewhere. This was the HSN 
sarcoma cell hne (originally induced in a male Lister Hooded rat with 3-4-benzpyrene 
(Currie et al 1973)) grown in the Lister Hooded rat (Anderson et al 1991B, 1992). There was 
no information available on the sensitivity of this particular tumour to E09 in vitro or in vivo. 
Similarly, there was no published data concerning the systemic effects and potential toxicity 
of E09 in the Lister Hooded rat. Previous work in Sprague-Dawley rats had safely 
administered 3m g/kg (18mg/m^) i.v. without any immediate toxicity. However, the 
animals treated at this dose were part of a pharmacokinetic study which ended at 24 hours, 
so tliere was no information available on late toxicities (Workman et al 1992C). Further 
studies in the Wistar rat had looked at a single inti'avenous dose of 0.45mg/kg and 
subsequently weekly doses of 0.45mg/kg for 4 doses, with no obvious long term toxicity 
other than local irritation at the injection site (Hendriks et al 1993).
This chapter therefore describes the preliminary studies which were carried out to assess:
i) the in vitro sensitivity of the HSN tumour to E09.
ii) the in vivo sensitivity of tire HSN tumour to E09.
iii) the growth of the HSN tumour in the liver of Lister Hooded rats.
iv) the effect of E09 on tumour bearing Lister Hooded rats.
v) tire initial intrahepatic administration of E09 on tumour bearing Lister Hooded
rats.
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6.2 MATERIALS
All reagents, equipment and suppliers used are listed in Appendix 1.
6.2.1 In Vitro Tumour Model
The HSN rat sarcoma cell line was kindly supplied by Dr Sue Eccles, Institute for Cancer 
Research, Sutton, Surrey via Dr Alison Wood, University Department of Surgery, Glasgow 
Royal Infirmary, Glasgow, UK. It was easily grown as a monolayer culture in Dulbeccos 
Modified Eagles Medium (DMEM) supplemented with 10% foetal calf serum (PCS). 
Pemcillin-Sheptomycin solution was added to the media at a final concentration of 100 lU to 
reduce bacterial contamination. The cells were grown and maintained in 75cm^ tissue culture 
flasks at 37°C in a humidified atmosphere of 95% oxygen and 5% carbon dioxide (Scotlab 
VSL incubator). All procedures involving the cell line were carried out under sterile 
conditions in M.D.H Interlab Class II tissue culture hoods.
6.2.2 In Vivo Tumour Models
6.2.2.1 HSN rat sarcoma in Nu/nu mice
N u /nu  mice (originally bred at Imperial Cancer Research Fund (ICRF), London) were 
supplied by Harlan UK Ltd or the ICRF unit at Clare Hall, London. The HSN rat sarcoma, 
was implanted subcutaneously using 4x10  ^HSN cells in SOOpl of serum-free media into the 
flank of each mouse. The histology of the tumour was checked by the Department of 
Pathology, Western General Hospital, Edinburgh. The N u /nu  mice were housed in Morden 
isolators, fed on RM3(E) mouse diet tieated by irradiation and given free access to water. 
Once established, the xenograft was maintained by serial subcutaneous passage of 1-3 mg of 
viable tumour via a ti'ochar needle to animals weighing between 20 and 25g. When tumours
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reached O.l-O.Scm  ^ animals were randomised for experimental studies or sacrificed for 
collection of tumour material.
6.2.2.2 Lister Hooded rats
Lister Hooded rats were obtained from Charles Rivers or from Harlan UK. The rats were 
kept under standard laboratory conditions of heating and lighting, fed a standard rat diet 
(CRM(E)) and were given access to water ad lib.
6.3 METHODS
6.3.1 In Vitro analysis of HSN sensitivity to E09
6x10  ^HSN cells were added to 18x12.Scm  ^flasks containing 5mls of DMEM/ECS and placed 
in the incubator for 72 hours. The media was then changed and E09 added in the following 
concentrations: lO'^M, lO'^M, lO'^M, lO'^M and lO'^M with a control flask containing media 
only. Each concentration of E09 and the control were set up in triplicate. After 24 hours the 
E09 was removed, the flasks rinsed with sterile PBS and 5mls of fresh DMEM/ECS added to 
each flask. After a further 48 hours m tire incubator, each flask was trypsinised with 1ml of 
trypsin (0.25%):versene(lmM EDTA, 0.5% phenol red) (in a ratio of 1:1). Once the cells had 
detached from the surface of the flask trypsinisation was neutralised by the addition of 2 mis 
of DMEM/ECS and the cell suspension transferred into a universal container. 200pl of this 
suspension was placed in a coulter counter pot containing 9.8mls normal saline to allow 
counting to take place.
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6.3.1.1 Analysis o f cell counts
Each sample was analysed three times with the coulter counter and the mean result 
obtained. The background count, from a control pot containing saline alone, was subtracted 
from tiris result to obtain the mean count for each sample. Once each sample had been 
counted the mean count for each concentration of E09 was calculated. The mean cell count 
for each heated group (T) was then divided by the conhol group value (C) and expressed as 
a percentage in order to allow the IC50 (the concenhation causing 50% growth inhibition 
compared to the conhol) for E09 to be determined.
6.3.2 Dose Finding Studies to Determine HSN Tumour Sensitivity to 
E09 In vivo in Nu/nu Mice
HSN bearing N u /n u  mice were randomised into four groups each containing seven animals, 
which were then heated by direct inhatumoural injection with 200pl of PBS/0.5% Tween 80, 
either alone as a conhol group or containing 125pg, 250pg or 500pg of E09. Measurement of 
the tumours was carried out every second day for a total of 21 days. Tumour volume was 
determmed by caliper measurement (see Chapter 4.3.1.1) and calculated usmg the formula: 
0.5 X  length x width^. The animals were sacrificed once tire study was completed.
The antitumour activity for each group was determined using the following formula:
Mean tumour value (cm )^ day x
___________________________________  X100%
Mean tumour value (cm )^ day o 
The results from each group were compared using the unpaired students t-test.
233
6.3.3 Assessment of Antitumour Activity of E09-loaded Albumin 
Microspheres on the HSN Tumour in vivo in Nu/nu Mice
HSN bearing N u /n u  mice were randomised into five groups containing 6-10 animals per 
group. The groups were treated with 200pi of PBS/0.5% Tween 80 containing 125pg E09, 
E09-loaded microspheres containing the equivalent of 125pg or 250pg E09, blank 
microspheres or PBS/0.5% Tween 80 only.
The microspheres were prepared as described in Chapter 2.4.3 (Table 2.3), but each batch 
was reconstituted in a different amount of PBS/0.5%Tween 80 so that the E09 dose given 
did not affect the overall injection volume. Measurement was carried out and antitumour 
activity determined as described previously. The results from each group were compared 
using the unpaired students t-test.
The initial experiment produced unsatisfactory results (see below. Chapter 6.4.3) and was 
therefore repeated using smaller tumour volumes (<0.2cm^) at to.
6.3.4 Implantation of HSN Tumour Cells In the Liver of the Lister 
Hooded rat
The HSN cells were grown in tissue culture, as described previously, until they had reached 
late log phase. They were harvested immediately prior to tire implantation procedure. 
Followmg trypsinisation and washing, the cell pellet was vigorously resuspended in 20mls 
of DMEM and the cell number counted using an haemocytometer. The cell suspension was 
centr ifuged again at 2000r.p.m and the resulting cell pellet resuspended in serum-free media 
to obtain a final concentration of 5x10  ^cells per ml.
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The rat was anaesthetised by rntiaperitoneal injection with a combination of midazolam 
(2m g/m l)/ sterile water/ Hypnorm (Fentanyl Citi-ate (0.315mg/ml) and Fluanisone 
(lOmg/ml)) in a fmal ratio of lml:2mls;lml at a dose of 3.3mls/kg. Once anaesthetised, a 
midline abdommal incision was performed and the liver identified. A suspension of 1x10  ^
HSN cells in 200pl of serum-free media was placed by subcapsular injection using a 21 
gauge Microlance needle into tire median and left lobes of the liver (one iimoculation per 
lobe). The liver was seen to blanch following the injection. Prior to removal of the needle a 
cotton bud soaked in 70% absolute alcohol solution was placed over the exit site (to try to 
minimise peritoneal spread) and mamtamed in position for 1-2 minutes until the bleeding 
had stopped. This was subsequently replaced by Fibrinogen/Thrombin combination sealant. 
The incision was closed using standard Mersilk sutures for the muscle layer and 12x2.5mm 
surgical clips for the skin layer. The rats were then given butorphanol (2mg/kg) 
subcutaneously as pain relief and allowed to recover.
6.3.5 Assessment of HSN Tumour Growth within the Liver
Following the implantation of tumour cells within the liver of the Lister Hooded rats, as 
described above (6.3.4), the animals were observed daily for signs of distress relating either 
to the surgical procedure or the presence of tumour witliin the liver itself. The rats were 
culled at defined time points (1, 2, 3, 4 & 5 weeks depending on the experiment) following 
tire procedure. Detailed inspection of tire abdominal cavity was then carried out to look for 
the presence of tumour witlrin the liver as well as for evidence of tumour spread. The Ever 
was then removed and the weight and volume of any tumour present within each lobe 
documented. The mean tumour volume was determined for each time poiirt and results 
compared using the unpaired student t-test.
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6.3.6 The Effect of Systemic E09 on the Tumour Bearing Lister 
Hooded Rat
HSN cells were prepared in vitro and implanted in the liver in eighteen Lister Hooded rats as 
described previously. The rats were divided into three groups containing six rats per group. 
Each group was then heated by tail vein injection with either 400pl of PBS/0.5% Tween 80 
alone or containing E09 at a dose of 3 ( 18 m g / m 2)  or 6 (36mg/m^) m g/kg. This dose was 
based on available preclinical data. The animals were observed daily for signs of toxicity 
following the tail vein injection and a post mortem examination was performed on any 
animal which died and any obviously affected organs removed for histological assessment.
Due to initial problems with toxicity, a further twelve Lister Hooded rats were divided into 
three groups of four and heated in an identical manner witlr 2m g/kg (12mg/m^), Im g/kg  
(6mg/m^) or 0.5m g/kg (3mg/m^) E09 in the same injection volume of 400|il PBS/0.5% 
Tween 80. The animals were culled 14 days following the tail vein injection.
Once a satisfactory dose of E09 to be used had been determined (2m g/kg - this was the 
highest dose which could be administered with no toxic deatlis), twenty-four Lister Hooded 
rats were divided into 2 groups and heated 7 days after tumour implantation by taü vein 
injection with either 400gl of PBS/0.5% Tween 80 as the control group, or E09 (2mg/kg) in 
PBS/0.5% Tween 80. The animals were observed daily. Six animals from each group were 
culled at 3 weeks and the remaining six animals from each group at 4 weeks post tumour 
implantation (i.e. at 2 and 3 weeks post tail vein injection). The livers from each animal were 
tlren examined for tumour presence and size. The tumour means (based on tumour volume) 
were calculated at two and three weeks for both the conhol group and the E09 group and 
plohed against time. Because each rat had two tumours present, the number of tumours 
present in each group was double the number of rats in each group. The tumour means 
were then compared using an unpaired students t-test.
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6.3.7 Feasibility Study on the Administration of Blank Albumin 
Microspheres Via the Hepatic Artery
In order to determine the feasibility of administering the microspheres via the hepatic artery 
and to establish tire optimal dose of microspheres for safe administration, blank human 
albumin microspheres were manufactured and prepared as described previously in Chapter 
2.4.3 (Table 2.3).
Ten Lister Hooded rats were divided into four groups of two or three rats per group. The 
rats were anaestlretised as described previously (Chapter 6.3.4) and following a midline 
abdominal incision, the hepatic artery was identified. Each group of rats received via the 
hepatic artery eitlrer 5mg of blank albumin microspheres resuspended in 250pl or 500pl of 
PBS/0.5% Tween 80 or lOmg of blank microspheres resuspended in 250pl or 500pl of 
PBS/0.5% Tween 80, via a 26 gauge Microlance needle. Immediately following removal of 
the needle, the hepatic artery was sealed with Fibrinogen/Thrombin combination sealant. 
The incision was closed using continuous standard Mersilk sutures for the muscle layer and 
surgical clips for the skm layer. The rats were then given butorphanol (2mg/kg) 
subcutaneously as pain relief and allowed to recover. Following recovery the rats were 
observed daily for 7 days and tlren culled.
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6.3.8 The Effect of E09-loaded Microspheres Administered via the 
Hepatic Artery on HSN Tumour in the Lister Hooded Rat. 
Comparison with Free Drug and Blank Microspheres
HSN cells were prepared m vitro and implanted in the liver in sixteen Lister Hooded rats. On 
this occasion however, all the cells (2x10'") were implanted in a single site in the left lobe of 
tire liver in an attempt to improve the consistency of tumour growth.
Ten days following tumour implantation the rats underwent a second laparotomy. The rats 
who had definite tumour visible in the implanted left lobe were divided into four groups on 
the basis of the treatment they were to receive via the hepatic artery. The conhol group 
received SOOpl of PBS/0.5% Tween 80 and the other groups received 500pl of PBS/0.5% 
Tween 80 containing 5mg of blank albumin microspheres, 5mg E094oaded albumin 
microspheres (containing the equivalent of 60 ± 6pg E09) or lOOpg free E09. Following 
adminishation the hepatic artery was sealed with Fibrinogen/Thrombin glue. The midline 
incision was closed using continuous standard Mersilk sutures for the muscle layer and 
surgical clips for the skin layer. The rats were then given butorphanol (2mg/kg) 
subcutaneously for pain relief and allowed to recover.
Followmg recovery the rats were observed daily for any signs of dishess. Any surviving 
animals were to be culled at 21 days following tumour implantation, the livers removed and 
the tumour size assessed.
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6.4 RESULTS
6.4.1 In Vitro Analysis of HSN Sensitivity to E09
The HSN cell line was shown to be sensitive to E09 with a marked fall in cell numbers as the 
concenti'ation of E09 increased (Table 6.1 & Figure 6.1). The IC50 can be estimated from the 
graph as 4nM E09 which is comparable with other cell lines such as HT29 (IC50 of 6.7nM) 
(Walton et al 1992A).
6.4.2 Dose Finding Studies to Determine HSN Tumour Sensitivity to 
E09 in vivo in Nu/nu Mice
E09 demonstrated significant antitumour activity against the HSN tumour in N u /nu  mice 
when administered intiatumourally. There was a trend towards an increase in antitumour 
activity with an increase in the E09 dose (Figure 6.2). When compared witlr the control 
group, using the unpaired students t-test, there was significant growtlr delay (p<0.05) at all 
doses of E09 from day two until the end of the experiment.
Therefore, a dose of 125|iig of E09 was chosen for future experiments because it produced 
significant growth delay and was not associated with any overt toxicity (two toxic deaths 
were recorded m tire SOOpg E09 group).
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£ 0 9  concenLmLion 
OiM)
Mean Cell Count 
(Standard Deviation)
Trea t ed/Co ntro I 
(%)
0 3596 (962) 100
1 3413 (1004) 95
10 638 (211) 18
100 101 (17) 2.8
1,000 8.0 (3.2) 0.22
10,000 5.3 (1.2) 0.15
Table 6.1 The Mean (and Standard Deviation) cell counts and calculated 
Treated/Control (T/C) values for HSN cells treated in vitro for 24 
hours with varying concentrations of E09 (nM).
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Figure 6.1 The effect of E09 concentration (nM) on the growth of HSN cells 
in vitro. The cell counts are expressed as a percentage of the 
mean treated cell count divided by the mean control cell count 
(T/C).
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Figure 6.2 Dose finding study to determine the antitumour activity of free 
E09 given by direct intratumoural injection on the HSN rat 
sarcoma cell line growing subcutaneously in the Nu/nu mouse. 
Each time point denotes the mean ± standard error (SE) for the 
group. Growth delay is significant from day 2 onwards (p<0.05) 
in all groups treated with E09 compared to the control group.
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6.4.3 Assessment of Antitumour Activity of E09-loaded Albumin 
Microspheres on the HSN Tumour in vivo in Nu/nu Mice
The first experiment was terminated at 14 days instead of the intended 21 days due to rapid 
tumour growth m all groups. Indeed, only 1-2 animals in each group (of the original ten 
animals) survived to 14 days. There were no significant differences detected between the 
conti'ol group (PBS/0,5% Tween 80) and any of the treatment groups which included blank 
microspheres, free E09 and E09-loaded microspheres (Figure 6.3).
These results were not consistent with those of the E09 dose finding study (6.4.2) where a 
significant anti tumour effect had been detected following the admmistration of 125pg E09. 
On further analysis of the results, it was felt that the tumours had been too advanced at the 
beginning of tlie experiment (90% tumours were > than 0.2cm^ at to) and had entered a phase 
of rapid growth. The increased tumour size may have also reduced the E09 concentration 
withm the tumour which may have resulted in reduced tumour sensitivity and hence a 
decreased anti tumour effect.
Therefore, this experiment was repeated with the initial tumour volume in each mouse 
<0.2cm.3. This second experiment continued to 21 days in the control and blank microsphere 
groups, when animals had to be sacrificed due to tumour size and to 28 days in the other 
groups. In comparison to the conti'ol group, a significant difference in tumour growth from 
day 2 onwards was detected in all the E09-tieated groups (Figure 6.4). No significant 
difference in activity however, could be detected between the 250pg and the 125pg E09 
microsphere groups and the free E09 group at any of the time points in the experiment. No 
significant difference in activity was detected between the control group treated with 
FBS/0.5%Tween 80 and the blank microsphere-treated group (Figure 6.4).
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Figure 6.3 Comparison of the antitumour activity of free E09 with E09- 
loaded albumin microspheres and blank albumin microspheres 
given by direct intratumoural injection on the HSN rat sarcoma 
cell line grown subcutaneously in Nu/nu mice. Each time point 
denotes the mean ± standard error for the group. No significant 
difference in tumour growth was detected in any of the treated 
groups when compared to the control group (PBS/0.5% Tween 
80).
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Figure 6.4 Comparison of the antitumour activity of free E09 with E09- 
loaded albumin microspheres and blank albumin microspheres 
given by direct intratumoural injection on the HSN rat sarcoma 
cell line grown subcutaneously in Nu/nu mice. The tumour 
volume at to was ^0.2cm^ in each group. Each time point 
denotes the mean ± standard error for the group. Growth delay 
is significant from day 2 onwards (p<0.05) in all groups treated 
with E09 (both free and microsphere) compared to the control 
groups (PBS/0.5% Tween 80 and blank microspheres).
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These results confirm the m vitro data and demonstrate/ that the HSN tumour, when grown 
in tire N u /nu  mouse, is sensitive to intratumoural administration of E09. However no 
significant difference m anti tumour activity was detected when free drug and the equivalent 
dose of E09 microspheres were compared. This is similar to the result which was obtained 
for the HT29 xenograft (Chapter 4.4.2.2.2). The sensitivity of the HSN tumour to E09 means 
that it is a suitable cell line to use in developing a more clinically relevant tumour model to 
study the anti tumour effects of the E09-loaded microspheres.
6.4.4 Implantation of HSN Tumour Cells in the Liver of the Lister 
Hooded rat
Initial experiments were performed to establish a surgical technique for implantation of the 
HSN tumour cells within the liver, including optimising the recovery of the rats from the 
anaesthetic.
Studies using Lister Hooded rats obtained from the supplier Charles River were 
unsuccessful for two reasons. The first was that the animals were very "anaesthetic 
sensitive". Using a standard anaesthetic regimen for rats, the initial experiments had a 
perioperative mortality rate of 60-80%. This was anaesthetic rather than surgery-related 
because some of the animals which died following the anaesthetic had not undergone any 
form of surgery. The second problem was that there appeared to be spontaneous tumour 
regression occurring 3-4 weeks following tumour implantation. This was shown in two 
separate experiments where tumour was found to increase in size from 2 weeks to 3 weeks 
and then decrease in size from 3 weeks to 4 weeks. This difference in tumour size between 
the third and fourth weeks was statistically significant in the first experiment (Figure 6.5).
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Figure 6.5 The growth of 1x10  ^ HSN rat sarcoma cells implanted
subcapsularly into the median and left lobes of the liver of the
Lister Hooded rat. Each time point denotes the mean tumour
volume ± standard error of 6-8 tumours. Tumour regression was 
seen between weeks 3 and 4, which reached statistical 
significance in Experiment 1 (p<0.05) in this particular substrain 
of rat.
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When the rats were obtained from a different breeder (Harlan, UK) the problem with 
anaesthetic sensitivity was not apparent (100% of animals survived the surgery) and 
spontaneous tumour regression was not seen. This difference was thought to be the result of 
using a different substrain of the Lister Hooded rat.
The surgical technique of subcapsular implantation of the HSN tumour cells in the liver was 
straightforward. Fibrinogen glue was found to be more useful in preventing leakage from 
the surface of the liver following needle removal than the 70% absolute alcohol solution 
which was initially utilised, both in terms of haemorrhage immediately post needle removal 
and tumour cell leakage in terms of the number of metastatic tumour sites seen at post 
mortem examination. There were no post-operative complications documented. The 
wounds healed well and the clips were removed uneventfully after 7 days.
6.4.5 Assessment of HSN Tumour Growth within the Liver
The growth of the HSN tumour within the liver was formally assessed in three separate 
experiments. In the initial experiment tumour size was assessed at 2 and 4 weeks post 
implantation with five animals present in each group (ten tumours for assessment). This 
confirmed that no tumour regression had occurred with the tumour at 4 weeks being 
significantly larger than at two weeks (p<0.005) (Figure 6,6). However, tlrere was significant 
variation present in the size of tire two tumours present within the same animal e.g. l.lOcm^ 
and O.Olcm  ^in one rat at two weeks and 1.47cm^ and 4.33cm^ in one rat at 4 weeks.
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Figure 6.6 The growth of 1x10® HSN rat sarcoma cells Implanted 
subcapsularly In the median and left lobes of the Lister Hooded 
rat at 2 and 4 weeks post Implantation. Each value represents 
the mean tumour value ± standard error of 10 tumours. The 
mean tumour volume has increased significantly by 4 weeks 
compared to 2 weeks (p<0.005).
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In order to get an indication of the rate of tumour growth and to further compare the growth 
of tumour within tlie two lobes of the same animal, the experiment was repeated using 
sixteen animals with assessments at 2, 3, 4 and 5 weeks. These results confirmed the 
continued growth of the tumour with time, which was statistically significant by 5 weeks 
(p< 0.05) (Figure 6.7), as well as the variation in the size of the two tumours in the same rat 
e.g. tumour sizes of 0.13cm^ and 3.65cm3 at 3 weeks post tumour implant in one rat.
A further experiment using fifteen rats with all the cells injected into the left lobe (2x10^) was 
then carried out just prior to the microsphere experiment. Animals were assessed at 1, 2 and 
3 weeks in order to decide on the most appropriate time for antitumour treatment. These 
results confirmed both the variability seen between animals (calculated coefficient of 
variation of 108%, 114% and 42% at 1, 2 and 3 weeks post tumour implantation) as well as 
the continued growth of the tumour with time. Increasing the cell numbers, as might be 
expected, increased the size of the tumour (Figure 6.8).
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Figure 6.7 The growth of 1x10® HSN rat sarcoma cells implanted
subcapsularly In the median and left lobes of the Lister Hooded 
rat at 2, 3, 4, and 5 weeks post Implantation. Each time point 
denotes the mean tumour volume ± standard error of 6-8 
tumours. The Increase in tumour volume was statistically 
significant by 5 weeks (p<0.05).
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Figure 6.8 The growth of 2x10® HSN rat sarcoma cells implanted 
subcapsularly in the left lobe of the Lister Hooded rat at 1, 2 and 
3 weeks post implantation. Each time point is the mean volume 
± standard error of 5 tumours.
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6.4.6 The Effect of Systemic E09 on Tumour Bearing Lister Hooded 
Rats
When the rats were treated with eitlrer PBS/0.5% Tween 80 alone or containing E09 at 3 or 
6nrg/kg, tlrere was no immediate toxicity obvious other than the previously documented 
local irritation at the injection site hr the E09-ti’eated groups (Hendriks et al 1993). However, 
by 48 hours post injection all the animals hr both E09 groups were dead. The deaths were 
unexpected as there had been no evidence of any premorbid ilhress. There were no deatlrs hr 
tire control group which suggested that the cause of death was E09-related. Post mortem 
examhratioir was unremarkable except that the kidneys in the E09-ti'eated arrimais appeared 
paler thair normal. Unfortunately, due to the timing of the deatlrs, histological analysis was 
not possible hr the E09-tieated groups.
When the study was repeated with lower doses (2mg/kg, Im g/kg  and 0.5mg/kg) of E09, 
there were no deaths hr any of the groups and again no toxicity was seen other than local 
irritation at the injection site.
Followmg completioir of the experinrent at 2 weeks post-hrjectioir, histological analyses were 
performed on the kidrreys of the rats treated with 2m g/kg E09 and compared with the 
coirtrol group (PBS/0.5% Tweeir 80). No obvious differences were seen on Haematoxylin 
and Eoshr (H+E) staining between the two groups (Figure 6.9). The dose of 2m g/kg was 
chosen for futirre experiments because this appeared to be the maximum tolerated dose.
When a larger anti tumour study was performed with this dose of E09 (2mg/kg) there was 
one death in the group treated with E09 which occurred 5 days after the E09 injection, but 
no other evidence of toxicity. Each group, including the control group, contained an animal 
which, at post mortem, had no evidence of any tumour present in either lobe of the liver.
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Figure 6.9 Histology of the kidney of the Lister Hooded rat following taii 
vein injection of 400pl of A) PBS/0.5% Tween 80 and B) E09 
2mg/kg. No obvious differences were detected between the two 
groups.
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These were likely to represent animals in which the tumour cells had not "taken" at the time 
of implantation but they were still included in the analysis of the results. In both groups, but 
especially the E09-treated group, considerable variability was seen in the size of the 
tumours present within both lobes of the liver, e.g. at 3 weeks post tumour implantation in 
the E09-ti’eated group, tumour volumes ranged between 0.09 and 5.89cm^ and at 4 weeks in 
the same group, tumour volumes ranged between 0.03 and 20.0 cm .^ There was also some 
variation, although less marked, between the two treated lobes within each animal e.g. at 4 
weeks in tlie E09-tieated group, tumour volumes of 0.75 and 2.94cm^ were present in the 
left and median lobes of one rat.
The mean results from this experiment show that there was no statistically significant 
difference between the control group and the E09-treated group at either 2 or 3 weeks post 
treatment (Figure 6.10). This suggested that the administiation of systemic E09 at this dose 
had no significant effect on the growth of the HSN tumour within tlie liver of the rats.
6.4.7 Feasibility Study on the Administration of Blank Albumin 
Microspheres via the Hepatic Artery
In the five Lister Hooded rats which received lOmg of microspheres in either 250 or 500pl of 
PBS/0.5% Tween 80, all the animals died within 24 hours of the injection, either during the 
procedure as a result of hepatic arterial rupture (three rats), or as a result of post operative 
haemorrhage (one rat), or hepatic arterial blockage by microspheres (one rat).
In five rats treated with 5mg of microspheres there were two deaths as a result of hepatic 
arterial rupture, but the remaining rats made a good recovery and survived the remainder of 
the experiment. There was no significant difference in survival between the 250pl and 500pl 
groups although the larger injection volume was easier for microsphere resuspension. 5mg 
of microspheres in 500|il PBS/Tween 80 was therefore chosen for further experiments.
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Figure 6.10 The effect of systemic E09 (2mg/kg) on the growth of 1x10® HSN 
rat sarcoma cells implanted in the median and left lobes of the 
liver in the Lister Hooded rat at 2 and 3 weeks following 
administration. Each time point represents the mean tumour 
volume ± standard error of 10-12 tumours. No significant 
difference was detected between the E09-treated group and the 
control group at either time point.
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6.4.8 The Effect of E09-loaded Microspheres Administered via the 
Hepatic Artery on HSN tumour in the Liver of the Lister Hooded 
rat: Comparison with Free Drug and Blank Microspheres
There were no problems experienced witli the rats during the surgery or in the recovery 
phase following hepatic tumour implantation. At the second laparotomy 10 days later, five 
animals were found to have no evidence of tumour present within the liver and these were 
tlrerefore withdrawn from the study.
Of the remaming fifteen animals which underwent the second part of the procedure 
involving hepatic artery injection, 10 of tire animals died; two during the procedure itself 
(both animals in the PBS/0.5% Tween 80 control group) and eight witlrin 24 hours (4/4  
animals treated witlr blank microspheres; 2 /3  animals treated with the E09-loaded 
microspheres and 2 /4  animals treated with free E09). The 5 animals which survived the 
immediate post-operative period recovered well and survived the remaining time course of 
the experiment (21 days post implantation).
Post mortem examinations carried out on the rats which died showed tliat there was no 
evidence of hepatic artery haemorrhage in any of the rats. The reason for the deaths in the 
microsphere groups was thought to be related to blockage of the hepatic artery by the 
microspheres. Problems as a result of subjecting the rats to a second laparotomy and 
anaesthetic were also considered because this had not been previously attempted.
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Histological analysis (using H+E staining) of the liver from the animals which survived to 
die end of Üie study, showed no obvious difference in liver architecture between the contr ol, 
free E09 and E09 microsphere-treated groups. In the areas of tumour within the liver there 
was no obvious difference seen between the control group and the free E09-treated group. 
However, in the E09 microsphere-treated animal the tumour appeared to be a little less 
cellular with an increase in the inflammatory cell component. The significance of this 
observation is uncertain, as only one animal in this group actually survived to the end of the 
experiment. No microspheres were seen in tlie sections of either the liver or the tumour of 
the microsphere-tieated animal (Figure 6.11).
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Figure 6.11 Histology of the liver implanted with HSN tumour in the Lister 
Hooded rat 11 days following administration of SOOpI of A) 
PBS/0.5% Tween 80 and B) lOOpg Free E09 via the hepatic 
artery.
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Figure 6.11 Histology of the liver implanted with HSN tumour in the Lister 
Hooded rat 11 days following administration of 500^1 of C) 
60±6|ig E09-loaded microspheres via the hepatic artery.
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6.5 DISCUSSION
The aim of the studies presented in this chapter was to attempt to investigate the antitumour 
activity of the E09-loaded microspheres in a clinically relevant tumour model system.
The sensitivity of the HSN rat sarcoma cell line to E09 was unknown. Therefore, 
preliminary experiments focused on establishing tlie cell line in vitro and then, prior to 
commencing in vivo studies, establishing that it was sensitive to E09. An IC50 of 4nM 
confirmed its sensitivity. This compared favourably with other cell lines which have been 
tested, particularly the HT29 tumour which has an IC50 of 6.7nM (Walton et al 1992A).
The E09 sensitivity of the HSN cell line was then confirmed in vivo in antitumour studies in 
N U /nu  mice. A significant antitumour response using only 1 2 5 p g  E09, administered 
mti'atumourally, suggested that it was more sensitive to E09 than other tumours previously 
studied such as the MAC 16 , MAC 26 and BE (Chapter 4.4,2). When the antitumour effect of 
the microspheres was compared with free drug by direct intratunioural injection, the 
microspheres had an antitumour effect which was equivalent to that of the same dose of 
free drug (125|Lig), a response similar to that seen in the HT29 tumour model (Chapter 
4.4.2.2.2).
Early studies with the HSN tumour in the rat were problematic, due to both anaesthetic 
sensitivity and more importantly, tumour regression which was confirmed in both 
subcutaneous and intrahepatic tumour deposits. This regression was statistically significant 
in the liver tumours at four weeks post implantation when compared with the tumour size 
at three weeks. This result obviously had important implications as such a model could not 
be used for antitumour studies.
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After discussion with the group at The University Department of Surgery, Glasgow Royal 
Infirmary, who had supplied the original HSN cells and who were using this model system 
witliout any such problems, the rat supplier was changed so tliat the rats were obtained 
from the same source as the Glasgow group (Harlan, UK). As a result the problems with 
both anaesthetic sensitivity and tumour regression ceased to be an issue. The substrain and 
not just the sti’ain of rat is therefore extremely important in establishing a tumour line in
VIVO.
No information was available concerning the toxicology of E09 m the Lister Hooded rat. 
Previous in vivo work in rats in general was also limited but 3m g/kg E09 in Sprague- 
Dawley rats (Workman et al 1992C) and weekly doses of 0.45mg/kg in the Wistar rat 
(Hendriks et al 1993) had boür been administered witliout any adverse effects being 
documented. An initial experiment showed that 3 and 6m g/kg (18 and 36mg/ m )^ was 
universally fatal in both groups treated with E09 48 hours following drug administration 
(no deatlis in the control group). Histological analysis of the kidneys of the E09-treated rats 
unfortunately was not possible due to the timing of their deatlis. Subsequent assessment of 
die kidneys of rats tieated with 2m g/kg E09 revealed no obvious abnormality on H+E 
staming. However, as the documented renal effect of E09 is minimal change 
glomerulonephritis (Schellens et al 1994, Verweij et al 1994), election microscopy would be 
required to detect this. Renal toxicity has not been identified previously in animal models 
(Hendriks et al 1993). Subsequent experiments found that although 2m g/kg E09 
represented tlie highest dose which could be safely administered, it did not appear to 
produce any significant antitumour activity.
During tlie establishment of a reliable tumour model, studies were carried out to document 
the growth of tlie tumour within the liver in order to determine the most appropriate time to 
initiate antitumour tr eatm ent. These studies produced variable tumour growth at each time
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point although the overall growth effect was statistically significant with time. Significant 
variation in the two tumour sites within the same animal was also seen. This variation meant 
that any anti tumour effect obtained with treatment would need to be large in order to be 
detectable at a particular time point.
There are several potential reasons for the observed variation. The main reason was thought 
to be ongoing problems witli the technical aspects of the surgical procedure. One important 
factor which also needed to be considered was the length of time the cells remained viable 
following in vitro harvesting. The animals which were treated later in the morning may have 
received cells which were less viable and therefore did not grow as well. An m vitro analysis 
using tiypan blue was performed in order to assess this further. This showed that >90% of 
tlie HSN cells were still viable 6 hours following harvesting and this was therefore unlikely 
to be the reason for the variation which was seen.
Another reason for continued variability in tumour growth may have been that insufficient 
cells were being injected on each occasion into each lobe to produce a consistent growth 
pattern. The experiment was repeated injecting double the number of cells into the same 
single lobe in each animal. However, this did not improve the consistency of tumour 
growth. More work is needed on the subcapsular injection of the tumour cells to achieve as 
consistent a growth rate as possible for future antitumour studies before the technique can 
be used for comparative purposes.
The other main surgical technique which needed considerable practice was the procedure 
used for the hepatic arterial injections. The final technique which was used differed slightly 
to the previously described technique (Anderson et al, 1991B) in that the needle was inserted 
dh'ectly into the hepatic artery rather than cannulating the gastroduodenal artery and then 
as tlie needle was removed, the injection site was immediately sealed with
263
Fibrinogen/Thrombin glue. This appeared to successfully prevent any problems with post 
operative arterial haemorrhage.
The dose of microspheres it was thought possible to inject into the hepatic artery was based 
on previous intra-arterial studies (Goldberg et al 1992, Anderson et al 1991B). Two different 
doses (5mg and lOmg) in two injection volumes (250|il and SOOpl) were chosen. The 
microspheres were carefully resuspended prior to use in order to minimise the potential risk 
of blocking the hepatic artery which would result in the death of the animal. The lower dose 
of microspheres in the larger injection volume was found to be the easiest to administer and 
this was tlrerefore chosen as the microsphere dose in the preliminary anti tumour study. This 
compared the anti tumour effect of E09-loaded microspheres with an equivalent dose of free 
E09 and blank albumin microspheres.
Unfortunately there were significant problems during this study. 5 /6  of the animals treated 
with microspheres (blank and E09-loaded) died durmg the procedure. This was thought to 
be the result of blockage of tire hepatic artery due to either poor microsphere resuspension 
or the possible effects of the Fibrinogen/ Thrombin glue. There were also two deaths in the 
conti’ol group and free E09 groups which may have been tire result of subjecting the animals 
to a second anaesthetic and laparotomy. Of the five animals which survived the procedure, it 
is not possible to draw any sigirificant conclusion from the results which were obtained. The 
experiment therefore needs to be repeated once the problems which have occurred m this 
experiment have been addressed.
264
In summary, the HSN cell line has been shown to be sensitive to E09 in vitro and in vivo. The 
cell line has been successfully implanted into the Ever of Lister Hooded rats although further 
work is required in order to improve both the consistency of tumour growth within the liver 
and the safety of the inti'a-arterial injection following tumour implantation. However, such a 
model is likely to be an appropriate method to determine whether encapsulating E09 into 
microspheres improves drug delivery to the tumour and hence antitumour activity 
following intra-arterial administr ation.
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Chapter 7
Summary
266
The aim of the studies described in this thesis was to encapsulate the indoloquinone E09 
into human albumin microspheres and to then characterise formally the microspheres which 
were produced. Following characterisation the antitumour activity of the microspheres was 
assessed. Pharmacokinetic analysis was performed to determine whether variations in 
antitumour activity could be explained by pharmacokinetic differences and to look for the 
presence of any E09 metabolites which might correlate with activity. Finally, a more 
clinically relevant model was developed to allow better assessment of the antitumour 
activity of the microspheres.
The bioreductive quinone, E09, has been successfully encapsulated into albumin 
microspheres using chemical cross-linking of albumin by gluteraldehyde during 
émulsification at room temperature. This method was chosen because it avoids the use of 
heat and strong chemicals for cross-linkage, particularly important with an unstable drug 
such as E09. The final method was a modification of the original method used, which was 
based on the encapsulation of MMC (Allan et al 1993). Reducing the concentration of 
gluteraldehyde in the cross-linkage step allowed the microspheres to be digested in the 
presence of trypsin. This was important because it allowed HPLC analysis of the 
microspheres to be performed, which potentially allowed both the chemical integrity and the 
total amount of E09 incorporated into the microspheres to be determined. It also increased 
the probability that the microspheres would be biodegradable following in vivo 
administration. Removal of the isopropanol wash step resulted in less E09 being lost from 
the microspheres during their preparation, but required the microspheres to be freeze-dried 
and resuspended using ultrasonication prior to use. The freeze-drying process had the 
additional benefit of being a useful way of preparing the microspheres for storage.
The characteristics of the E09 microspheres were determined because of the important role 
they play in determining both the activity and the disposition of the encapsulated drug
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(Chen et al 1994). The characteristics which we considered to be important were 
microsphere size and biodegradability together with the retention of the drug's chemical 
integrity following the encapsulation process. The degree of incorporation of E09 into the 
microspheres together with the rate of drug release from the microspheres was also 
assessed.
Microspheres of different sizes were produced by varying the speed of the mixer used in the 
émulsification process. The microspheres which were produced at the slower speed of 
1600r.p.m. produced particles which had a mean median size of 19.9pm. Approximately 
70% of the particles were greater than 12pm in diameter, the size required to become 
trapped within the first capillary bed they encounter. This made them the most suitable of 
all the microspheres produced for locoregional administration. The incorporation of E09 
into the microspheres did not significantly alter microsphere size, though this may have 
been related to the amount of drug which was incorporated. It would be interesting to 
determine whether the final size of the particles would be altered if the amount of E09 
incorporated into the microspheres were increased.
The amount of drug which can be encapsulated is important because of the physical 
limitations with regard to the maximum amount of microspheres (300mg) which can be 
successfully administered (Goldberg et al 1988). Only a low rate of encapsulation (1.24 ± 
0.2mg/100mg microspheres) was achieved, but this was comparable to results from the 
otlier studies which used a similar method (Allan et al 1993, Chen et al 1988). Unlike the 
methods of microsphere production which used heat dénaturation (Fugimoto et al 1985A), 
this represents the amount of intact E09 which is actually released from the microspheres. It 
may be an under representation of E09 incorporation because it does not take into account 
any drug which may be covalently complexed to the albumin within the microspheres 
which would be released as the particles are digested in vivo. The release characteristics of
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the E09-loaded microspheres however, would suggest that the amount of E09 incorporated 
in this way is low.
This degree of drug-loading means that if the maximum amount of microspheres (300mg) 
were administered via tlie hepatic artery, the dose of E09 which would be given is 3-4.5mg. 
This is considerably less than the average systemic dose of 22-40mg (depending on the 
schedule) of E09 which has previously been administered. Therefore further studies should 
attempt to increase drug loading by increasing the amount of E09 used in the microsphere 
preparation. If this were successful, then re-characterisation of these new microspheres in 
terms of size and release characteristics would be required. The drug load however may be 
of lesser importance if altered metabohsm of E09 occurs following encapsulation into 
microspheres. Previous studies have suggested (Willmott et al 1987A, Cummings et al 
1992A) tliat tlie microspheres induce a hypoxic environment and this may result in 
augmentation of E09's activity.
Results from the in vitro rate release studies showed that the E09 was rapidly released from 
tlie microspheres and had fully eluted from the column within six hours, a result similar to 
that obtained for the free drug, which suggests that the microspheres act as a carrier for the 
E09 rather than as a means of sustained drug release. This is in keeping with E09's mode of 
action (cross-linkage of DNA, single-stand breaks and the generation of reactive oxygen 
species (Bailey et al 1994, Walton et al 1991)) where it is the peak concentration of E09 rather 
than prolonged delivery of a low dose of drug which is more likely to produce maximum 
cell damage. This would be in agreement with the Phase II trial data where the highest rate 
of stable disease was demonstrated in the group treated with the 3-weekly E09 schedule 
(22mg/m2) compared with the weekly schedule (12mg/m^) (Pavlidis et al 1996).
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Although formal characterisation of the microspheres has been performed, further studies 
would be required in terms of both quality control and aseptic preparation before the 
microspheres would be ready for use in clinical trials with patients.
The characteristics of the E09-loaded microspheres suggested they had the potential for 
antitumour activity. They were compared with the equivalent dose of free E09 (250|ig), 
given by the same route (intratumoural injection) and were initially assessed in vivo in four 
tumour types; the murine adenocarcinomas of colon MAC 26 and MAC 16, and tire human 
colonic adenocarcinoma xenografts HT29 and BE. Previous in vitro studies had shown that 
in aerobic conditions, cell lines which were high in the activity of the 2 electron reducing 
enzyme DT-Diaphorase were more sensitive to the antitumour effect of E09 than cell lines 
which had low enzyme activity (CoUard et al 1995, Fitzsimmons et al 1996, Plumb et al 
1994A, Smitskamp-Wihns et ai 1994, Walton et al 1992A). However, in Üre presence of 
hypoxia, the opposite effect was seen with cells with low DT-Diaphorase activity showing a 
greater increase in sensitivity compared to cells which had higher levels of enzyme activity 
(Bando et al 1995, Plumb et al 1994B, 1994C, Robertson et al 1994). The MAC 16 and HT29 
tumours are known to have high levels of DT-Diaphorase enzyme activity when compared 
with the MAC 26 tumour. The BE tumour has no active DT-Diaphorase. It was felt that 
tiiese four tumour types would allow the assessment of E09's antitumour activity in relation 
to DT-Diaphorase levels and if, as previous studies have suggested, microspheres do induce 
hypoxia, the effect this might have on antitumour activity.
The in vivo antitumour studies showed that in the HT29 tumour the E09-loaded 
microspheres demonstrated equivalent activity to that of the free drug. In the MAC 16 
tumour the microspheres were found to be less efficient than the free drug and in the BE and 
MAC 26 tumour types no antitumour activity was seen in the microsphere-tieated groups. 
These results suggested that in the tumour types with low DT-Diaphorase activity (MAC 26
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and BE), there was no augmentation of effect in the presence of hypoxia (if the microspheres 
induce hypoxia), which is in contrast to previous in vitro studies (Bando et al 1995, Plumb et 
al 1994B, 1994C, Robertson et al 1994). However, several factors other than the levels of 
bioreductive enzymes may have influenced the results. The degree of hypoxia present 
within each of the tumour types could have significantly influenced the outcome, 
particularly as the four tumour types vary widely in their differentiation and vascularisation 
patterns. It would have been useful to have determined whether it was possible to induce 
hypoxia in each of the tumour types using the microspheres before performing antitumour 
studies. In this respect, preliminary experiments using Magnetic Resonance Spectroscopy in 
one tumour type were performed and suggested that the intiatumoural injection of 
microspheres, results in the induction of a hypoxic environment which lasts approximately 
20 minutes (Spanswick, personal communication). Tumour vascularisation as well as 
influencing hypoxia, will also affect the concentration of drug present within the tumour. 
Therefore, it may have been more useful to have studied a panel of xenografts with similar 
degrees of differentiation and vascularisation patterns, but differing levels of bioreductive 
enzymes in order to assess the relationship between the levels of bioreductive enzymes and 
the antitumour activity of free E09 and E09-loaded microspheres.
Pharmacokinetic studies were set up to try and determine whether the variation in 
antitumour activity between the free drug and microsphere-treated groups could be 
explained by pharmacokinetic differences. These studies failed to demonstrate any 
significant difference in the concentration of E09 between the free drug and the 
microsphere-treated groups in both tumour and plasma analysis. The results were however 
extremely variable. Furthermore, the amount of E09 detected at To, the initial time point of 
the analysis, was less than 5% of the original dose of E09 given by direct intratumoural 
injection, which made it difficult to know just how meaningful the results were. The results 
suggested that antitumour activity was independent of the E09 concentration within the
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tumour and that there was minimal evidence of sustained drug release in the microsphere- 
treated groups, which was in agreement with the previous in vitro characterisation studies.
The variability in the PK data shows that initial pharmacokinetic studies should have been 
performed on one of the tumour types in which differences between free E09 and E09- 
loaded microspheres had been detected in the antitumour studies, e.g. BE or MAC 26. 
Analysis of these results would have identified the wide variation which was seen in the 
results at an early stage, and would have allowed the study to have been redesigned prior to 
analysis of the other tumour types. Changes which would have been made to the study 
design, are a reduction in the number of later time points, as these were of limited use 
together, with an increase in the number of animals used at each remaining time point.
As the relative amount of drug detected at "To" was small, more studies should be 
performed to determine the reason for this. Removal of both tire tumour and peritumoural 
tissues for drug assessment would have given some indication as to whether a significant 
amount of E09 had been placed peritumourally or whether the low concentration was in 
fact due to the rapid drug metabolism in the 2-3 minutes required to obtain the first sample.
The development of any metabolites which might correlate with antitumour activity was 
also assessed. Chromatography analysis failed to detect any one metabolite which could be 
related to E09 activation, which agrees with the previous in vitro studies (Cummings et al 
1998). There were no extraction efficiencies and standard curves available for E05A or E09 
metabolites, so the results were qualitative and descriptive rather than quantitative. A more 
useful method of determining E09's activity might have been to use a technique which 
measures the direct consequences of E09 activation such as DNA adduct formation. This is 
based on the fact that E09 is metabolised into short-lived and tlrerefore largely undetectable 
reactive intermediates rather than long-lived stable metabolites.
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The use of direct intratumoural injections compared the effect of free E09 with the 
equivalent dose of E09 in microspheres once they were physically at the tumour site. This 
method maximises the likely antitumour effect, particularly of the free drug, but minimises 
any problems associated with systemic drug administration and may therefore not be the 
best method of assessing a drug delivery system. Direct intratumoural injection will also fail 
to assess the chemoembolic vascular effects of the microspheres on the tumour. For this 
reason, the HSN tumour model was investigated where the HSN tumour was established in 
the liver of the Lister Hooded rat. The administration of free E09 and E09-loaded 
microspheres could then be compared following administration via the hepatic artery. In 
retrospect, because of the limited value of the mouse antitumour studies, it may have been 
better to have concentrated on this model system earlier in the project.
The HSN tumour was shown to be very sensitive to E09 both in vitro and in vivo 
(intratumoural injection in N u /n u  mice), but there were significant problems with the in vivo 
rat model. Further work is required to improve the consistency of tumour growth within 
the liver. Increasing further the number of cells used for subcapsular implantation might 
help reduce the variation which was seen. The efficiency and safety of tlie hepatic arterial 
injection also needs to be improved. The method which we used (direct intra-arterial 
injection) was different from the published technique which carried out intra-arterial 
injection via caimulation of die gastroduodenal artery (Anderson et al 1991B). It would be 
useful to compare our method with the original method which, although technically more 
difficult, eliminates the need to seal the hepatic artery with Fibrinogen/Thrombin glue 
which was probably responsible for the problems we encountered with blockage of the 
hepatic artery.
Alternative models of tumour growth could be considered if the rat model failed to produce 
consistent tumour growth within the hver. One such model is the previously described VX-
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2 tumour grown on the hind leg of the albino rabbit and treated under general anaesthesia 
by injection of microspheres/ free drug/placebo via the femoral artery (Fugimoto et al 
1985A). This model would have the additional advantage of allowing regular assessment of 
tumour growth following treatment.
Once tlie preclinical tumour model was reliably established, antitumour studies would 
compare the systemic (venous) administration of free E09 with the intra-arterial 
administration of free E09, E09-loaded microspheres, blank microspheres and PBS/0.5% 
Tween 80. Different doses of E09-loaded microspheres would be compared for antitumour 
activity and toxicity. Pharmacokinetic studies to include examination of tumour tissue 
would also be performed.
If the preclinical model suggested that E09-loaded microspheres had better antitumour 
activity than either intra-arterial or systemic free E09 and toxicity was acceptable, then 
clinical assessment of the E09 microspheres would be considered. Albumin microspheres 
have previously been safely administered to patients via the hepatic artery (Goldberg et al 
1991C). During dose finding studies the administration of a defined amount of E09-loaded 
microspheres via the hepatic artery to patients about to undergo formal hepatic resection of 
tumour would be considered. Subsequent examination of the resected tumour would give 
some indication of the microsphere distiibution within the tumour tissue in comparison to 
the normal liver. Analysis of the E09 concentration within the tumour tissue would also be 
performed together with the measurement of the tumour's bioreductive enzymes. These 
studies would help to assess the validity of this method prior to embarking on prospective 
randomised tiials utilising this approach.
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APPENDIX A - REAGENT SUPPLIERS
. Supplier
Absolute Alcohol Hayman Ltd
Butorphanol Willow Francis Veterinary
Carbon dioxide (solid) BOC
Cotton seed oil Sigma Chemical Co Ltd
CRE (E) Rat diet SDS
Disodium Hydrogen Orthophosphate BDH Merck Ltd
DPX Mounting Media Fisons Chemicals Ltd
Dulbecco's ModEied Eagle's Medium Gibco LEe Technologies Ltd
E09 A gEt from Kyowa Hakko Kogyo Co 
(under the auspices of Dr H Furukawa and 
Mr J Kelly) suppEed by Dr H Hendriks, NDDO
Fibrinogen/ThrombEi 
combination sealant Scottish National Blood Transfusion Service
Foetal caE serum Gibco LEe Technologies Ltd
Gluteraldehyde: Grade I 
(25% Aqueous) Sigma Chemical Co Ltd
Harris's Haematoxylin Sigma Chemical Co Ltd
Helium BOC
Human serum albumin 
(Fraction V) Sigma Chemical Co Ltd
Hypnorm (fentanyl citrate/ 
fluanisone) Janssen Animal Health
Hypnovel (midazolam) Roche Products Ltd
Lithium Carbonate BDH Merck Ltd
Methanol Rathburn Chemicals Ltd
Mitomycin C Kyowa Hakko Kogyo Co
Nitrogen (Gas/Liquid) BOC
Penicillin-Sti'eptomycin Gibco LEe Technologies Ltd
Petr oleum spirit/ether (ANALAR) 
(Boiling range 120-160°C) BDH Merck Ltd
Phosphate Buffered Saline In house
Polyoxy ethylene sorbitan 
monolaurate (Tween 20) Sigma Chemical Co Ltd
Polyoxyethylene sorbitan 
monoleate (Tween 80) Sigma Chemical Co Ltd
Propan-2-ol (Isopropanol) Rathburn Chemicals Ltd
RM3(E) Mouse diet SDS
Sodium DEiydrogen Orthophosphate BDH Merck Ltd
Sodium dodecyl sulphate BDH Merck Ltd
Sorbitan monoleate (Span 80) Sigma Chemical Co Ltd
TrypsEi (Type III) Sigma Chemical Co Ltd
Trypsin/Versene Gibco LEe Technologies Ltd
Xylene Fisons Chemicals Ltd
Y Eosin (alcoholic) Sigma Chemical Co Ltd
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APPENDIX B - APPARATUS SUPPLIERS
Beckman GPR centrEuge Beckman Instiuments Ltd
Bond Elut C18-OH (3cc & Icc columns) Varian Ltd
Decon FSlOO Ulhasonic waterbath Decon Ultrasonics Ltd
Edwards Modulyo Freeze-dryer Edwards High Vacuum International
Endecott stamless steel sieve (63pm pore diameter) Endecotts Ltd
Eppindorf MicrocentrEuge Eppendorf Ltd
Falcon (tissue culture) Flasks Becton Dickinson
Hewlett Packard Liquid Chromatograph (Model 1090) Hewlett Packard Ltd
Leitz Ortholux 11 microscope E. Leitz (Instruments) Ltd
LiChrosorb RP-18 HPLC Cartridge BDH Merck Ltd
LiChrospher 100 RP-18 precolumn BDH Merck Ltd
LiChrocart Manu-fix Holder BDH Merck Ltd
LKB Broma 7000 Ultrorac Fraction CoUector LKB Broma Ltd
LKB Broma 2120 Varioperspex Peristaltic Pump LKB Broma Ltd
Malvern 2600 Particle Sizer Malvern UK
M.D.H Interlab tissue culture hood (Class II) M.D.H Ltd
MersEk sutures Ethicon
Michel clips (12 x 2.5mm) International Market Supply
Microlance needles Becton Dickinson
Milli-UlO water purEication system MiEepore (U.K.) Ltd
Minitab Release 11 programme Minitab Inc
Morden Isolators Morden ScientEic Ltd
Scotlab VSL incubator Scotlab Ltd
SEverson Mixer (Model SL2T) 
(with emulser screen) SEverson MachEies Ltd
Syringe Filters (0.45pm) Millepore (U.K.) Ltd
Vac ElutSPS24 Phenomenex
Vacuum pump filters 
(0.45 and 0.6pm) MiEepore (U.K.) Ltd
Waters AUiance System Waters Ltd
ZM Coulter Counter Coulter Electr onics
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APPENDIX C - SUPPLIER ADDRESSES
' Summer /  '' " ' Address
Beckman Instilments Ltd. Progress Road, High Wickham, Bucks, UK.
Becton Dickinson Cowley, UK
BDH Merck Ltd. Merck House, Poole, Dorset, UK
BOC Dear Park Road, London, UK.
Charles River Margate, UK
Coulter Electronics Luton, Bedfordshire, UK
Decon Ultiasonics Ltd Conway Street, Hove, Sussex, UK
Edwards High Vaccum 
International Manor Royal, Crawley, West Sussex, UK
Endecotts Ltd Lombard Road, London, UK
E. Leitz (Instruments) Ltd Luton, UK.
Eppendorf Ltd Merck House, Poole, Dorset, UK
Ethicon Edinburgh, UK
Fisons Chemicals Ltd Bishop Meadow Road, Loughborough, UK
Gibco LEe Technologies Ltd Renfrew Road, Paisley, Scotland.
Harlan UK Ltd. Shaw's Farm, Blackthorn, Bicester, UK.
Hayman Ltd Eastways Park, Witham, Essex, UK
Hewlett Packard Ltd Wokingham, BerkshEe, UK.
International Market Supply Congleton, UK
Janssen Animal Health High Wycombe, UK
Kyowa Hakko Kogyo Co Martindale Pharmaceutics, Romford, UK
LKB Broma Ltd Uppsala, Sweden.
M.D.H Ltd Walwarth Road, Andover, UK
MElipore (UK) Ltd Blackmoor Lane, Watford, UK
Minitab Inc 3081 Enterprise Drive, State College, PA 16801, USA
Morden ScientEic Ltd Penicuik, Scotland
NDDO Free University, Amsterdam, Netlierlands.
Phenomenex Queens Avenue, Macclesfield, Cheshire, UK
Rathburn Chemicals Ltd Walkerburn, Scotland.
Roche Products Ltd Welwyn Garden City, UK
SDS Witham, Essex, UK.
Scotlab Ltd Kirkshaws Road, Coatbridge, Scotland
Scottish National Blood 
Transfusion Service Protein Fractionation Centr e, Edinburgh, UK
Sigma Chemical Co. Ltd Fancy Road, Poole Dorset, UK.
SEverson Machines Ltd Waterside, Chesham, Bucks, UK
Varian Ltd. 24201 Frampton Avenue, Harbour City, CA 90710, USA
Waters Ltd The Boulevard, Blackmoor Lane, Watford, UK
Willow Francis Veterinary Crawley, UK
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